var title_f23_20_23872="Tumor vessels seen with white light";
var content_f23_20_23872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    White light imaging of tumor vessels in cholangiocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangioscopy showing tumor vessels in a patient with cholangiocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23872=[""].join("\n");
var outline_f23_20_23872=null;
var title_f23_20_23873="Patient information: Hemangioma (The Basics)";
var content_f23_20_23873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87107\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/31/496\">",
"         Hemangioma on lip",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hemangioma (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8997811\">",
"      <span class=\"h1\">",
"       What are hemangiomas?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hemangiomas are mounds that form in the body when the blood vessels in that area grow in an abnormal way. They most often form on the skin and are usually pink or red, or skin-colored with blotches of pink or red (",
"      <a class=\"graphic graphic_picture graphicRef87009 \" href=\"UTD.htm?0/31/496\">",
"       picture 1",
"      </a>",
"      ). These mounds are sometimes referred to as tumors, but they are NOT caused by cancer, and they are usually harmless.",
"     </p>",
"     <p>",
"      Hemangiomas are most common in children. They are not usually visible at birth. Instead, they usually show up during the first few days or months of life. They can appear on any part of the body, but they are most common on the head or face. When they first show up, they can grow very quickly. Later on, they usually shrink and eventually disappear.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8997843\">",
"      <span class=\"h1\">",
"       Are hemangiomas painful or uncomfortable?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. Hemangiomas can look scary, but they don&rsquo;t usually cause any harm. In rare cases, though, they can form sores, bleed, or get infected. When hemangiomas form inside the body, they can cause serious problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8997858\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if your child develops a new mound somewhere on his or her body, see a doctor or nurse. The doctor or nurse can figure out what&rsquo;s wrong and if any treatment is needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8997873\">",
"      <span class=\"h1\">",
"       How are hemangiomas treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most hemangiomas do not need to be treated. In some cases, doctors will treat a hemangioma if it:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Is very large or located in a part of the body where it can cause health problems, such as near the eye or liver",
"       </li>",
"       <li>",
"        Could cause permanent harm to the child&rsquo;s appearance",
"       </li>",
"       <li>",
"        Gets sore, starts bleeding, or gets infected",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When treatment is needed, doctors can prescribe medicines to shrink hemangiomas or to keep them from growing. They don&rsquo;t prescribe these medicines in all cases, because the medicines can cause serious side effects and because most hemangiomas go away without treatment.",
"     </p>",
"     <p>",
"      In some cases, doctors recommend surgery to remove a hemangioma, or laser treatment to make it less visible. In rare cases, they recommend a treatment called &ldquo;embolization,&rdquo; which blocks blood flow to the hemangioma and causes it to shrink",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8997888\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important thing you can do is to help your child feel normal. Having a hemangioma can be hard for a child. Other people (especially other children) might stare or draw attention to your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8997903\">",
"      <span class=\"h1\">",
"       When will my child&rsquo;s hemangioma go away?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That is hard to predict but here are some numbers that should help:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        50 percent of hemangiomas have gone away by the time a child turns 5",
"       </li>",
"       <li>",
"        70 percent have gone away by the time a child turns 7",
"       </li>",
"       <li>",
"        90 percent have gone away by the time a child turns 9",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Keep in mind that your child&rsquo;s skin might not look completely normal even after the hemangioma shrinks. Still, it makes sense to wait and see what happens to your child&rsquo;s skin before starting treatments that might not be necessary.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/20/23873?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87107 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23873=[""].join("\n");
var outline_f23_20_23873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997811\">",
"      What are hemangiomas?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997843\">",
"      Are hemangiomas painful or uncomfortable?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997858\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997873\">",
"      How are hemangiomas treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997888\">",
"      Is there anything I can do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8997903\">",
"      When will my child&rsquo;s hemangioma go away?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/31/496\">",
"      Hemangioma on lip",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23874="Patient information: Sunburn (The Basics)";
var content_f23_20_23874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15739\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/18/22816\">",
"         Sunburn",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/8/17539\">",
"          Sunburn",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/46/42722\">",
"         Patient information: Melanoma skin cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/43/25266\">",
"         Patient information: Skin burns (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/26/26018\">",
"         Patient information: Skin cancer (non-melanoma) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/6/28772\">",
"         Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32625\">",
"         Patient information: Skin burns (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/30/18913\">",
"         Patient information: Sunburn (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/60/33729\">",
"         Patient information: Sunburn prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sunburn (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sunburn-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1482198852\">",
"      <span class=\"h1\">",
"       What is a sunburn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A sunburn happens when the skin gets burned from invisible light called ultraviolet (UV) light. UV light comes from the sun and can cause a sunburn when a person is in the sun for too long. People can also get a sunburn on a cloudy day, because UV light can go through clouds.",
"     </p>",
"     <p>",
"      Another way people can get a sunburn is from a tanning bed. Tanning beds use UV light to give people a tan.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198859\">",
"      <span class=\"h1\">",
"       Why should I avoid getting a sunburn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to avoid getting a sunburn, because people who get a lot of sunburns have a higher chance of getting certain other problems. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Skin cancer &mdash; There are different types of skin cancer. Most skin cancers can be treated easily. But sunburn increases the risk of getting a serious type of skin cancer, called &ldquo;melanoma.&rdquo;",
"       </li>",
"       <li>",
"        Wrinkles and other skin changes that usually happen when people get older",
"       </li>",
"       <li>",
"        Eye problems called &ldquo;cataracts&rdquo; that can cause trouble seeing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198866\">",
"      <span class=\"h1\">",
"       What can increase my chance of getting a sunburn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your chance of getting a burn from the sun increases if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have pale skin and light-colored hair",
"       </li>",
"       <li>",
"        Are on a mountain or in a place that is closer to the sun",
"       </li>",
"       <li>",
"        Take certain medicines that can cause the skin to burn more easily",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198873\">",
"      <span class=\"h1\">",
"       What are the symptoms of a sunburn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a sunburn happen 3 to 5 hours after being in the sun and include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness (",
"        <a class=\"graphic graphic_picture graphicRef71537 \" href=\"UTD.htm?22/18/22816\">",
"         picture 1",
"        </a>",
"        ) &mdash; The redness is worst 12 to 24 hours after being in the sun and usually fades over 3 days.",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Skin that feels hot when touched",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, sunburns can be severe. Severe sunburns can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blisters (",
"        <a class=\"graphic graphic_picture graphicRef52757 \" href=\"UTD.htm?17/8/17539\">",
"         picture 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Severe pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198880\">",
"      <span class=\"h1\">",
"       Can I treat a sunburn on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can treat a mild sunburn on your own by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taking a pain-relieving medicine",
"       </li>",
"       <li>",
"        Using a lotion or spray made for treating sunburns &mdash; These products usually have aloe or a numbing medicine in them.",
"       </li>",
"       <li>",
"        Staying out of the sun until the redness and pain go away",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198887\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call your doctor or nurse if you have a severe sunburn. Depending on your symptoms, he or she will tell you if you can treat your sunburn at home or if you need to see a doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198894\">",
"      <span class=\"h1\">",
"       Can sunburns be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can prevent sunburns by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Staying out of the sun in the middle of the day (from 10 a.m. to 4 p.m.), when the sun&rsquo;s light is strongest",
"       </li>",
"       <li>",
"        Staying under a sun umbrella, tree, or other shady spot",
"       </li>",
"       <li>",
"        Wearing sunscreen &mdash; Put sunscreen on all parts of the body that are not covered by clothes. Then reapply sunscreen every 2 to 3 hours, or after you sweat or swim. It&rsquo;s important to choose a sunscreen that:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Has an SPF of 30 or greater &mdash; SPF is a number that tells you how well a sunscreen protects the skin from UV light.",
"       </li>",
"       <li>",
"        Protects against 2 types of UV light, called &ldquo;UVA&rdquo; and &ldquo;UVB.&rdquo; (Sunscreens that offer both UVA and UVB protection are sometimes called &ldquo;broad spectrum.&rdquo;)",
"       </li>",
"       <li>",
"        Has not expired or is not more than 3 years old",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wearing lip balm that has an SPF of 30 or greater",
"       </li>",
"       <li>",
"        Wearing sunglasses, a wide-brimmed hat, long-sleeved shirt, or long pants",
"       </li>",
"       <li>",
"        Not using tanning beds",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482198901\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"       Patient information: Skin cancer (non-melanoma) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"       Patient information: Melanoma skin cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=see_link\">",
"       Patient information: Skin burns (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       Patient information: Sunburn (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"       Patient information: Sunburn prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"       Patient information: Skin burns (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/20/23874?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15739 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23874=[""].join("\n");
var outline_f23_20_23874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198852\">",
"      What is a sunburn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198859\">",
"      Why should I avoid getting a sunburn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198866\">",
"      What can increase my chance of getting a sunburn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198873\">",
"      What are the symptoms of a sunburn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198880\">",
"      Can I treat a sunburn on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198887\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198894\">",
"      Can sunburns be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482198901\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/18/22816\">",
"      Sunburn",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/8/17539\">",
"       Sunburn",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=related_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=related_link\">",
"      Patient information: Skin burns (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=related_link\">",
"      Patient information: Skin burns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23875="Permethrin: Pediatric drug information";
var content_f23_20_23875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Permethrin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"    see \"Permethrin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=see_link\">",
"    see \"Permethrin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A200&reg; Lice [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Complete Lice Treatment System [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse Lice Treatment [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Lice Control Spray [OTC];",
"     </li>",
"     <li>",
"      Rid&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kwellada-P&trade;;",
"     </li>",
"     <li>",
"      Nix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiparasitic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Pediculocide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Scabicidal Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Topical: Full-term neonates: Scabies: A single application of permethrin 5% cream was shown to be safe and effective in a full-term neonate (PNA: 21 days) when applied from scalp to toes for 6 hours before rinsing with soap and water (Quarterman, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"      see \"Permethrin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Infants and Children &ge;2 months and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Head lice: After hair has been washed with shampoo, rinsed with water and towel dried, apply a sufficient volume of creme rinse to saturate the hair and scalp; also apply behind the ears and at the base of the neck; leave on hair for 10 minutes before rinsing off with water; remove remaining nits. May repeat in 1 week if lice or nits still present; in areas of head lice resistance to 1% permethrin, 5% permethrin has been applied to clean, dry hair and left on overnight (8-14 hours) under a shower cap.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Scabies: Apply cream from head to toe; leave on for 8-14 hours before washing off with water; for infants, also apply on the hairline, neck, scalp, temple, and forehead; may reapply in 1 week if live mites appear.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 5% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [creme rinse formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Complete Lice Treatment System: 1% (1s) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Creme Rinse: 1% (60 mL) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Creme Rinse Lice Treatment: 1% (60 mL) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [for bedding, furniture and garments/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Lice Control Spray: 0.25% (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [for bedding, furniture and garments/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A200&reg; Lice: 0.5% (170.1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rid&reg;: 0.5% (150 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes liquid spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Avoid contact with eyes during application; shake creme rinse well before using. Apply cream in the evening and leave on overnight to maximize exposure of the mites to the drug.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Single application treatment of infestation with",
"     <i>",
"      Pediculus humanus capitis",
"     </i>",
"     (head louse) and its nits; treatment of",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     (scabies) (FDA approved in ages &ge;2 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, rash of scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, numbness, scalp discomfort, stinging, or tingling; edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrethroid, pyrethrin, any component, or to chrysanthemums",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; do not use near the eyes or on mucous membranes such as inside the nose, mouth, or vagina",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in oral animal reproduction studies. The amount of permethrin available systemically following topical application is &le;2%. The CDC considers the use of permethrin or  pyrethrins with piperonyl butoxide the drugs of choice for the treatment of pubic lice during pregnancy (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium ion influx through nerve cell membrane channels in parasites resulting in delayed repolarization, paralysis, and death of organism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Minimal (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By ester hydrolysis to inactive metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=see_link\">",
"      see \"Permethrin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clothing and bedding should be washed in hot water or by dry cleaning to kill the scabies mite. Shoes and other nonwashable items should be placed in a tightly sealed plastic bag for at least 3 days.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical cream formulation contains formaldehyde which is a contact allergen",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Currie BJ and McCarthy JS, \"Permethrin and Ivermectin for Scabies,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(8):717-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23875/abstract-text/20181973/pubmed\" id=\"20181973\" target=\"_blank\">",
"        20181973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Head Lice,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1997, 39(992):6-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23875/abstract-text/9008683 /pubmed\" id=\"9008683 \" target=\"_blank\">",
"        9008683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23875/abstract-text/1870912 /pubmed\" id=\"1870912 \" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krowchuk DP, Tunnessen WW Jr, and Hurwitz S, &ldquo;Pediatric Dermatology Update,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(2 Pt 1):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23875/abstract-text/1641293/pubmed\" id=\"1641293\" target=\"_blank\">",
"        1641293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quarterman MJ and Lesher JL, &ldquo;Neonatal Scabies Treated With Permethrin 5% Cream,&rdquo;",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 1994, 11(3):264-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23875/abstract-text/7971563 /pubmed\" id=\"7971563 \" target=\"_blank\">",
"        7971563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12696 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23875=[""].join("\n");
var outline_f23_20_23875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208544\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208545\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049343\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444122\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049338\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208529\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208517\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049346\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208581\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049349\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049337\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299857\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208525\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208526\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823809\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049336\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049348\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049341\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049350\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12696\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12696|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=related_link\">",
"      Permethrin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=related_link\">",
"      Permethrin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23876="Pelvic osteomyelitis";
var content_f23_20_23876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic osteomyelitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23876/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/20/23876/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H539708272\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic osteomyelitis may arise hematogenously, secondary to trauma or surgery via direct inoculation of pathogens into bone, or via contiguous spread of infection from soft tissues within or outside the bony walls of the pelvis.",
"   </p>",
"   <p>",
"    Issues related to pelvic osteomyelitis (also referred to as pubic osteomyelitis) will be reviewed here. General issues related to the pathogenesis and classification of osteomyelitis and the clinical features of other types of osteomyelitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708280\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors for pelvic osteomyelitis include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacteremia related infection of intravascular catheters or other implanted devices",
"     </li>",
"     <li>",
"      Trauma (including athletic injuries)",
"     </li>",
"     <li>",
"      Pressure ulcers",
"     </li>",
"     <li>",
"      Pelvic or urologic surgery, particularly procedures such as bladder suspension or prostatectomy",
"     </li>",
"     <li>",
"      Obstetrical injuries or abortion",
"     </li>",
"     <li>",
"      Cardiac catheterization",
"     </li>",
"     <li>",
"      Intravenous drug abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, cases arise spontaneously without an identifiable cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/6\">",
"     6",
"    </a>",
"    ]. Such cases are likely complications of bacteremia that arose from an unrecognized site or event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708288\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic walls contain bone, ligaments, and muscles. The bony pelvis consists of two hip bones (os coxae) that are joined in front by the pubic symphysis. The os coxae articulate posteriorly with the sacrum. The hip (coxal) bones consist of the ilium, the ischium, and the pubis. Both the pubis and ischium are further divided into their respective bodies and rami. The os coxae have been likened to a propeller with two oppositely bent blades with a central shaft (the acetabulum).",
"   </p>",
"   <p>",
"    The pelvis contains two joints: the sacroiliac joint and the symphysis pubis. The sacroiliac joint has a synovial lining; the symphysis pubis consists of apposed cartilaginous layers on either side of an interpubic disk consisting of fibrocartilage. Fibrous ligaments such as iliolumbar ligament further stabilize the bony pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708295\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of osteomyelitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical aspects of pelvic osteomyelitis warrant special emphasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be a long interval between a precipitating cause (such as trauma or surgery) and the onset of pelvic osteomyelitis, and fever may be absent. These factors may contribute to diagnostic delay.",
"     </li>",
"     <li>",
"      Patients with pubic osteomyelitis characteristically have severe pelvic pain associated with point tenderness overlying the symphysis pubis. They usually have a difficulty walking and manifest a characteristic wide-based waddling gait.",
"     </li>",
"     <li>",
"      Hematogenous pelvic osteomyelitis in children can mimic septic arthritis of the hip, an acute abdomen, and sciatica [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with ileal osteomyelitis may complain of gluteal, lumbar, or abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with pyogenic sacroiliitis and secondary pelvic osteomyelitis often have vague poorly localized pain. However, focal tenderness on exam is usually present with pressure or percussion over the sacroiliac region.",
"     </li>",
"     <li>",
"      Patients with pelvic osteomyelitis may develop abscesses in soft tissues adjacent to the bony pelvis or dissect into areas that are quite distant from the site of bony involvement. For example, pubic osteomyelitis can lead to bilateral abscesses in the adductor muscles of the thigh [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708303\">",
"    <span class=\"h2\">",
"     Osteitis pubis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term osteitis pubis was coined in 1924 to describe an idiopathic postoperative complication of suprapubic cystotomy. Patients with this condition have bony destruction of the margins of the symphysis pubis, severe pelvic pain, and a characteristic wide-based waddling gait [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/13\">",
"     13",
"    </a>",
"    ]. Subsequently, osteitis pubis has been recognized as a complication of a wide range of urologic and gynecologic surgical procedures. It has been described in association with pregnancy, hernia repairs, and pyelonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/7\">",
"     7",
"    </a>",
"    ]. Sinus tracts, a characteristic manifestation of osteomyelitis, have been described in some patients. Fever is usually absent.",
"   </p>",
"   <p>",
"    The pathogenesis of osteitis pubis is uncertain. Possible etiologies include infection, mechanical trauma to the symphysis, local vascular damage, or reflex sympathetic dystrophy. Some experts believe that all cases of osteitis pubis are secondary to infection (eg, that osteitis pubis is synonymous with pubic osteomyelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/7\">",
"     7",
"    </a>",
"    ]. Others believe that pubic osteomyelitis and osteitis pubis are separate conditions (ie, that osteitis pubis is not an infectious disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/14\">",
"     14",
"    </a>",
"    ]. Even though this controversy remains unresolved, the possibility of infection (osteomyelitis) should be carefully assessed in every patient with presumed osteitis pubis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39142?source=see_link\">",
"     \"Osteitis pubis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708311\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other forms of osteomyelitis, culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathological examination of a bone biopsy is required in order to make a definitive diagnosis. Compatible symptoms in the setting of relevant risk factors, together with positive blood cultures and radiographic evidence of osteomyelitis, may also be diagnostic. Aspiration and cultures of pus obtained from abscesses that are contiguous to bony pelvic abnormalities may supplant the need for bone biopsy in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of osteomyelitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pathogens responsible for pelvic osteomyelitis vary depending on the pathogenesis of the infection. Hematogenous infections are commonly due to S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/8\">",
"     8",
"    </a>",
"    ]. Postoperative pelvic osteomyelitis infections and infections secondary to decubitus ulcers are commonly mixed infections due to bowel or perineal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiograph is not sensitive for osteomyelitis, although it may be useful to exclude other causes of pain such as tumor or fractures. Computed tomography (CT) is more sensitive than plain radiography in detecting pelvic osteomyelitis but less sensitive than magnetic resonance imaging (MRI). CT may be useful in detecting soft tissue swelling and abscess formation in contiguous soft tissues, particularly when aspiration or drainage procedures are planned.",
"   </p>",
"   <p>",
"    MRI is the most sensitive radiographic modality for detection of pelvic osteomyelitis. Marrow abnormalities typical of osteomyelitis may be detected by MRI before lytic or other typical changes of osteomyelitis appear. In one retrospective study, 19 of 20 children with pelvic osteomyelitis had diagnostic findings of osteomyelitis by MRI; plain radiographs were diagnostic in only one child [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/15\">",
"     15",
"    </a>",
"    ]. Of 12 children who underwent CT, eight had bony changes characteristic of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708319\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment of pelvic osteomyelitis are the same as for other types of osteomyelitis: debridement of infected or necrotic tissues and a long course of antimicrobial therapy directed at the causative pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few unique aspects of the treatment of pelvic osteomyelitis warrant special emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thorough debridement of infected ileal, acetabular, or ischeal bone in the pelvis may be exceedingly difficult because of the proximity of overlying or adjacent structures such as the sacral plexus or because of difficult access for areas deep with the pelvis. In some cases, particularly children, a long course (eg, 6 to 8 weeks) of intravenous antibiotics may be curative even without a thorough debridement [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Debridement of the symphysis pubis may result in further instability and secondary gait problems. Some cases of pubic osteomyelitis have been managed with long courses of antimicrobial therapy without extensive debridement after needle biopsy demonstrated a causative pathogen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/7,18\">",
"       7,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pelvic osteomyelitis due to sacral decubitus ulcers generally requires surgical debridement for cure. In many cases tissue reconstruction is required following debridement and intravenous antimicrobial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/19\">",
"       19",
"      </a>",
"      ]. Such infections are often polymicrobial and multi-drug resistant pathogens may be present. Cure of advanced osteomyelitis due to adjacent sacral decubitus ulcers may be impossible. Hemicorpectomy has been utilized for a few such cases; morbidity and mortality from such extensive surgery is high [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23876/abstract/20\">",
"       20",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539708326\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic osteomyelitis may arise hematogenously, secondary to trauma or surgery via direct inoculation of pathogens into bone, or via contiguous spread of infection from soft tissues within or outside the bony walls of the pelvis. (See",
"      <a class=\"local\" href=\"#H539708272\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predisposing factors for pelvic osteomyelitis include bacteremia related infection of implanted devices, trauma, pressure ulcers, pelvic or urologic surgery, obstetrical procedures, and intravenous drug abuse. (See",
"      <a class=\"local\" href=\"#H539708280\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There may be a long interval between a precipitating cause (such as trauma or surgery) and the onset of pelvic osteomyelitis, and fever may be absent. Patients with pubic osteomyelitis characteristically have severe pelvic pain associated with point tenderness overlying the symphysis pubis. They usually have a difficulty walking and manifest a characteristic wide-based &ldquo;waddling gait.&rdquo; (See",
"      <a class=\"local\" href=\"#H539708295\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteitis pubis consists of bony destruction of the margins of the symphysis pubis, severe pelvic pain, and a characteristic wide-based waddling gait. Fever is usually absent. Osteitis pubis may occur as a result of infection or non-infectious causes. (See",
"      <a class=\"local\" href=\"#H539708303\">",
"       'Osteitis pubis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis and treatment of pelvic osteomyelitis is as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of osteomyelitis in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of pelvic osteomyelitis consists of debridement of infected or necrotic tissues and a long course of antimicrobial therapy directed at the causative pathogens. However, in some cases thorough debridement may be anatomically difficult",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      may result in instability and secondary gait problems. In such cases a long course of antimicrobial therapy without extensive debridement may be sufficient. However, pelvic osteomyelitis due to sacral decubitus ulcers generally requires surgical debridement for cure. (See",
"      <a class=\"local\" href=\"#H539708319\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/1\">",
"      Ukwu HN, Graham BS, Latham RH. Acute pubic osteomyelitis in athletes. Clin Infect Dis 1992; 15:636.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplon, DM, Iannotti, H. Prostatic capsular perforation resulting in pubic osteomyelitis: a rare complication of KTP laser prostatectomy. J Endourology 2008; 22:2705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/3\">",
"      Graham CW, Dmochowski RR, Faerber GJ, et al. Pubic osteomyelitis following bladder neck surgery using bone anchors: a report of 9 cases. J Urol 2002; 168:2055.",
"     </a>",
"    </li>",
"    <li>",
"     Dinan, JJ, Two cases of primary osteomyelitis of the pubic bone Can Med J 1939; 41:436.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/5\">",
"      Guthrie R, Monk J. Osteomyelitis of the symphysis pubis: a complication of cardiac catheterisation. Br J Clin Pract 1989; 43:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/6\">",
"      Dourakis SP, Alexopoulou A, Metallinos G, et al. Pubic osteomyelitis due to Klebsiella pneumoniae in a patient with diabetes mellitus. Am J Med Sci 2006; 331:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/7\">",
"      Sexton DJ, Heskestad L, Lambeth WR, et al. Postoperative pubic osteomyelitis misdiagnosed as osteitis pubis: report of four cases and review. Clin Infect Dis 1993; 17:695.",
"     </a>",
"    </li>",
"    <li>",
"     Highland, TR, LaMont, RL. Osteomyelitis of the pelvis in children. J Bone J Surg (Am) 1983; 65:230.",
"    </li>",
"    <li>",
"     Takemoto, RC, Strongwater, AM. Pelvic osteomyelitis mimicking septic hip arthritis: a case report. J Pediatr Ortho 2009; 18:248.",
"    </li>",
"    <li>",
"     Beaupre, A, Carroll, N. The three syndromes of iliac osteomyelitis in children. J Bone J Surg Am 1979: 61.",
"    </li>",
"    <li>",
"     Yoshida S, Nakagomi K, Goto S Abscess formation in the prevesical space and bilateral thigh muscles secondary to osteomyelitis of the pubis. Scan J Urol Nephrol 2004; 38:440.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/12\">",
"      del Busto R, Quinn EL, Fisher EJ, Madhavan T. Osteomyelitis of the pubis. Report of seven cases. JAMA 1982; 248:1498.",
"     </a>",
"    </li>",
"    <li>",
"     Beer, E. Periostitis and ostitis of the symphysis  and rami of the pubis following suprapubic cystotomies. Int J Med Surg 1924: 237:233.",
"    </li>",
"    <li>",
"     Rostenthal, RE, Spickard, WA, Markham, RD. Osteomyelitis of the symphysis pubis: a separate disease from osteitis pubis. J Bone J Surg (Am) 1982; 64:123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/15\">",
"      McPhee E, Eskander JP, Eskander MS, et al. Imaging in pelvic osteomyelitis: support for early magnetic resonance imaging. J Pediatr Orthop 2007; 27:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/16\">",
"      Davidson D, Letts M, Khoshhal K. Pelvic osteomyelitis in children: a comparison of decades from 1980-1989 with 1990-2001. J Pediatr Orthop 2003; 23:514.",
"     </a>",
"    </li>",
"    <li>",
"     Kumar, J, Ramachandran, M, Little, D, Zenios, M. Pelvic osteomyelitis in children. J Pediatri Orthop 2010; 19:38.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/18\">",
"      COVENTRY MB, MITCHELL WC. Osteitis pubis: observations based on a study of 45 patients. JAMA 1961; 178:898.",
"     </a>",
"    </li>",
"    <li>",
"     Rennert, R, Golinko, M, Yan, A, et al Developing and evaluation outcomes of an evidence-based protocol for the treatment of osteomyelitis in Stage IV pressure ulcer: a literature and wound electronic medical record database review. Ostomy Wound Management 2009; 55:42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23876/abstract/20\">",
"      Janis JE, Ahmad J, Lemmon JA, et al. A 25-year experience with hemicorporectomy for terminal pelvic osteomyelitis. Plast Reconstr Surg 2009; 124:1165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14007 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-3D84CAA1B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23876=[""].join("\n");
var outline_f23_20_23876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H539708326\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708272\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708280\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708288\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708295\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H539708303\">",
"      Osteitis pubis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708311\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708319\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539708326\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39142?source=related_link\">",
"      Osteitis pubis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23877="Ergotamine: Drug information";
var content_f23_20_23877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergotamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/44/18116?source=see_link\">",
"    see \"Ergotamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/49/18196?source=see_link\">",
"    see \"Ergotamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ergomar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine: Sublingual: One tablet under tongue at first sign, then 1 tablet every 30 minutes if needed; maximum dose: 3 tablets/24 hours, 5 tablets/week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with impaired hepatic function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ergomar&reg;: 2 mg [peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush sublingual tablets. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abort or prevent vascular headaches, such as migraine, migraine variants, or so-called &ldquo;histaminic cephalalgia&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Absence of pulse, bradycardia, cardiac valvular fibrosis, cyanosis, edema, ECG changes, gangrene, hypertension, ischemia, precordial distress and pain, tachycardia, vasospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Retroperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pleuropulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergotamine or any component of the formulation; peripheral vascular disease; hepatic or renal disease; coronary artery disease; hypertension; sepsis; ergot alkaloids are contraindicated with strong inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Vasospasm or vasoconstriction can occur, possibly resulting in decreased cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may also lead to ischemic colitis, intermittent claudication, aggravation of angina, or precipitation of MI. Do not use is any patient at risk or predisposed to vascular effects of ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors:",
"     <b>",
"      [U.S. Boxed Warning]: Ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); concomitant use associated with acute ergot toxicity (ergotism).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with extreme caution or avoid use in the elderly; due to vasoconstrictive properties and cardiovascular adverse effects associated with ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Discontinuation after extended use may result in withdrawal symptoms (eg, rebound headache).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Ergotamine. Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F166306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Caffeine may increase GI absorption of ergotamine. Grapefruit juice may cause increased blood levels of ergotamine, leading to increased toxicity. Management: Avoid caffeinated tea, cola, coffee, or other significant sources of caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause prolonged constriction of the uterine vessels and/or increased myometrial tone leading to reduced placental blood flow. This has contributed to fetal growth retardation in animals.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F166298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergotamine is excreted in breast milk and may cause vomiting, diarrhea, weak pulse, and unstable blood pressure in the nursing infant. Consider discontinuing the drug or discontinuing nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Ergomar Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (20): $358.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avamigran (PH);",
"     </li>",
"     <li>",
"      Cafergot (MX, SE);",
"     </li>",
"     <li>",
"      Caftar (MX);",
"     </li>",
"     <li>",
"      Clavigrenin akut (DE);",
"     </li>",
"     <li>",
"      Cornutamin (CZ);",
"     </li>",
"     <li>",
"      Enxak (BR);",
"     </li>",
"     <li>",
"      Ergam (HU);",
"     </li>",
"     <li>",
"      ergo sanol (DE);",
"     </li>",
"     <li>",
"      Ergo-Kranit (DE);",
"     </li>",
"     <li>",
"      Ergocaf (MX);",
"     </li>",
"     <li>",
"      Ergodryl Mono (AU);",
"     </li>",
"     <li>",
"      Ergokapton (AT);",
"     </li>",
"     <li>",
"      Ergosanol (DE, LU);",
"     </li>",
"     <li>",
"      Ergosanol SL (CH);",
"     </li>",
"     <li>",
"      Ergosanol Spezial N (LU);",
"     </li>",
"     <li>",
"      Ergotamin (DE);",
"     </li>",
"     <li>",
"      Ergotamin Medihaler (DK);",
"     </li>",
"     <li>",
"      Ergotamin &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Ergotamina tartrato (IT);",
"     </li>",
"     <li>",
"      Ergotaminum Tartaricum (PL);",
"     </li>",
"     <li>",
"      Ergotan (IT);",
"     </li>",
"     <li>",
"      Ergotartrat (AT);",
"     </li>",
"     <li>",
"      Gynergen (IT);",
"     </li>",
"     <li>",
"      Lingraine (GB, IE);",
"     </li>",
"     <li>",
"      Medihaler Ergotamine (NZ);",
"     </li>",
"     <li>",
"      Medihaler-Ergotamine (GB);",
"     </li>",
"     <li>",
"      Migranil (PK);",
"     </li>",
"     <li>",
"      Migretamine (JP);",
"     </li>",
"     <li>",
"      Migrexa (DE, HR);",
"     </li>",
"     <li>",
"      RubieNex (DE);",
"     </li>",
"     <li>",
"      Secagyn (IL);",
"     </li>",
"     <li>",
"      Sydolil (MX);",
"     </li>",
"     <li>",
"      Tetralgin Haler (AR);",
"     </li>",
"     <li>",
"      Trinergot (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha-adrenergic receptors depending upon their site; is a highly active uterine stimulant; it causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Erratic; enhanced by caffeine coadministration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carlton MC, Kunkel DB, and Curry SC, &ldquo;Ergotism Treated With Cyproheptadine,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):552.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlton MC, &ldquo;Great Balls of Fire: St Anthony and Ergotism,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):560.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards WM, &ldquo;Accidental Poisoning of Newborn Infants With Ergonovine Maleate. A Lesson Application To All Delivery Rooms,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1971, 10(5):257-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Husum B, Metz P, and Rasmussen JP, &ldquo;Nitroglycerin Infusion for Ergotism,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1979, 2(8146):794-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGuigan MA, &ldquo;Ergot Alkaloids,&rdquo;",
"      <i>",
"       Clin Toxicol Rev",
"      </i>",
"      , 1984, 6:1-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orton DA and Richardson RJ, &ldquo;Ergotamine Absorption and Toxicity,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1982, 58(675):6-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/20/23877/abstract-text/7088766/pubmed\" id=\"7088766\" target=\"_blank\">",
"        7088766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9416 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23877=[""].join("\n");
var outline_f23_20_23877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708746\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166343\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166313\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166314\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837918\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837919\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166289\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166275\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166292\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166291\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166341\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166295\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166279\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166339\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166284\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166306\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166286\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166297\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166298\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323132\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166299\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166278\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166294\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9416|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/44/18116?source=related_link\">",
"      Ergotamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/49/18196?source=related_link\">",
"      Ergotamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23878="Treatment of pancreatic fistulas";
var content_f23_20_23878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pancreatic fistulas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Santhi Swaroop Vege, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Michael L Kendrick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23878/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23878/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/20/23878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pancreatic fistula (PF) is an abnormal connection between the pancreas and adjacent or distant organs, structures, or spaces. The main cause is leakage of pancreatic secretions from disrupted pancreatic ducts due to pancreatic disease, trauma, or surgery. PFs can cause significant morbidity due to malnutrition, skin excoriation, and infection.",
"   </p>",
"   <p>",
"    PFs are frequently classified as internal or external depending upon whether they communicate with an internal organ or the skin, respectively. Other classification systems are based upon the etiology of pancreatic disease, amount of enzyme-rich output per day (low-output versus high-output), and the mechanism resulting in the PF (",
"    <a class=\"graphic graphic_table graphicRef66011 \" href=\"UTD.htm?19/44/20171\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment of pancreatic fistulas will be reviewed here. The clinical features, diagnosis, and prevention of PFs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=see_link\">",
"     \"Clinical features, diagnosis, and prevention of pancreatic fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for pancreatic fistulas (PFs) can be conservative (medical), percutaneous (radiologic), endoscopic, or surgical (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69452 \" href=\"UTD.htm?9/14/9445\">",
"     image 1",
"    </a>",
"    ). In most patients, initial therapy for both external and internal fistulas should be conservative since resolution can be expected in about three-fourths of patients. An important exception to this general approach is the presence of infected pancreatic necrosis. In such patients, necrosectomy and debridement are generally recommended because the mortality rate with conservative treatment can be very high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXTERNAL FISTULAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conservative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main principles of conservative management of external pancreatic fistulas (PFs) include the following four features. Success rates of approximately 80 percent can be expected with these conservative measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasojejunal feeding to correct malnutrition and minimize pancreatic stimulation. This approach avoids the risk of venous catheter-related infection and the greater cost associated with parenteral nutrition. Enteral nutrition has also been demonstrated to be associated with significantly higher 30-day fistula closure rates and shorter time to closure of postoperative pancreatic fistula than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic antibiotics to prevent or treat infectious complications.",
"     </li>",
"     <li>",
"      Correction of fluid and electrolyte disturbances.",
"     </li>",
"     <li>",
"      Adequate skin care for the excoriations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these measures, we use somatostatin analogues selectively in patients with high-output PF that result in electrolyte abnormalities or skin breakdown (100 micrograms subcutaneously three times a day). The available data suggest somatostatin preparations may be effective in the reduction of fistula output but not the rate of fistula closure. In a 2012 meta-analysis of seven randomized trials that included 297 patients of which 102 had pancreatic fistulas, closure rates were not significantly higher in patients treated with somatostatin analogues compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/2\">",
"     2",
"    </a>",
"    ]. A placebo-controlled randomized trial of 107 patients with digestive fistulas (71 with PFs) found that prolonged release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    (30 mg intramuscularly) decreased PF output by more than 50 percent at day three in a significantly higher proportion of patients with all fistulas (65 versus 38 percent with placebo) or just PFs (69 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, a randomized trial and an observational study found no benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The direct clinical benefit of reducing PF output volume remains poorly defined. In many patients, the output is low volume and in the absence of other complications, these can be managed with the above measures on an outpatient basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic treatment is a reasonable next step if the conservative measures fail to heal PFs in few weeks. This method is emerging as a safe and effective procedure for this indication, provided it is performed in highly experienced tertiary centers in the setting of a multidisciplinary approach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of endoscopic therapy are drainage of fluid collections adjacent to the bowel, relief of pressure in the pancreatic duct by placing a stent across the duodenal papilla, and dilation of obstructing strictures downstream from the ductal disruption (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78573 \" href=\"UTD.htm?12/25/12690\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Complications of pancreatic duct stents may include stent occlusion, stent migration, duodenal erosion, and infection. Prophylactic antibiotics are generally administered just prior to the procedure. While some endoscopists have found it advantageous to bridge ductal disruptions with stents, others have found that even transpapillary stents placed proximal to the disruption may effectively manage leaks. Advocates of the latter approach support the idea that by providing a path of least resistance downstream from the disruption, pancreatic fluid will preferentially flow antegrade to the duodenum rather than outside of the pancreas. With the above methods, a collective success rate of 85 percent has been reported from 47 patients described in four studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While operatively placed drains after elective pancreatic resection may control a PF (effectively creating an external fistula), percutaneous drainage or radiologic manipulation of existing drains is frequently required. Definitive radiologic treatment of chronic external fistulae, whether postoperative or from other etiology, is not well defined. Both simple drainage with catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/8\">",
"     8",
"    </a>",
"    ] and embolization of PFs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/9\">",
"     9",
"    </a>",
"    ] have been reported in small series of patients. One report described radiologic intervention in 70 patients with a PF selected from series of 445 patients undergoing pancreatic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/10\">",
"     10",
"    </a>",
"    ]. Aggressive interventional radiology treatment resulted in resolution without the need for surgery in 96 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative intervention remains the mainstay of treatment when conservative, percutaneous, or endoscopic methods fail. Although data is limited regarding timing of surgical intervention, most would wait three to six months for the development of a very fibrotic tract. Before intervention, it is important to anatomically map the fistula by imaging modalities as described above. In the acute setting of pancreatic anastomotic disruption, oversewing of the pancreatic stump or even completion pancreatectomy may be necessary. While high mortality rates after such completion pancreatectomy have been reported from Japan and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/11\">",
"     11",
"    </a>",
"    ], experience from the Netherlands suggested lower mortality compared to percutaneous or surgical enteric drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enteric drainage of chronic pancreaticocutaneous fistulae is generally effective, although it may be associated with fistula recurrence, particularly if cystenterostomy is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/13\">",
"     13",
"    </a>",
"    ]. Pertinent factors determining the operative approach are the location of the disruption, status of the pancreatic remnant \"upstream\" from the ductal disruption, presence of necrosis, vascular thrombosis, and prior interventions.",
"   </p>",
"   <p>",
"    A review of the several surgical series (total of 112 patients) identified the following surgical approaches that have been described for treatment of chronic PFs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left pancreatic resection with splenic conservation for ductal",
"      <span class=\"nowrap\">",
"       leaks/disruption",
"      </span>",
"      in the body or tail",
"     </li>",
"     <li>",
"      Roux-en-Y pancreaticojejunostomy",
"     </li>",
"     <li>",
"      Roux-en-Y cystojejunostomy",
"     </li>",
"     <li>",
"      Roux-en-Y fistulojejunostomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall success rate was 90 percent and mortality rate was 6 percent. For fistulojejunostomy, the fistula tract must be mature and the anastomosis performed close to the pancreas, since long-term failure has been attributed to obliteration of the fistula track with time.",
"   </p>",
"   <p>",
"    Whether the specific method of reconstruction after pancreatic resection contributes to rates of pancreatic fistula is still debated. The following illustrates the range of finding in representative reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective comparison of pancreaticogastrostomy (n = 177) versus pancreaticojejunostomy (n = 97) found no statistically significant difference in PF rates (12 versus 14 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 250 patients undergoing pancreaticoduodenectomy compared outcomes of patients who underwent pancreaticogastrostomy (n = 167) versus pancreaticojejunostomy (n = 83) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/15\">",
"       15",
"      </a>",
"      ]. The incidence of postoperative PFs was significantly lower among patients with pancreaticogastric reconstruction compared to those with pancreaticojejunal reconstruction (2 versus 20 percent).",
"     </li>",
"     <li>",
"      In a report of 908 patients who underwent pancreatectomy at a single institution, 158 (17 percent) developed a postoperative fistula, leak, or abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/16\">",
"       16",
"      </a>",
"      ]. Of 88 patients who had a surgical drain placed at initial resection, adequate drainage was achieved in only 16 (18 percent). Reoperation was required in 26 of 158 patients (16 percent). Overall mortality was 5 percent. Independent predictors of prolonged drainage included a drain output &gt;200 mL during the first 48 hours and a distal (versus proximal) pancreatectomy.",
"     </li>",
"     <li>",
"      Another series randomly assigned 179 patients undergoing pancreaticoduodenectomy or distal pancreatectomy either to have no drains or closed suction drains placed following surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/17\">",
"       17",
"      </a>",
"      ]. There was no significant difference in the overall incidence of in-hospital complications in the two groups. However, when considering only PF, intraabdominal collection, or abscess, the incidence was greater in the drained group (n = 19) versus the no-drain group (n = 8), suggesting that drainage after resection may contribute to pancreas-specific complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-butyl-2-cyanoacrylate is delivered as a stable monomer in liquid state, but polymerizes into a solid on contact with body fluids at neutral pH suggesting it has the potential to seal a leak in the pancreatic duct. A pilot study evaluated this approach in 12 patients with peripancreatic or pancreaticocutaneous fistulas who were unfit for surgery due to comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/18\">",
"     18",
"    </a>",
"    ]. Endoscopes with lubricated tips were used to deliver N-butyl-2-cyanoacrylate to the site of the duct leak. The adhesive was applied to seal the fistula. Complete fistula closure was achieved in 8 of 12 patients. Pseudocyst drainage was found to be necessary to achieve successful sealing of fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTERNAL FISTULAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative measures include the management principles of severe acute pancreatitis (broad spectrum antibiotics, enteral nutrition, and correction of fluid and electrolyte imbalances). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary role of percutaneous approaches is for patients with postoperative collections after pancreatic resection. These fistulae frequently resolve with external drainage over three to six weeks in most patients. With this approach, the rate of reoperation for patients with postoperative pancreatic anastomotic leak has been dramatically reduced. For fistulae that are not postoperative in etiology, percutaneous approaches are typically in disfavor secondary to the risk of subsequent external fistulae and recurrence. Thus, percutaneous drainage of an internal collection that is not postoperative in etiology should be considered only when conservative, endoscopic, or surgical treatment methods are not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endoscopic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of endoscopic therapy in management of internal pancreatic fistulas is to promote internal drainage of pancreatic secretions, thereby reducing flow through the fistula tract. This is typically accomplished by placement of a pancreatic stent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatic sphincterotomy and less commonly by transgastric or transduodenal drainage. Pancreatic duct drainage can also be accomplished by placement of a nasopancreatic stent. The efficacy and safety of these approaches are uncertain and experience is limited. Pancreatic endotherapy should be attempted only by highly experienced endoscopists.",
"   </p>",
"   <p>",
"    One uncertainty surrounding pancreatic stenting for a disrupted duct is whether the stent needs to traverse the disruption or whether passage of a stent through the pancreatic sphincter sufficiently reduces ductal pressure to promote flow toward the duodenum and away from the fistula tract. Studies evaluating this issue have produced conflicting results. A reasonable conclusion from these data is that passage of a stent through the disruption may be somewhat more effective than transpapillary stenting alone, but the latter may also be effective. The following examples illustrate findings in the largest series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of eight patients with pancreatic ascites who were treated endoscopically without large volume paracentesis found it unnecessary to cross the disruption with a stent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/19\">",
"       19",
"      </a>",
"      ]. Endoscopic retrograde cholangiopancreatography (ERCP) identified the disrupted site in all eight patients. However, the disruption was accessible to the stent in only four patients. Stents were exchanged after three to six weeks. Seven of the eight patients had clinical resolution of ascites in six weeks.",
"     </li>",
"     <li>",
"      A retrospective study of 43 patients with disrupted pancreatic ducts found that stent bridging the disruption had better outcomes than transpapillary stenting without bridging the disruption [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another review described nine patients who underwent transpapillary stent placement endoscopically for pancreaticocutaneous fistulas after failing medical therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/21\">",
"       21",
"      </a>",
"      ]. The stent crossed the disruption in only three patients. Stents were maintained for 10 to 14 days. In eight patients the fistulas closed between two and seven days. The one failure was in the transpapillary that did not bridge. Complications included one stent occlusion leading to pseudocyst infection and one stent migration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several potential complications from pancreatic stenting. Thus, its role should be confined to centers with personnel who are highly experienced with pancreatic endotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic drainage procedures may be possible in patients with disconnected pancreatic duct syndrome but are associated with a high rate of recurrent symptoms, requiring repeat intervention or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Disruption at the tail (although relatively uncommon) required surgery in all three patients in one review [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NECROTIC PANCREATIC FLUID COLLECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have described endoscopic approaches to necrotic pancreatic fluid collections. The largest report included 138 consecutive patients with organized pancreatic necrosis who underwent endoscopic transmural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transpapillary drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23878/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors used both transgastric and transduodenal approaches and also had an irrigating system (either a nasopancreatic drain or pancreatic lavage tube placed through a percutaneous endoscopic gastrostomy for the irrigating catheter).",
"   </p>",
"   <p>",
"    Complete endoscopic resolution was achieved in 113 patients (82 percent). Resolution occurred significantly more often in patients with chronic compared with acute pseudocysts or necrosis (92 versus 74 and 72 percent, respectively). Complications were more common in patients with necrosis compared to those with chronic or acute pseudocysts (37 versus 17 and 19 percent, respectively). Pancreatic fluid collections recurred in 18 patients (16 percent) during a median of 2.1 years of follow-up. Recurrences were more likely in patients with necrosis compared with those with acute or chronic pseudocysts (29 versus 9 and 12 percent, respectively).",
"   </p>",
"   <p>",
"    While this and others' experience show that such therapy is feasible, it is important to recognize that such an approach has to be undertaken only in tertiary centers with high degree of endoscopic expertise where the outcomes can be prospectively studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pancreatic fistula (PF) is an abnormal connection between the pancreas and adjacent or distant organs, structures, or spaces. PFs are frequently classified as internal or external depending upon whether they communicate with an internal organ or the skin, respectively. The main cause is leakage of pancreatic secretions from disrupted pancreatic ducts due to pancreatic disease, trauma, or surgery. PFs can cause significant morbidity due to malnutrition, skin excoriation, and infection.",
"   </p>",
"   <p>",
"    The preceding discussion provides the rationale for the following management recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest initial conservative therapy for most PFs (broad spectrum antibiotics, correction of fluid and electrolyte disturbances, nasojejunal feeding) without necrotic collections. With a conservative approach, 70 to 80 percent of PFs will resolve within four to six weeks.",
"     </li>",
"     <li>",
"      If conservative measures fail, we further characterize the fistula with a computed tomography (CT) scan",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endoscopic retrograde cholangiopancreatography (ERCP), reserving fistulography for external PFs.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      magnetic resonance cholangiopancreatography (MRCP) may also be useful. For external fistulas, we then proceed to endoscopic transpapillary therapy to dilate any strictures of the pancreatic duct, identify the site of ductal leak, and place a stent preferably across the",
"      <span class=\"nowrap\">",
"       leak/disruption.",
"      </span>",
"      If fluid leakage persists, or if endoscopic drainage is not feasible due to technical reasons, surgical intervention is considered. Depending upon the site of the fistula, the surgical procedure of choice may be a left pancreatectomy, Roux-en-Y enteric drainage of the pseudocyst, or occasionally completion pancreatectomy.",
"     </li>",
"     <li>",
"      For internal fistulae (pseudocysts and organized pancreatic necrosis), if conservative measures fail, we suggest endoscopic drainage or direct endoscopic necrosectomy with or without transpapillary therapy with stents. Magnetic resonance imaging (MRI) before such treatment will identify debris that favors use of large bore stents with irrigating catheters. If this fails or is technically not feasible, percutaneous drainage is used, although there is an occasional risk of internal fistula becoming external with such an approach (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56043 graphicRef66786 \" href=\"UTD.htm?11/44/11977\">",
"       image 3A-B",
"      </a>",
"      ). In recent years, surgical necrosectomy or debridement for necrotic collections or pseudocyst-enteric drainage is being used less often for internal fistulae because of the more frequent use of endoscopic methods.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/1\">",
"      Klek S, Sierzega M, Turczynowski L, et al. Enteral and parenteral nutrition in the conservative treatment of pancreatic fistula: a randomized clinical trial. Gastroenterology 2011; 141:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/2\">",
"      Gans SL, van Westreenen HL, Kiewiet JJ, et al. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg 2012; 99:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/3\">",
"      Gayral F, Campion JP, Regimbeau JM, et al. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg 2009; 250:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/4\">",
"      Sancho JJ, di Costanzo J, Nubiola P, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg 1995; 82:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/5\">",
"      Cullen JJ, Sarr MG, Ilstrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg 1994; 168:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/6\">",
"      Arvanitakis M, Delhaye M, Bali MA, et al. Endoscopic treatment of external pancreatic fistulas: when draining the main pancreatic duct is not enough. Am J Gastroenterol 2007; 102:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/7\">",
"      Alexakis N, Sutton R, Neoptolemos JP. Surgical treatment of pancreatic fistula. Dig Surg 2004; 21:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/8\">",
"      Cabay JE, Boverie JH, Dondelinger RF. Percutaneous catheter drainage of external fistulas of the pancreatic ducts. Eur Radiol 1998; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/9\">",
"      Hirota M, Kamekawa K, Tashima T, et al. Percutaneous embolization of the distal pancreatic duct to treat intractable pancreatic juice fistula. Pancreas 2001; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/10\">",
"      Pedrazzoli S, Liessi G, Pasquali C, et al. Postoperative pancreatic fistulas: preventing severe complications and reducing reoperation and mortality rate. Ann Surg 2009; 249:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/11\">",
"      Smith CD, Sarr MG, vanHeerden JA. Completion pancreatectomy following pancreaticoduodenectomy: clinical experience. World J Surg 1992; 16:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/12\">",
"      van Berge Henegouwen MI, De Wit LT, Van Gulik TM, et al. Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg 1997; 185:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/13\">",
"      Voss M, Ali A, Eubanks WS, Pappas TN. Surgical management of pancreaticocutaneous fistula. J Gastrointest Surg 2003; 7:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/14\">",
"      Aranha GV, Hodul P, Golts E, et al. A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy. J Gastrointest Surg 2003; 7:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/15\">",
"      Oussoultzoglou E, Bachellier P, Bigourdan JM, et al. Pancreaticogastrostomy decreased relaparotomy caused by pancreatic fistula after pancreaticoduodenectomy compared with pancreaticojejunostomy. Arch Surg 2004; 139:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/16\">",
"      Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 2008; 207:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/17\">",
"      Conlon KC, Labow D, Leung D, et al. Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg 2001; 234:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/18\">",
"      Seewald S, Brand B, Groth S, et al. Endoscopic sealing of pancreatic fistula by using N-butyl-2-cyanoacrylate. Gastrointest Endosc 2004; 59:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/19\">",
"      Bracher GA, Manocha AP, DeBanto JR, et al. Endoscopic pancreatic duct stenting to treat pancreatic ascites. Gastrointest Endosc 1999; 49:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/20\">",
"      Telford JJ, Farrell JJ, Saltzman JR, et al. Pancreatic stent placement for duct disruption. Gastrointest Endosc 2002; 56:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/21\">",
"      Kozarek RA, Ball TJ, Patterson DJ, et al. Endoscopic transpapillary therapy for disrupted pancreatic duct and peripancreatic fluid collections. Gastroenterology 1991; 100:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/22\">",
"      Lawrence C, Howell DA, Stefan AM, et al. Disconnected pancreatic tail syndrome: potential for endoscopic therapy and results of long-term follow-up. Gastrointest Endosc 2008; 67:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/23\">",
"      Pelaez-Luna M, Vege SS, Petersen BT, et al. Disconnected pancreatic duct syndrome in severe acute pancreatitis: clinical and imaging characteristics and outcomes in a cohort of 31 cases. Gastrointest Endosc 2008; 68:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23878/abstract/24\">",
"      Baron TH, Harewood GC, Morgan DE, Yates MR. Outcome differences after endoscopic drainage of pancreatic necrosis, acute pancreatic pseudocysts, and chronic pancreatic pseudocysts. Gastrointest Endosc 2002; 56:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5636 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23878=[""].join("\n");
var outline_f23_20_23878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXTERNAL FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conservative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTERNAL FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiologic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endoscopic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NECROTIC PANCREATIC FLUID COLLECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5636|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/14/9445\" title=\"diagnostic image 1\">",
"      Pancreatic fistula series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/25/12690\" title=\"diagnostic image 2\">",
"      Pancreatic fistula ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/14/34019\" title=\"diagnostic image 3A\">",
"      Pancreatic necrosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/13/14549\" title=\"diagnostic image 3B\">",
"      Pancreatic necrosis drainage CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/44/20171\" title=\"table 1\">",
"      Classification of pancreatic fistulas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=related_link\">",
"      Clinical features, diagnosis, and prevention of pancreatic fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23879="Clinical manifestations and diagnosis of acute rheumatic fever";
var content_f23_20_23879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of acute rheumatic fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Allan Gibofsky, MD, JD, FACP, FCLM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23879/contributors\">",
"     John B Zabriskie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23879/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/20/23879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever (ARF) is a nonsuppurative sequela that occurs two to four weeks following group A streptococcus pharyngitis and may consist of arthritis, carditis, chorea, erythema marginatum, and subcutaneous nodules. Damage to cardiac valves may be chronic and progressive, resulting in cardiac decompensation.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of ARF will be reviewed here. The epidemiology, pathogenesis, treatment and prevention of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link\">",
"     \"Treatment and prevention of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, acute rheumatic fever is generally preceded by group A streptococcal (GAS) tonsillopharyngitis, but not by GAS skin infection infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1\">",
"     1",
"    </a>",
"    ]. However, data from developing areas where acute rheumatic fever and rheumatic heart disease are endemic suggest that this association is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among aboriginal communities of Australia, for example, the most common manifestation of group A streptococcal infection is pyoderma; symptomatic group A streptococcal tonsillopharyngitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharyngeal colonization are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A possible explanation is that recurrent pyoderma due to group A streptococci may afford protection against pharyngeal colonization and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternatively, group G or group C streptococci with certain group A streptococcal antigens or enzymes may be important for the pathogenesis of acute rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/2\">",
"     2",
"    </a>",
"    ]. Among Australian aboriginals with ARF, group G and group C streptococci have been identified in the throat but not the pyoderma lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever occurs most frequently in children from 5 to 15 years of age; it is rare among children in the first three years of life and among adults.",
"   </p>",
"   <p>",
"    The diagnosis of ARF is established largely on clinical grounds. The initial description of clinical manifestations, known as the Jones criteria, were first published by Jones in 1944 and revised in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Subsequently, the American Heart Association (AHA) established guidelines for the diagnosis of rheumatic fever in 1992, and the Jones Criteria Working Group of the AHA reviewed this document in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute rheumatic fever is characterized by group A streptococcal infection followed by clinical manifestations outlined below [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The five major manifestations are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Migratory arthritis (predominantly involving the large joints)",
"     </li>",
"     <li>",
"      Carditis and valvulitis (eg, pancarditis)",
"     </li>",
"     <li>",
"      Central nervous system involvement (eg, Sydenham chorea)",
"     </li>",
"     <li>",
"      Erythema marginatum",
"     </li>",
"     <li>",
"      Subcutaneous nodules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The four minor manifestations are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthralgia",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Elevated acute phase reactants [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]",
"     </li>",
"     <li>",
"      Prolonged PR interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The probability of acute rheumatic fever is high in the setting of group A streptococcal infection followed by two major manifestations or one major and two minor manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Two minor manifestations are not diagnostic; follow up of such patients has not demonstrated delayed onset of acute rheumatic fever.",
"   </p>",
"   <p>",
"    Monoarthritis may be observed in patients treated with antiinflammatory drugs. Therapy with glucocorticoids or nonsteroidal antiinflammatory drugs before the signs and symptoms of acute rheumatic fever become distinct may make it difficult to establish the diagnosis of acute rheumatic fever. In such cases, it is difficult to determine the need for secondary rheumatic fever prophylaxis. There is no evidence that temporarily withholding such therapy has any adverse effects.",
"   </p>",
"   <p>",
"    There are three circumstances in which a presumptive diagnosis of acute rheumatic fever can be made without strict adherence to the above criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chorea as the only manifestation.",
"     </li>",
"     <li>",
"      Indolent carditis as the only manifestation in patients who come to medical attention months after acute group A streptococcal infection.",
"     </li>",
"     <li>",
"      Recurrent rheumatic fever in patients with a history of rheumatic fever or rheumatic heart disease. In the absence of pericarditis or involvement of a new valve, it may be difficult establish a diagnosis of acute carditis during an acute attack. Therefore, a presumptive diagnosis of recurrent acute rheumatic fever may be made with one major or two minor criteria if there is evidence of a recent group A streptococcal infection. Caution against using a single clinical finding (eg, monoarthritis, fever, arthralgia) as a criterion for the diagnosis of recurrent disease has been suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strict adherence to the Jones criteria in areas of high prevalence may result in underdiagnosis. This was illustrated in a report of 555 cases of confirmed acute rheumatic fever among Australian aboriginals in whom monoarthritis and low-grade fever were important manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of arthritis due to rheumatic fever consists of inflammation affecting several joints in quick succession, each lasting for a few days to a week [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/10\">",
"     10",
"    </a>",
"    ]. The knees, ankles, elbows, and wrists are affected most commonly; the leg joints are typically involved first. The onset of arthritis in different joints usually overlaps, giving the appearance that the disease \"migrates\" from joint to joint. Thus, the terms \"migrating\" or \"migratory\" are used to describe the polyarthritis of rheumatic fever. Onset and resolution of arthritis may be rapid (within 1 to 2 days) and the arthritis may be severe enough to severely limit movement. Joint involvement is more common and more severe in teenagers and young adults than in children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthritis usually is the earliest symptomatic manifestation of ARF, although asymptomatic carditis may develop first. Joint pain usually is more prominent than objective signs of inflammation and is almost always transient. Typically inflammation is present in multiple joints, and each joint is inflamed for no more than one week. Radiography of an affected joint may demonstrate a slight effusion but is usually unremarkable.",
"   </p>",
"   <p>",
"    The natural history of the polyarthritis in ARF is altered by empiric treatment with nonsteroidal antiinflammatory drugs. In such cases arthritis subsides quickly in the joints affected and does not \"migrate\" to new joints. In one series of patients with rheumatic fever who were treated for associated arthritis, involvement of a single large joint was common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/10\">",
"     10",
"    </a>",
"    ]. In another series including 555 Aboriginal patients in Australia, monoarticular arthritis was also described in 17 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of the synovial fluid in rheumatic fever with arthritis generally demonstrates sterile inflammatory fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic fever causes a pancarditis, affecting the pericardium, epicardium, myocardium, and endocardium. The presence of valvulitis is established by auscultatory findings together with echocardiographic evidence of mitral or aortic regurgitation. However, echocardiography findings may be non-specific. Damage to cardiac valves may be progressive and chronic, resulting in cardiac decompensation. Clinical manifestations and diagnosis of carditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=see_link&amp;anchor=H16376507#H16376507\">",
"     \"Natural history, screening, and management of rheumatic heart disease\", section on 'Acute rheumatic fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sydenham chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sydenham chorea (also known as chorea minor or \"St. Vitus dance\") is a neurologic disorder consisting of abrupt, nonrhythmic involuntary movements, muscular weakness, and emotional disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/12\">",
"     12",
"    </a>",
"    ]. Neurologic examination fails to reveal sensory losses or involvement of the pyramidal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=see_link\">",
"     \"Sydenham chorea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The movements frequently are more marked on one side, are occasionally unilateral (hemichorea), and cease during sleep. Muscle weakness is best demonstrated by asking the patient to squeeze the examiner's hands. The pressure of the patient's grip increases and decreases capriciously, a phenomenon known as relapsing grip or \"milk maids sign.\" Diffuse hypotonia may be present. Emotional changes manifest with outbursts of inappropriate behavior including crying and restlessness. In rare cases, psychologic manifestations are severe and may result in transient psychosis.",
"   </p>",
"   <p>",
"    Chorea can present up to eight months after streptococcal infections; this is a longer latent period than other rheumatic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/13\">",
"     13",
"    </a>",
"    ]. Some patients with chorea have no other clinical symptoms but should undergo evaluation for carditis with echocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Erythema marginatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema marginatum is an evanescent, pink or faintly red, non-pruritic rash involving the trunk and sometimes the limbs but not the face [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/14\">",
"     14",
"    </a>",
"    ]. The lesion extends centrifugally with return of the skin in the center to a normal appearance. The outer edge of the lesion is sharp; the inner edge is diffuse. The lesion is also known as \"erythema annulare\" since the margin of the lesion is usually continuous, making a ring (",
"    <a class=\"graphic graphic_picture graphicRef50841 \" href=\"UTD.htm?29/3/29744\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71804 \" href=\"UTD.htm?7/56/8070\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Individual lesions may appear, disappear, and reappear in a matter of hours. A hot bath or shower may make them more evident. Erythema marginatum usually occurs early in the course of ARF in patients with acute carditis, but may persist or recur when all other manifestations of disease have disappeared [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/15\">",
"     15",
"    </a>",
"    ]. Cases have been reported in patients with chronic carditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/10\">",
"     10",
"    </a>",
"    ]. In some cases the lesions are first noticed late in the course of the illness or even during convalescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subcutaneous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous nodules in ARF are firm, painless lesions ranging from a few millimeters to 2 cm in size. The nodules are usually located over a bony surface or prominence or near tendons (usually extensor surfaces) and are usually symmetric. The overlying skin is not inflamed and usually can be moved over the nodules (",
"    <a class=\"graphic graphic_picture graphicRef54984 \" href=\"UTD.htm?1/53/1875\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/16\">",
"     16",
"    </a>",
"    ]. The number of nodules varies from a single lesion to a few dozen; the average number is three or four.",
"   </p>",
"   <p>",
"    Rheumatic subcutaneous nodules generally appear after the first weeks of illness, usually in patients with relatively severe carditis. Typically nodules are present for one or more weeks; they rarely persist for more than a month.",
"   </p>",
"   <p>",
"    Nodules of ARF are smaller and more short-lived than the nodules of rheumatoid arthritis. The elbows are involved most frequently in both rheumatic fever and rheumatoid arthritis; they may be distinguished in that rheumatic fever nodules occur most commonly on the olecranon, while rheumatoid nodules usually are found 3 to 4 cm distally.",
"   </p>",
"   <p>",
"    In contemporary outbreaks of ARF, nodules have been the least common manifestation (less than 5 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Late sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic heart disease is the most severe sequela of acute rheumatic fever. It usually occurs 10 to 20 years after the original illness and is the most common cause of acquired valvular disease in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The mitral valve is more commonly involved than the aortic valve. Mitral stenosis, caused by severe calcification of the mitral valve, is the classic finding in rheumatic heart disease.",
"   </p>",
"   <p>",
"    The incidence of rheumatic heart disease in patients with a history of ARF is variable; in general, valvular damage manifesting as a murmur later in life is likely to occur in about 50 percent of patients with evidence of carditis at initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever is characterized by group A streptococcal infection followed by the clinical manifestations outlined above. The diagnostic evaluation includes studies to establish the diagnosis of GAS infection, evaluate acute phase reactants, and assess cardiac function. The utility of the various criteria for ARF likely varies as a function of disease incidence. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Carditis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Streptococcal pharyngitis may be diagnosed in one of the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive throat culture for group A beta-hemolytic streptococci",
"     </li>",
"     <li>",
"      Positive rapid streptococcal antigen test",
"     </li>",
"     <li>",
"      Elevated or rising antistreptolysin O antibody titer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Throat cultures are negative in about 75 percent of patients by the time manifestations of rheumatic fever appear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-streptolysin O (ASO) titers vary with age, season, and geography [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/22\">",
"     22",
"    </a>",
"    ]. Healthy children of elementary school age commonly have titers of 200 to 300 Todd units per mL; asymptomatic pharyngeal strep carriers tend to have very low titers, just above detectable. Following streptococcal pharyngitis, the antibody response peaks at about four to five weeks, which usually is during the second or third week of rheumatic fever. Antibody titers fall off rapidly in the next several months and after six months have a slower decline. For these reasons, it may be useful to collect one specimen when the diagnosis of ARF is first suspected and another two weeks later.",
"   </p>",
"   <p>",
"    About 80 percent of patients with documented ARF demonstrate a rise in antistreptolysin titer, although this cannot be used as a measure of rheumatic activity. A negative antistreptolysin titer should prompt testing for other antistreptococcal antibodies such as anti-DNAse B (detectable for six to nine months following infection), streptokinase, and antihyaluronidase; commercial tests for these antibodies are available. About 90 percent of patients with documented ARF have positive findings if two antigens are evaluated; about 95 percent have positive findings if three antigens are evaluated.",
"   </p>",
"   <p>",
"    Acute-phase reactants are increased in ARF. Both serum C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) are invariably elevated during the active rheumatic process unless they are suppressed by antirheumatic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/23\">",
"     23",
"    </a>",
"    ]. CRP or ESR is useful for monitoring \"rebounds\" of inflammation as treatment is tapered. A normal result obtained a few weeks after discontinuing antirheumatic therapy suggests that the course of the illness is complete (unless chorea appears). The CRP is probably more useful since it typically normalizes over a matter of days once an episode of acute inflammation has resolved, while the ESR may stay elevated for up to two months after a transient inflammatory stimulus.",
"   </p>",
"   <p>",
"    A mild normochromic normocytic anemia of chronic inflammation may be observed during acute rheumatic fever. Suppressing the inflammation usually improves the anemia; iron therapy generally is not indicated.",
"   </p>",
"   <p>",
"    Complement levels are usually normal in ARF. In contrast, hypocomplementemia is typically observed in the setting of poststreptococcal glomerulonephritis.",
"   </p>",
"   <p>",
"    Analysis of the synovial fluid in rheumatic fever with arthritis generally demonstrates sterile inflammatory fluid. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Arthritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Issues related to electrocardiogram and echocardiogram findings are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Carditis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to polyarticular joint pain in children and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=see_link\">",
"     \"Evaluation of the child with joint pain or swelling\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Poststreptococcal reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigators have speculated that some cases of arthritis occurring after a streptococcal infection may not be caused by ARF. This disorder has been called poststreptococcal reactive arthritis (PSRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. Issues related to reactive arthritis in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link&amp;anchor=H20#H20\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations have been used to support the notion that PSRA is a separate disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The latent period between the antecedent streptococcal infection and the onset of migratory arthritis is shorter (one to two weeks) than the two to three weeks usually seen in classic ARF.",
"     </li>",
"     <li>",
"      The response of the arthritis to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other nonsteroidal medications is poor in comparison to the dramatic response seen in classic ARF.",
"     </li>",
"     <li>",
"      Evidence of carditis is not seen in these patients, and the severity of the arthritis is quite marked.",
"     </li>",
"     <li>",
"      Extraarticular manifestations such as tenosynovitis and renal abnormalities often are seen in these patients.",
"     </li>",
"     <li>",
"      Acute phase reactants (ESR, CRP) tend to be lower than in the setting of ARF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these patients may actually have ARF, with the above observations being explained by other factors. As an example, variations in the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in affected children may be caused by inadequate salicylate levels. Furthermore, an unusual clinical course should not be sufficient to exclude the diagnosis of ARF. Migratory arthritis without evidence of other major Jones criteria, if supported by two minor manifestations, still must be considered acute rheumatic fever, especially in children.",
"   </p>",
"   <p>",
"    Clearly defining this reactive arthritis as a rheumatic fever variant has important implications for secondary prophylactic treatment. Some investigators feel that PSRA is a benign condition without need for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/26\">",
"     26",
"    </a>",
"    ]. On the other hand, both the 1992 guidelines and the 2002 update reached the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the relationship between PSRA and acute rheumatic fever remains unresolved, patients who fulfill the Jones criteria should be considered to have acute rheumatic fever.",
"     </li>",
"     <li>",
"      Among patients who do not fulfill the Jones criteria, the diagnosis of PSRA should be made only after excluding other rheumatic diseases such as Lyme disease and rheumatoid arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our experience, these patients usually fulfill the Jones criteria (one major, two minor). Thus, they should be treated as if they have acute rheumatic fever, and appropriate antibiotic prophylaxis should be prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This view is supported by a study in which 50 percent of children with signs of migratory arthritis alone went on to develop significant valvular damage after a long follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/34\">",
"     34",
"    </a>",
"    ]. These children presented with their streptococcal illness between 1939 and 1955, before penicillin therapy was widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Poststreptococcal reactive arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another series included 12 children who were diagnosed with PSRA between 1978 and 1985 and were treated with 10 days of penicillin, but no prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23879/abstract/35\">",
"     35",
"    </a>",
"    ]. One child developed classic acute rheumatic fever with valvulitis 18 months after the initial episode. This proportion is similar to the approximately 10 percent of patients who develop recurrent ARF with valvulitis after an initial episode of ARF that did not include carditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute rheumatic fever (ARF) is a nonsuppurative sequela of group A streptococcus pharyngitis that occurs two to four weeks following infection. The diagnosis of ARF is established largely on clinical grounds. The probability of acute rheumatic fever is high in the setting of group A streptococcal infection followed by two major manifestations or one major and two minor manifestations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The five major manifestations are migratory arthritis (predominantly involving the large joints), carditis and valvulitis (eg, pancarditis), central nervous system involvement (eg, Sydenham chorea), erythema marginatum, and subcutaneous nodules. The four minor manifestations are arthralgia, fever, elevated acute phase reactants, and prolonged PR interval. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthritis usually is the earliest symptomatic manifestation of ARF. The natural history consists of inflammation affecting several joints in quick succession with overlapping onset, giving the appearance that the disease \"migrates\" from joint to joint. Joint pain usually is more prominent than objective signs of inflammation and is almost always transient. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rheumatic fever causes a pancarditis, affecting the pericardium, epicardium, myocardium, and endocardium. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Carditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sydenham chorea (also known as chorea minor or \"St. Vitus dance\") is a neurologic disorder consisting of abrupt, nonrhythmic involuntary movements, muscular weakness, and emotional disturbances. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sydenham chorea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythema marginatum is an evanescent, pink or faintly red, non-pruritic rash involving the trunk and sometimes the limbs but not the face (",
"      <a class=\"graphic graphic_picture graphicRef50841 \" href=\"UTD.htm?29/3/29744\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71804 \" href=\"UTD.htm?7/56/8070\">",
"       picture 2",
"      </a>",
"      ). The lesion extends centrifugally with return of the skin in the center to a normal appearance. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Erythema marginatum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subcutaneous nodules are firm, painless lesions ranging from a few millimeters to 2 cm in size (",
"      <a class=\"graphic graphic_picture graphicRef54984 \" href=\"UTD.htm?1/53/1875\">",
"       picture 3",
"      </a>",
"      ). The nodules are usually located over a bony surface or prominence or near tendons (usually extensor surfaces) and are usually symmetric. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Subcutaneous nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Investigators have speculated that some cases of arthritis occurring after a streptococcal infection may not be caused by ARF. Evidence of carditis is not seen in these patients. This disorder has been called poststreptococcal reactive arthritis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Poststreptococcal reactive arthritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/1\">",
"      Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/2\">",
"      McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/3\">",
"      McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006; 43:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/4\">",
"      Noel TP, Zabriskie J, Macpherson CN, Perrotte G. Beta-haemolytic streptococci in school children 5-15 years of age with an emphasis on rheumatic fever, in the tri-island state of Grenada. West Indian Med J 2005; 54:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/5\">",
"      Jones TD. The diagnosis of rheumatic fever. JAMA 1944; 126:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/6\">",
"      Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 1965; 32:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/7\">",
"      Ferrieri P, Jones Criteria Working Group. Proceedings of the Jones Criteria workshop. Circulation 2002; 106:2521.",
"     </a>",
"    </li>",
"    <li>",
"     Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consulatation. 2001: Geneva, Switzerland.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/9\">",
"      Carapetis JR, Currie BJ. Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. Arch Dis Child 2001; 85:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/10\">",
"      FEINSTEIN AR, SPAGNUOLO M. The clinical patterns of acute rheumatic fever: a reapraisal. Medicine (Baltimore) 1962; 41:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/11\">",
"      Wallace MR, Garst PD, Papadimos TJ, Oldfield EC 3rd. The return of acute rheumatic fever in young adults. JAMA 1989; 262:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/12\">",
"      SACKS L, FEINSTEIN AR, TARANTA A. A controlled psychologic study of Sydenham's chorea. J Pediatr 1962; 61:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/13\">",
"      Eshel G, Lahat E, Azizi E, et al. Chorea as a manifestation of rheumatic fever--a 30-year survey (1960-1990). Eur J Pediatr 1993; 152:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/14\">",
"      BURKE JB. Erythema marginatum. Arch Dis Child 1955; 30:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/15\">",
"      Perry CB. Erythema marginatum (rheumaticum). Arch Dis Child 1937; 12:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/16\">",
"      BALDWIN JS, KERR JM, KUTTNER AG, DOYLE EF. Observations on rheumatic nodules over a 30-year period. J Pediatr 1960; 56:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/17\">",
"      Ayoub EM. Resurgence of rheumatic fever in the United States. The changing picture of a preventable illness. Postgrad Med 1992; 92:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/18\">",
"      Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med 1994; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/19\">",
"      Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J 1991; 12 Suppl B:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/20\">",
"      Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 1995; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/21\">",
"      Meira ZM, Goulart EM, Colosimo EA, Mota CC. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. Heart 2005; 91:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/22\">",
"      RANTZ LA, RANDALL E, RANTZ HH. Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man. Am J Med 1948; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/23\">",
"      Harris TN. The erythrocyte sedimentation rate in rheumatic fever: Its significance in adolescent and overweight children. Am J Med Sci 1945; 210:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/24\">",
"      Schaffer FM, Agarwal R, Helm J, et al. Poststreptococcal reactive arthritis and silent carditis: a case report and review of the literature. Pediatrics 1994; 93:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/25\">",
"      Arnold MH, Tyndall A. Poststreptococcal reactive arthritis. Ann Rheum Dis 1989; 48:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/26\">",
"      Aviles RJ, Ramakrishna G, Mohr DN, Michet CJ Jr. Poststreptococcal reactive arthritis in adults: a case series. Mayo Clin Proc 2000; 75:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/27\">",
"      Jansen TL, Janssen M, de Jong AJ, Jeurissen ME. Post-streptococcal reactive arthritis: a clinical and serological description, revealing its distinction from acute rheumatic fever. J Intern Med 1999; 245:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/28\">",
"      Mackie SL, Keat A. Poststreptococcal reactive arthritis: what is it and how do we know? Rheumatology (Oxford) 2004; 43:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/29\">",
"      Moorthy LN, Gaur S, Peterson MG, et al. Poststreptococcal reactive arthritis in children: a retrospective study. Clin Pediatr (Phila) 2009; 48:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/30\">",
"      Barash J, Mashiach E, Navon-Elkan P, et al. Differentiation of post-streptococcal reactive arthritis from acute rheumatic fever. J Pediatr 2008; 153:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/31\">",
"      van Bemmel JM, Delgado V, Holman ER, et al. No increased risk of valvular heart disease in adult poststreptococcal reactive arthritis. Arthritis Rheum 2009; 60:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/32\">",
"      Gibofsky A, Zabriskie JB. Rheumatic fever: new insights into an old disease. Bull Rheum Dis 1993; 42:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/33\">",
"      Moon RY, Greene MG, Rehe GT, Katona IM. Poststreptococcal reactive arthritis in children: a potential predecessor of rheumatic heart disease. J Rheumatol 1995; 22:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/34\">",
"      CREA MA, MORTIMER EA Jr. The nature of scarlatinal arthritis. Pediatrics 1959; 23:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23879/abstract/35\">",
"      De Cunto CL, Giannini EH, Fink CW, et al. Prognosis of children with poststreptococcal reactive arthritis. Pediatr Infect Dis J 1988; 7:683.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3177 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23879=[""].join("\n");
var outline_f23_20_23879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Carditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Erythema marginatum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subcutaneous nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Late sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Poststreptococcal reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3177|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/3/29744\" title=\"picture 1\">",
"      Erythema marginatum on trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/56/8070\" title=\"picture 2\">",
"      Erythema marginatum close up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/53/1875\" title=\"picture 3\">",
"      Rheumatic subcutaneous nodules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=related_link\">",
"      Natural history, screening, and management of rheumatic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=related_link\">",
"      Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23880="Epidemiology and control of Chagas disease";
var content_f23_20_23880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and control of Chagas disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23880/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/20/23880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi, most commonly transmitted by triatomine bugs. The major manifestations are Chagas cardiomyopathy and gastrointestinal disease. Issues related to the epidemiology and control of Chagas disease will be reviewed here. Other issues related to Chagas disease are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the western hemisphere, Chagas disease is responsible for a higher burden of morbidity and mortality than any other parasitic disease, including malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. T. cruzi infects humans and more than 100 species of non-human mammals. Vector-borne transmission occurs exclusively in the Americas, where an estimated 8 to 10 million people are infected (",
"    <a class=\"graphic graphic_table graphicRef58263 \" href=\"UTD.htm?25/16/25869\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Historically, the disease occurred predominantly in rural areas of Latin America where poor housing conditions promoted frequent contact with infected vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the epidemiology of the disease is changing due to migration of individuals within and outside of endemic areas, as well as introduction of successful programs to reduce transmission in endemic areas. Hundreds of thousands of infected individuals live in cities across Latin America and in the United States, Spain, and other European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618493519\">",
"    <span class=\"h2\">",
"     Vector transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vector-borne transmission via infected triatomine bugs is the major route of Chagas transmission (",
"    <a class=\"graphic graphic_figure graphicRef53632 \" href=\"UTD.htm?5/28/5577\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66260 \" href=\"UTD.htm?21/39/22138\">",
"     picture 1",
"    </a>",
"    ). In Mexico, Central America, and northern South America, the main vectors are Rhodnius prolixus and Triatoma dimidiata. In Central Brazil, Bolivia, and further south, the main vectors are Triatoma infestans and Panstrongylus megistus (",
"    <a class=\"graphic graphic_table graphicRef73573 \" href=\"UTD.htm?13/26/13740\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The infective trypomastigote form of the T. cruzi parasite is present in large numbers in the feces of infected triatomine bugs. During or immediately after a blood meal, the triatomine bug defecates on the skin of the host, allowing the organism to enter through the bite wound. The organism can also enter via intact conjunctiva or mucous membranes. Most domestic triatomine species feed nocturnally and are able to complete their blood meal without awakening the host [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of vector-borne T. cruzi is closely linked to the biological and ecological characteristics of the triatomine vectors and the reservoir hosts (including both domestic and sylvatic mammals). The triatomine passes through five nymphal stages; only the adults are winged. Triatomine bugs of both sexes must take blood meals to develop through their nymphal stages to adults. In addition, females require blood meals to lay eggs. Thus, both nymphs and adults may be infected with T. cruzi, but infection rates increase with development stage and age.",
"   </p>",
"   <p>",
"    T. cruzi infection is transmitted to wild mammals by sylvatic triatomine species; these bugs often colonize the nests of rodent or marsupial reservoir hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Sylvatic triatomine adults may fly into human dwellings and cause sporadic human infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Domestic transmission occurs in settings where triatomine vectors have become adapted to living in human dwellings and nearby animal enclosures. Domestic mammals such as dogs, cats, and guinea pigs play important roles as triatomine blood meal sources and T. cruzi reservoir hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Some triatomine species can infest both domestic and sylvatic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/12\">",
"     12",
"    </a>",
"    ]. Triatomines also may feed on blood from birds and reptiles, but these animals are not susceptible to T. cruzi infection.",
"   </p>",
"   <p>",
"    There are more than 130 triatomine bug species in the Americas, many of which can transmit T. cruzi [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A small number of highly domiciliated vectors are of disproportionate importance in the human epidemiology of disease (",
"    <a class=\"graphic graphic_table graphicRef73573 \" href=\"UTD.htm?13/26/13740\">",
"     table 2",
"    </a>",
"    ). Poor-quality housing with adobe or unfinished brick walls provides crevices and other hiding places for triatomine bugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Roofs made of thatch are an attractive habitat for several species [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/15\">",
"     15",
"    </a>",
"    ]. Domestic infestation rates in endemic areas can be high (eg, 25 to 100 percent of houses infested). A house and its immediate surroundings may support large colonies of both juvenile and adult bugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/13,14,16\">",
"     13,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In endemic settings, T. cruzi infection is usually acquired in childhood. Infection persists for life, so the seroprevalence in an area with sustained vector-borne transmission increases with age (reflecting cumulative incidence) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/17\">",
"     17",
"    </a>",
"    ]. Before widespread vector control was instituted in the early 1990s, more than 60 percent of adults were infected with T. cruzi in some endemic communities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Cross-sectional community surveys have demonstrated that most infected individuals are asymptomatic (have the indeterminate form); an estimated 70 to 80 percent remain asymptomatic throughout their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. The prevalence of clinical disease increases with age, reflecting onset of cardiac and gastrointestinal manifestations in early adulthood with progression over a period of years to decades [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The southern region of the United States has established enzootic cycles of T. cruzi involving several triatomine vector species and mammalian hosts, such as raccoons, opossums, and domestic dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Seven autochthonous vector-borne infections in humans have been reported since 1955 (four in Texas and one each in California, Tennessee, and Louisiana) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. The rarity of vector-borne transmission in the United States has been attributed to housing conditions that minimize vector-human contact and lower transmission efficiency of the North American vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. However, undetected cases of autochthonous vector-borne transmission likely occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER MODES OF TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vector-borne transmission via infected triatomine bugs is the major route of Chagas disease transmission. Transmission can also occur vertically from mother to fetus, via transfusion of infected blood components, via transplantation of an organ from an infected donor, via ingestion of contaminated food or drink, or via laboratory exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/3\">",
"     3",
"    </a>",
"    ]. In the absence of successful antitrypanosomal treatment, infection is life-long; spontaneous cure is extremely rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618493691\">",
"    <span class=\"h2\">",
"     Vertical transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;As vector-borne and transfusion transmission routes diminish, the proportion of Chagas disease cases attributable to vertical transmission has grown; an estimated 26 percent of new infections now occur through mother-to-child transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/1\">",
"     1",
"    </a>",
"    ]. Congenital transmission can occur via women who themselves were infected congenitally, perpetuating the disease in the absence of the vector [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/32\">",
"     32",
"    </a>",
"    ]. Reported transmission rates from infected mothers vary from 1 to &gt;10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Factors reported to increase the risk of congenital transmission include younger maternal age, HIV, and higher parasite load by quantitative PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/35,37-40\">",
"     35,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most congenitally infected infants are asymptomatic or have non-specific signs; specific laboratory screening is needed to detect congenital infections in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/41\">",
"     41",
"    </a>",
"    ]; PCR is a useful tool [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/36,38,42\">",
"     36,38,42",
"    </a>",
"    ]. Several endemic countries have congenital Chagas disease screening programs that rely on prenatal serological screening followed by microscopic examination of concentrated cord blood from infants of seropositive mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. In addition, IgG serology is recommended after nine months of age for infants with negative screening tests at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/38,41\">",
"     38,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In routine screening programs, only a small proportion of at-risk infants complete all steps of the algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/47\">",
"     47",
"    </a>",
"    ]. The low sensitivity of neonatal screening tests combined with low follow-up rates later in infancy may lead to substantial underestimation of the transmission rate; one study estimated that only half of all infected infants are detected by routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/38\">",
"     38",
"    </a>",
"    ]. Use of more sensitive molecular tools has the potential to increase the proportion of infants detected early in life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/38,48\">",
"     38,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No cases of congenital transmission have been documented in the United States, although 63 to 315 unrecognized congenital infections are estimated to occur each year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/4,49\">",
"     4,49",
"    </a>",
"    ]. Several congenitally infected infants have been reported in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/36,50,51\">",
"     36,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant correlation has been observed between positive PCR in pregnancy and vertical transmission of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/52\">",
"     52",
"    </a>",
"    ], and treatment of infected women prior to pregnancy has been shown to reduce vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/36,38,42,53\">",
"     36,38,42,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion transmission of T. cruzi was first documented in 1952 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The risk of T. cruzi transmission per infected unit transfused is estimated to be 10 to 25 percent; platelet transfusions are thought to pose a higher risk than other components, such as packed red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early 1990s, the prevalence of T. cruzi infection in donated blood units in Latin America ranged from 1 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/58\">",
"     58",
"    </a>",
"    ]. Serological screening of blood components for T. cruzi has since become accepted as an important component of Chagas disease control initiatives and is now compulsory in nearly all endemic countries, though compliance is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Since this intervention, the risk of transmission through blood transfusion has diminished greatly but has not been eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The risk in Latin American countries where screening has been implemented is estimated to be 1:200,000 units [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/57,60\">",
"     57,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus far, five transfusion-associated T. cruzi infections have been documented in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. All infected recipients were immunosuppressed and presented with more severe symptoms than immunocompetent individuals.",
"   </p>",
"   <p>",
"    In the United States, voluntary blood bank screening was initiated in 2007 and is estimated to cover 75 to 90 percent of the blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/56,62\">",
"     56,62",
"    </a>",
"    ]. Most screening centers use the Ortho ELISA screening test; all initially reactive units are retested in duplicate using the same screening test. Repeatedly reactive donations have confirmatory testing by the radioimmune precipitation assay (RIPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/62\">",
"     62",
"    </a>",
"    ]. A small number of facilities perform screening tests only for donors who report relevant risks, such as residence in or travel to endemic countries. A second serological screening test, the Abbott Prism Chagas, was approved on April 30, 2010 by the FDA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/66\">",
"     66",
"    </a>",
"    ]. This test had very high sensitivity and specificity in clinical trial data, and is compatible with the automated PRISM system already in use in many blood banks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/67\">",
"     67",
"    </a>",
"    ]; implementation in some blood banks is expected to occur in the near future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H13#H13\">",
"     \"Blood donor medical history\", section on 'Chagas disease and babesiosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H19#H19\">",
"     \"Laboratory testing of donated blood\", section on 'Chagas disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among more than 14 million donated units screened in the United States between January 2007 and June 2008, the overall seroprevalence was 1:27,500; the highest rates were observed in Florida and California [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/56\">",
"     56",
"    </a>",
"    ]. Of 104 T. cruzi-infected donors identified, 28 percent were born in Mexico, 26 percent in the United States, 16 percent in El Salvador, and 11 percent in Bolivia; the remaining donors were born in nine other Central and South American countries. Among confirmed infected donors born in the United States, 10 reported no specific risk factors for T. cruzi infection. All of these individuals reported outdoor activities in the southern United States, suggesting potential autochthonous exposure to the infected vector or animal reservoirs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uninfected recipients who receive an organ from a T. cruzi-infected donor may develop acute T. cruzi infection, although transmission is not universal. In a series of 16 uninfected recipients of kidneys from infected donors, three patients acquired T. cruzi infection (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/68\">",
"     68",
"    </a>",
"    ]. There are 19 cases of Chagas disease transmission by organ transplantation documented in the literature (13 kidney, 1 kidney and pancreas, 3 liver, 2 heart transplants) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/68-76\">",
"     68-76",
"    </a>",
"    ]. One case of transmission via unrelated cord blood transplantation has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an infected organ donor is identified, close monitoring of the recipient is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link&amp;anchor=H107060922#H107060922\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\", section on 'Donor transmission in organ transplant recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Oral transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral transmission of acute T. cruzi infection via ingestion of contaminated food was first reported in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Oral transmission has been described in regions where infected sylvatic vectors and reservoir hosts are well known, as well as in areas thought to be free of infected vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/8,78,80\">",
"     8,78,80",
"    </a>",
"    ]. Juice prepared from sugarcane or the palm fruit a&ccedil;a&iacute; is an important vehicle; these preparations are believed to have been contaminated by infected triatomine bugs or their feces at some point in processing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/81\">",
"     81",
"    </a>",
"    ]. In theory, undercooked meat from infected reservoir host animals could also pose risk for transmission, but laboratory data suggest that the infectivity of amastigotes in meat may be lower than that for trypomastigotes in crushed triatomines or their feces [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute morbidity in orally-transmitted infections appears to be more severe than among patients with vector-borne infection. Acute myocarditis and fulminant congestive heart failure occur more frequently in such outbreaks, and case-fatality rates are higher than among patients with vector-borne infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control of oral transmission depends on promotion of better hygiene in food and beverage preparation and sustained vector control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory-acquired T. cruzi infection has occurred via needlestick inoculation or mucous membrane exposure to parasite culture, blood from infected laboratory animals, or infected triatomine fecal material [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management approach in such circumstances is not certain; some favor presumptive antitrypanosomal treatment in cases of moderate- to high-risk exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/83\">",
"     83",
"    </a>",
"    ]. In the absence of presumptive treatment, weekly monitoring by buffy coat microscopy, culture,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PCR for four weeks is appropriate, followed by monthly serology for three to four months. Symptoms suggestive of acute infection should prompt close clinical follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CONTROL PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first coordinated national vector control program began in Brazil in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/84\">",
"     84",
"    </a>",
"    ]. Between 1991 and 2004, four sub-regional control programs were established, funded largely by the governments of the countries involved and coordinated by the Pan American Health Organization. The major aims were to control transmission by domestic vectors and to prevent blood-borne T. cruzi transmission. Subsequently, programs to address congenital T. cruzi infection were added in a number of other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/41,85\">",
"     41,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission by domestic vectors has been reduced via residual application of long-lasting insecticides in human dwellings and peridomestic structures. This intervention was first demonstrated to be effective against domestic triatomine vectors in the 1940s. Improving the quality of domestic structures is also a useful control mechanism as this eliminates triatomine bug hiding places and decreases vector colonization of houses. Surveys of sentinel populations are used to monitor the impact of control initiatives; such populations may include children &lt;5 years or young men newly recruited to the army [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Southern Cone Initiative, the first subregional control program to be established, has led to elimination of T. cruzi transmission by Triatomine infestans in Chile (1999), Uruguay (1997), Brazil (2006), and several provinces of Argentina and Paraguay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/61,87\">",
"     61,87",
"    </a>",
"    ]. Its success inspired the establishment of several other Chagas control initiatives (",
"    <a class=\"graphic graphic_table graphicRef58263 \" href=\"UTD.htm?25/16/25869\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/84\">",
"     84",
"    </a>",
"    ]. Subsequently, T. cruzi transmission by Rhodnius prolixus was interrupted throughout Guatemala in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this progress, foci of vector-borne transmission persist in most endemic countries of Latin America. The success of the Southern Cone Initiative has been challenged by reinfestation from residual vector colonies and the development of insecticide resistance. Gran Chaco remains a heavily infested ecological zone shared by Argentina, Bolivia, and Paraguay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618493872\">",
"    <span class=\"h1\">",
"     RISK TO TRAVELERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk to short-term travelers to Latin America is extremely low. Most vector-borne transmission occurs among people living in poor housing conditions and after years of exposure to infected vectors. Based on entomological and epidemiological data from a highly endemic community, one study estimated that, on average, 1000 to 2500 contacts with infected vectors are needed to result in infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/89\">",
"     89",
"    </a>",
"    ]. Thus, for each single instance of vector exposure, the efficiency of transmission is very low.",
"   </p>",
"   <p>",
"    Travel-related acute T. cruzi infection has been documented in a Canadian traveler to Mexico and an American traveler to Costa Rica [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/90\">",
"     90",
"    </a>",
"    ]. Travelers can minimize risk of infection by avoiding poorly-constructed accommodations and sleeping under insecticide-treated bed nets with the sides tucked in to prevent entry of vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23880/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618493929\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi, principally transmitted by triatomine bugs. Vector-borne transmission in poor housing conditions occurs exclusively in the Americas, where an estimated 8 to 10 million people are infected. The epidemiology of the disease is changing due to successful reduction of transmission in endemic areas as well as migration of individuals within and outside of endemic areas. Hundreds of thousands of infected individuals live in cities across Latin America and in the United States, Spain, and other European countries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infective trypomastigote form of the T. cruzi parasite is present in large numbers in the feces of infected triatomine bugs. During or immediately after a blood meal, the triatomine bug defecates on the skin of the host, allowing the organism to enter through the bite wound or via intact conjunctiva or mucous membranes. The risk of infection in the setting of short-term exposure is low; one study estimated that 1000 to 2500 contacts with infected vectors were needed to result in infection. (See",
"      <a class=\"local\" href=\"#H1618493519\">",
"       'Vector transmission'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1618493872\">",
"       'Risk to travelers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In endemic areas, T. cruzi infection is usually acquired in childhood and persists for life. Therefore, the seroprevalence in an area with sustained vector-borne transmission increases with age (reflecting cumulative incidence). Before widespread vector control was instituted, more than 60 percent of adults were infected with T. cruzi in some endemic communities. About 70 to 80 percent of infected individuals have lifelong asymptomatic infection. The prevalence of clinical disease increases with age, reflecting onset of cardiac and gastrointestinal manifestations in early adulthood with progression over a period of years to decades. (See",
"      <a class=\"local\" href=\"#H1618493519\">",
"       'Vector transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chagas disease transmission can also occur vertically from mother to fetus, via transfusion of infected blood components, via organ transplantation from an infected donor, via ingestion of contaminated food or drink, or via laboratory exposure. In the United States, voluntary blood bank screening was initiated in 2007 and is estimated to cover 75 to 90 percent of the blood supply. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Other modes of transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most congenitally infected infants are asymptomatic or have non-specific signs; specific laboratory screening is needed to detect congenital infections in infants. Several endemic countries have congenital Chagas disease screening programs; however, only a small proportion of at-risk infants complete all steps of the algorithm. (See",
"      <a class=\"local\" href=\"#H1618493691\">",
"       'Vertical transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission by domestic vectors has been reduced via residual application of long-lasting insecticides in human dwellings and peridomestic structures. Despite this progress, foci of vector-borne transmission persist in most endemic countries of Latin America. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Control programs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Organizaci&oacute;n Panamericana de la Salud. Estimaci&oacute;n cuantitativa de la enfermedad de Chagas en las Americas. Organizaci&oacute;n Panamericana de la Salud, Montevideo, Uruguay 2006.",
"    </li>",
"    <li>",
"     World Health Organization. The World Health Report 2004: Changing history. World Health Organization, Geneva, Switzerland, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/3\">",
"      Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/4\">",
"      Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/5\">",
"      Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010; 115:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/6\">",
"      Lent H, Wygodzinsky P. Revision of the Triatominae (Hemiptera, Reduviidae), and their significance as vectors of Chagas' disease. Bull Am Mus Nat Hist 1979; 63:123.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Expert Committee. Control of Chagas Disease. Brasilia, Brazil: World Health Organization, 2002:1-109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/8\">",
"      Coura JR, Junqueira AC, Fernandes O, et al. Emerging Chagas disease in Amazonian Brazil. Trends Parasitol 2002; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/9\">",
"      Cohen JE, G&uuml;rtler RE. Modeling household transmission of American trypanosomiasis. Science 2001; 293:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/10\">",
"      Gurtler RE, Cohen JE, Cecere MC, et al. Influence of humans and domestic animals on the household prevalence of Trypanosoma cruzi in Triatoma infestans populations in northwest Argentina. Am J Trop Med Hyg 1998; 58:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/11\">",
"      HERRER A. CHAGAS' DISEASE IN PERU. I. THE EPIDEMIOLOGICAL IMPORTANCE OF THE GUINEA PIG. Trop Geogr Med 1964; 16:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/12\">",
"      Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/13\">",
"      Levy MZ, Bowman NM, Kawai V, et al. Periurban Trypanosoma cruzi-infected Triatoma infestans, Arequipa, Peru. Emerg Infect Dis 2006; 12:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/14\">",
"      Mott KE, Muniz TM, Lehman JS Jr, et al. House construction, triatomine distribution, and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil. Am J Trop Med Hyg 1978; 27:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/15\">",
"      Grijalva MJ, Escalante L, Paredes RA, et al. Seroprevalence and risk factors for Trypanosoma cruzi infection in the Amazon region of Ecuador. Am J Trop Med Hyg 2003; 69:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/16\">",
"      Pless M, Juranek D, Kozarsky P, et al. The epidemiology of Chagas' disease in a hyperendemic area of Cochabamba, Bolivia: a clinical study including electrocardiography, seroreactivity to Trypanosoma cruzi, xenodiagnosis, and domiciliary triatomine distribution. Am J Trop Med Hyg 1992; 47:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/17\">",
"      Feliciangeli MD, Campbell-Lendrum D, Martinez C, et al. Chagas disease control in Venezuela: lessons for the Andean region and beyond. Trends Parasitol 2003; 19:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/18\">",
"      Mott KE, Lehman JS Jr, hoff R, et al. The epidemiology and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil. Am J Trop Med Hyg 1976; 25:552.",
"     </a>",
"    </li>",
"    <li>",
"     Magill AJ, Reed SG. American Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Deseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/20\">",
"      Maguire JH, Hoff R, Sherlock I, et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 1987; 75:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/21\">",
"      Beard CB, Pye G, Steurer FJ, et al. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg Infect Dis 2003; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/22\">",
"      Kjos SA, Snowden KF, Craig TM, et al. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol 2008; 152:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/23\">",
"      Yabsley MJ, Noblet GP. Seroprevalence of Trypanosoma cruzi in raccoons from South Carolina and Georgia. J Wildl Dis 2002; 38:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/24\">",
"      Reisenman CE, Lawrence G, Guerenstein PG, et al. Infection of kissing bugs with Trypanosoma cruzi, Tucson, Arizona, USA. Emerg Infect Dis 2010; 16:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/25\">",
"      Dorn PL, Perniciaro L, Yabsley MJ, et al. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 2007; 13:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/26\">",
"      Navin TR, Roberto RR, Juranek DD, et al. Human and sylvatic Trypanosoma cruzi infection in California. Am J Public Health 1985; 75:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/27\">",
"      Ochs DE, Hnilica VS, Moser DR, et al. Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi. Am J Trop Med Hyg 1996; 54:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/28\">",
"      Schiffler RJ, Mansur GP, Navin TR, Limpakarnjanarat K. Indigenous Chagas' disease (American trypanosomiasis) in California. JAMA 1984; 251:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/29\">",
"      WOODY NC, WOODY HB. American trypanosomiasis (Chagas' disease); first indigenous case in the United States. J Am Med Assoc 1955; 159:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/30\">",
"      Kjos SA, Gillespie JJ, Olson JK, Snowden KF. Detection of Blastocrithidia spp. (Kinetoplastida: Trypanosomatidae) in Chagas disease vectors from Texas, USA. Vector Borne Zoonotic Dis 2009; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/31\">",
"      Klotz SA, Dorn PL, Klotz JH, et al. Feeding behavior of triatomines from the southwestern United States: an update on potential risk for transmission of Chagas disease. Acta Trop 2009; 111:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/32\">",
"      Schenone H, Gaggero M, Sapunar J, et al. Congenital Chagas disease of second generation in Santiago, Chile. Report of two cases. Rev Inst Med Trop Sao Paulo 2001; 43:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/33\">",
"      Azogue E, Darras C. [Prospective study of Chagas disease in newborn children with placental infection caused by Trypanosoma cruzi (Santa Cruz-Bolivia)]. Rev Soc Bras Med Trop 1991; 24:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/34\">",
"      Basombr&iacute;o MA, Nasser J, Segura MA, et al. [The transmission de Chagas disease in Salta and the detection of congenital cases]. Medicina (B Aires) 1999; 59 Suppl 2:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/35\">",
"      Torrico F, Alonso-Vega C, Suarez E, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg 2004; 70:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/36\">",
"      Murcia L, Carrilero B, Munoz-Davila MJ, et al. Risk factors and primary prevention of congenital Chagas disease in a nonendemic country. Clin Infect Dis 2013; 56:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/37\">",
"      Bittencourt AL. Possible risk factors for vertical transmission of Chagas' disease. Rev Inst Med Trop Sao Paulo 1992; 34:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/38\">",
"      Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009; 49:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/39\">",
"      Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis 1995; 21:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/40\">",
"      Andrade SG. The influence of the strain of Trypanosoma cruzi in placental infections in mice. Trans R Soc Trop Med Hyg 1982; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/41\">",
"      Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. Rev Soc Bras Med Trop 2003; 36:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/42\">",
"      Virreira M, Truyens C, Alonso-Vega C, et al. Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns. Am J Trop Med Hyg 2007; 77:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/43\">",
"      Luquetti AO, Dias JC, Prata A. [Diagnosis and treatment of congenital infection caused by Trypanosoma cruzi in Brazil]. Rev Soc Bras Med Trop 2005; 38 Suppl 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/44\">",
"      Sosa-Estani S. [Congenital transmission of Trypanosoma cruzi infection in Argentina]. Rev Soc Bras Med Trop 2005; 38 Suppl 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/45\">",
"      Feilij H, Muller L, Gonzalez Cappa SM. Direct micromethod for diagnosis of acute and congenital Chagas' disease. J Clin Microbiol 1983; 18:327.",
"     </a>",
"    </li>",
"    <li>",
"     Programa Nacional de Control de Chagas. Chagas Cong&eacute;nito: Estrategias de Diagn&oacute;stico y Control. 2nd ed: Digital Dreams, Cochabamba, Bolivia, 2007:1-89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/47\">",
"      Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop Med Int Health 2000; 5:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/48\">",
"      Russomando G, de Tomassone MM, de Guillen I, et al. Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg 1998; 59:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/49\">",
"      Buekens P, Almendares O, Carlier Y, et al. Mother-to-child transmission of Chagas' disease in North America: why don't we do more? Matern Child Health J 2008; 12:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/50\">",
"      Jackson Y, Myers C, Diana A, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis 2009; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/51\">",
"      Mu&ntilde;oz J, Port&uacute;s M, Corachan M, et al. Congenital Trypanosoma cruzi infection in a non-endemic area. Trans R Soc Trop Med Hyg 2007; 101:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/52\">",
"      Virreira M, Torrico F, Truyens C, et al. Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg 2003; 68:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/53\">",
"      Sosa-Estani S, Cura E, Velazquez E, et al. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009; 42:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/54\">",
"      PEDREIRA DE FREITAS JL, AMATO NETO V, SONNTAG R, et al. [First tests on the accidental transmission of Chagas disease to man by blood transfusion]. Rev Paul Med 1952; 40:36.",
"     </a>",
"    </li>",
"    <li>",
"     Wendel S, Brener Z. Historical Aspects. In: Chagas Disease - American Trypanosomiasis: Its impact on transfusion and clinical medicine, Wendel S, Brener Z, Camargo ME, Rassi A (Eds), Sao Paulo, Brazil: International Society of Blood Transfusion, Sao Paulo 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/56\">",
"      Bern C, Montgomery SP, Katz L, et al. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/57\">",
"      Wendel S, Leiby DA. Parasitic infections in the blood supply: assessing and countering the threat. Dev Biol (Basel) 2007; 127:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/58\">",
"      Schmu&ntilde;is GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991; 31:547.",
"     </a>",
"    </li>",
"    <li>",
"     Pan American Health Organization. Chagas Disease (American Trypanosomiasis). 2010. file://www.paho.org/english/ad/dpc/cd/chagas.htm (Accessed on May 31, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/60\">",
"      Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/61\">",
"      Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 2006; 100:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Blood donor screening for chagas disease--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/63\">",
"      Cimo PL, Luper WE, Scouros MA. Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med 1993; 89:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/64\">",
"      Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 1999; 341:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/65\">",
"      Young C, Losikoff P, Chawla A, et al. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47:540.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. FDA News Release: FDA Approves Chagas Disease Screening Test for Blood, Tissue and Organ Donors. 2010. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210429.htm (Accessed on May 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/67\">",
"      Chang CD, Cheng KY, Jiang LX, et al. Evaluation of a prototype Trypanosoma cruzi antibody assay with recombinant antigens on a fully automated chemiluminescence analyzer for blood donor screening. Transfusion 2006; 46:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/68\">",
"      Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/69\">",
"      Barc&aacute;n L, Luna C, Luna&oacute; C, et al. Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transpl 2005; 11:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/70\">",
"      Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/72\">",
"      Chocair PR, Sabbaga E, Amato Neto V, et al. [Kidney transplantation: a new way of transmitting chagas disease]. Rev Inst Med Trop Sao Paulo 1981; 23:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/73\">",
"      de Faria JB, Alves G. Transmission of Chagas' disease through cadaveric renal transplantation. Transplantation 1993; 56:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/74\">",
"      Ferraz AS, Figueiredo JF. Transmission of Chagas' disease through transplanted kidney: occurrence of the acute form of the disease in two recipients from the same donor. Rev Inst Med Trop Sao Paulo 1993; 35:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/75\">",
"      Figueiredo JF, Martinez R, da Costa JC, et al. Transmission of Chagas disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg 1990; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/76\">",
"      Souza FF, Castro-E-Silva O, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc 2008; 40:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/77\">",
"      For&eacute;s R, Sanju&aacute;n I, Portero F, et al. Chagas disease in a recipient of cord blood transplantation. Bone Marrow Transplant 2007; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/78\">",
"      Pereira KS, Schmidt FL, Guaraldo AM, et al. Chagas' disease as a foodborne illness. J Food Prot 2009; 72:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/79\">",
"      Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012; 54:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/80\">",
"      Alarc&oacute;n de Noya B, D&iacute;az-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010; 201:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/81\">",
"      N&oacute;brega AA, Garcia MH, Tatto E, et al. Oral transmission of Chagas disease by consumption of a&ccedil;a&iacute; palm fruit, Brazil. Emerg Infect Dis 2009; 15:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/82\">",
"      Roellig DM, Ellis AE, Yabsley MJ. Oral transmission of Trypanosoma cruzi with opposing evidence for the theory of carnivory. J Parasitol 2009; 95:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/83\">",
"      Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev 2001; 14:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/84\">",
"      Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/85\">",
"      Blanco SB, Segura EL, G&uuml;rtler RE. [Control of congenital transmission of Trypanosoma cruzi in Argentina]. Medicina (B Aires) 1999; 59 Suppl 2:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/86\">",
"      Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/87\">",
"      Dias JC. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz 2007; 102 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/88\">",
"      G&uuml;rtler RE, Kitron U, Cecere MC, et al. Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci U S A 2007; 104:16194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/89\">",
"      Rabinovich JE, Wisnivesky-Colli C, Solarz ND, G&uuml;rtler RE. Probability of transmission of Chagas disease by Triatoma infestans (Hemiptera: Reduviidae) in an endemic area of Santiago del Estero, Argentina. Bull World Health Organ 1990; 68:737.",
"     </a>",
"    </li>",
"    <li>",
"     Unpublished data, A. McCarthy, University of Ottawa, 2008; CDC, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23880/abstract/91\">",
"      Kroeger A, Villegas E, Ordo&ntilde;ez-Gonz&aacute;lez J, et al. Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials. Am J Trop Med Hyg 2003; 68:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5698 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23880=[""].join("\n");
var outline_f23_20_23880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1618493929\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1618493519\">",
"      Vector transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER MODES OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1618493691\">",
"      Vertical transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Oral transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory accidents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CONTROL PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1618493872\">",
"      RISK TO TRAVELERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1618493929\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5698\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5698|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/28/5577\" title=\"figure 1\">",
"      Trypanosoma cruzi life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5698|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/39/22138\" title=\"picture 1\">",
"      Triatomine bugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5698|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/16/25869\" title=\"table 1\">",
"      T cruzi seroprevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/26/13740\" title=\"table 2\">",
"      Major triatomine species of Chagas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=related_link\">",
"      Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23881="Nephrology pattern 1";
var content_f23_20_23881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC7o2oWU8czWUiztASGUYyCK0bPVftRjuDEoBBjcMOnYj6V59e+FdY8K+PvM02F59NvJC0MuSV2HnDe49K6XT9V8y4lgeLyIhIYwq9MZ710yjF6x1P0DDSdaN5HQpar5csSu/2U9IzzgZ6Cpk05BHh2LDrz2NPsbYK8ZVmdSOCDW3FbKD84ZgeCSMgfSsJSsFSryPcox3LGLZK2+FBjDrzjp1qSOPybdpBny5MYxwT7U28WCWRooMebEuWAOalmuWuNHCpEGfHBA6dc0WM90uU8v+JWo6zDcW0GmTSHT+DIoXo/POfSr+k2NzqRtEdv3jxLn0yecfWtqa2e4+eMEuB8wz2rQ0Ii1uUnEZLK3K5/ziulztGyOtJUouzuziPEHho3Gqrp1zMYyj7d3UHmu10rwvHpdjJZWvPynOexB7/nit3V9E0jxVcLP9pnsbxhggDgkDvXTaf4fWwjDzzfaGWIKZWGNx6ZNc9TEaJN6nBVx8YxV9JdrHmD2M1m2cZQZyQevNdJpN8s6RFWUO5wyjrnHJqXxLZhIgEdWLZBI4xXOxwmwuIzHuZzywI4qtKkbnUpLEQv1M7xF4etPHF7eNMJoXsn8pCrfK20d/f3+lcv4TtrTw1rstvFCxjZzvklbJ78D6V6fp0FtbfarpXeJ7qUMwJ4DHjj603XfDmmaxZSPLGPMZDG8sZIzz3FNVeX3Xsc0XyaW12M34X+I9a8QLqeoarKBpRYx2MDAbkA9cdeK6HS4LTSYbl7SEJNOSxKjhR6/WuT17WdO8JxadZCAQRSOIkSLCgE9/1rQ1i81CPU47O0VTDIUycdc9c+1TKHM+bZP9DNUor3Yl+5uYpPLhYqTKDnnnBry9dQ8O2GsarHozTS6pao7QjHyGQdQPXBFehan4SvNTa3v7SQqsGC0Yzg854PauK8MfCzUP8AhOW1Fd7WwmaXDjHUnIJ79a0hOnFO7LctdGrdfIwPA/jvWLbXWj1ieWa2nfbIJcgoxPBA/pXoVx4t0691AaZJazwxyyeXHK+NsjDngdR0NdzqHwq0vUtXi1CYsQhDhNuCD1HfmsDXvD3hnwlqv9raiLie6Tm0ti2V8w8bgPrk1LxFKq9I6nNDFUpNcju+xh/ELXY9C8NQ26Wc9ypPysr7dikdz3HavNfh22qNq0Wp6XcMNPkuBG5Y8xNncV/KvTrazt/HeizRTRTQxKCrpkLIvsD+Rq/4X03wv4a0C7s7eOCG2hkDTNLJufzOm5if6CrU/ZpwS1OiXLCadtOvzO5dXe0RxHKrMPvoMbumat28TPG0c03lOP4zgn6kUxrrNpG6SnydvyBcFR781g2mmxf2nHObyeecuXfzG4I9MVwpX3OFRc076Glrt1Jpto7k+YFJA9CPXgf0pLa+M+lw3j2rb2TJUrytSPcTNqElpNprG0Ee4XRKkEn+Hb1rM8QRXk9tmyuooSDtVCOCPehJPRlUkpWTNePUbeS1iBUoewcYA/Gp1hVWDxSFFPJUdDXP6ClxeW5h1hFDxhlR4zwfw9TWzZq0aSwRMzR5CrnqPWiSSYqkFBtRLd1dRxQySPHgIpJ7AcdazYdSGosJ4Lr9yg4a36A/Uf54qtqFrdXdtPbSXESKzbCXIAPHT+VUrCyGi6IdR1CRUtoCRFHDwGVehPvwT9KpRVvMI04QWr1OijgScG4kdp2YfeY8fTirR+zwkBYkXdwue/4Vy/gzxBb3f9oiVZrWS2xJLHOMAZyAeuMe9V9b8OX+saol9Hd+faFlkR4AWKKP4VOcY60OFpWm7Gco+/yydkd3HcQ9Jl3ZwqRjp71HIRJbzKI0SNhtZQufwzWVYQXrXS3N1am3tUG2JWPzZ9SPpW3N81pKOBuXGcdB61k0kc04xhJW1PPPGl01j4fupNOVVn3hAVXotcR4k8X6jpmjWkacX0se4ysPu8kDrXoV7GXGJiqqCFckc/54rP13SdM1dI4ruASon3QWwcZ9vwrspSjCyaue1CKS7nCeAfEF7qllNJqZJkWQLHIy4yD2/wA+tdL4B1vUrXV7lRI7I2fvDgfWur0LwnZrbJFbQ+TGuWVQOv8AjWxH4UEA/dFY4W5JI5oqV6bbVtyKuKoKPs5s8O0O41/VfiPrWpa5JLFDCWDKVIQKDhQPwFel6PbWlg7XNraIsjOXHyDk/wB41s6np1paQnLbnfqeMY96o6ftvzGlowfe20Y7UOpzxWm2hVOcPZWjsX4or7V5twZ5NowCeAtN0e9ltb82Vz8vz7SvofWu50ywjsY1VPvYAz2rwv42axd+GfENvqGn8RXkyxu5XIBA5x9R/WsKTVWfs+5wUMVDESlStaNtD0jUrNAvkhyIwpIaPsTUDKjaV5KA4A2KWO4njrnv3qCG9W50I3ZdvNmtg6kHgnaf0zXP/Ci8e48Ex3V9Kd9uHhYMf4w2P5EUKLSd+n/BNEpJe9un+Js2Uc+n6dJOzCSdW2SO/ZQOw9aztUi0nXdB1CC3mhfUAu/aCAVYd8VqwkiG6IAZZW6npwOa47wP8P7fSfGeoaqL83CPE7KgzgZPT3qtHdydmdEnvJ9P6seUeDvDPiLSvGbXFrHmzD5c5wrZJ4wOtfQGlW1vk/YrKOC4uGBlYIqmTHqfWuf8fSXPh6zsnsQYzcyshlKZxnp1/wA8V0vhxRc6dE0khNyiqWcjHPrj8K2qT9pBTfoEnTULw2v/AF8jzX4pfD7Uda8Rw30BU8COQOcHg9c/ia77S7RdP022tMb/ACowuc4rYmdmuhFMyNEW4IqubCW5O+CZFjHAL9W9/wDPpWPtJcih0QRmlFc2hy9xrn2TT8yTyDbGRHFsyC3bmuS0y2+03QcEby2SCOveqPxA1m60rUkhghUKE3bGXIPPT9K2fCUsV0IbuJNiyrvVSc4z/k118nJDm7nfS5UnKKOx0uzdpQYw21R8zZ6fSt8lbWEiMFtw4xVbS5B/Z+Y/vFsk+9Ymvf2jIiC0Jxnqvfnpx2rkS53Znm1OapLXYTVr1YJXjChLqRW2kjr6DNS6YrvZEscOcbgOMHHP61na/pt3f2ls7xg3MW1sk4JrStpGjaaFWxKY8tnp/nitHbl0Omm/dILS2LXGxCQ8hK5HGDVy60SWCYOh+Ujlt361lQTFNQ2kSKoOWwe/eu3tv9LksoiuAQDnbzipqScNQr1p02pLYqaXp86mOUruKN82evsfeuvvLYXNk0KkrkfKc5qx5ahduBtHasW685Lg+VIxIBwvauRyc2eHOtLEzvtY5O4gkGpCF9xJ4wSBVbxTYxW8EbQSqJXXDRnqDXYXD+e3myRAyheOOn41wvixCk80rtI6ohAB69O1dNKTlJHr4Wq5zV9LGbpV03lNHJGHhIAII4JHetuwX53CMfLbll3cGuI8N6u17dtDLGkMa4KNnOc9c+9ddZzCK4JiJwCApx78Gtq0LO531Y31RleLPDFl4lnsvt00yCzn81Nnf/Y/+vXTKIHhjdRllXac8mmcXLyLIAW3E7gBkH1xVm6jVJgsZQhVBJHOT/nNZt3sjkaSdup0nhCF44Ji7AROeAfb/JrbntA8QSALGRyCB3ri7a8mikT96CIxnkdPSugs/ECSSNBJtZlGVKnBPHpXNODvdHj4uhV9o6kdTSuL2LTbHzbyQDGF3L3JrxX4w2V34qjjl0zcHVh5Zb27+2ea63xlq41e/j0+1YI0A8wZ/iP+FeQfDaLxGfHF42oJdbUZ1u2lGEJ5wo7YzjGK6MPS5V7RuzR1YLDeytOa953+49R+Hegy6Fovlysk13Oyh8fdLYGQM/54rk/GWn3X9tXSXemWf74nZKj/ADEg8ZHf8q7m91F7QQQ6fHuZRhpDzyeuPw4qnHZPdz/aZAzyd5CMnFXCbUnN9TrhFuTqS0RzCXXiC50+DTIU8gRkh5TxuUnpnsPpW5He2PhrTLSO9uJpJmJSNjklz1ODn/8AVWk42qASMHgD1qPW9K0TWprGTVJGC2anbFGdoyevP4U3NPdaeQ56bIn0y9utatpWt9y2yNzJIeDx61mX6a2kwW0jS5jc48yIhghz359K5fWtbSW9h0triPR9EgOzyYJPnmyTjJ/z1qWDVINAd7nTZJoUVMPGXL4O7gj8qtUmtUty6dOok2kl/XU2IrjVbe6WK4RmLZyCuD/+qur0K9iulZS/kSMpBck4J9P/AK9ZeleOtF1Cxsp9UuY40mOxXkwrHnH6GtbxL4fjlsv7Q0u6CYClChyrDP8AWsZ3vyzVjGrWUmqdVcrfVbGf48s9UvdHNtprICH3AF8Fjj+9VBvNudLh0u8juHjSHymkhA2qx4JGetSQ/acL5kh8pm5AGCKveLdLv9M8M3N/axtJOsLSKoY8EDPT6ZNJPlSi2NqFFKE2tTmr/wAFzt4Y1vSbfUp5dT1RkbznXb5aKd2B+Ndz4G2+E/DNjpd/cmd412u+cndjJ/CvK/Dfja6vb2KxuVE+9MiaEYCdcBh7mtT4njxHpdnpb6DHJcJK+2fyY9zA8Y/DrzWs6cm/Zze5lWoxmuWb3/Q7nxdr97pus2CW6n7FMpLyMMqWz09qsJquozGNsYgXAAXoa47w0viGaFU16504x7cmBgWYd/8Adz06VFDrGni4WD7cbeSKXBgkbaVx/Dg9qj2P2VrYunh6XIoNK68tz0i+js7/AE1t5Cz/AHQ/fNcZrlxFoQtXuiIxcMVV3PCAYrC1/Q9f1/WY7nSPFH2OMSh/svl4TsDyDz+Nd5e29vrkA0dfLuZogpkMg4yD6+vFQlyW1v3M6aeHfK3p18kaula1ptvp8dzqF5ZwRkhUMrgEk9Dz61q63qkNjYlgN7SLhAO+R/KvP/Hnw/07xWNLtbm2ki+xOMiJwvmcYwT+HpXQalYFbSGI4U28QjQA5AAAA5PXpWLjB2Z5/sKVSqpt6PocNqXiOw07VLPSpS819eNzg7gmfX6/yr0Xwbo0VrEbvC5fPlheg7E/WvELLQ5JviL/AGlOsjurEIpBIUYIz+vFe86D5lppcbDLLk7l7jv/AFrfEWUEo9TszByjRsnq2UfHfjTSvDWmzCa/tUvmUiKJ5VBJ+ma8f1xU8W+D47K8Lu8N15qMuM4I/wAf510uvfCzw/rniK98Q+JtRkMLS7lgL7FVfQ//AFqnn0zSonittAiRLOLCgD0/GijyRirXvvcvLoUqacLX63/QxtT1l9A0bSbKCBnErhHJ/hUDj8TXN+F5dSu9M1AvG8Ed5dk20DjaypkZYDrmux1/TDcXliuxQ5lRuVzhVBP68Vz/AMTNW/e21ratGlxp0MlxJdB8GMHACke/9K3g76Jav/hzvVueLXVnate22naDcPdsVtrdRuckkljgD884qSLUrSw1oWwby0ngHlruGTznGPXg1yVnr0Fv4Es5/EMZvTIqyMxAG4E/Ln8xS2fiHS9fe3uvs5t3s9io+ckD0+lT7F63WhDpOUnHoyf4q6jPYX+iC4w+m+ZhlPJBz1zT/HvjSLwlo1iIoRcSXWdoBx8o9fzqDxpr2iTaRFYalcBotwkjZkJKkdRnFPufCVn450W0uXuGj8tf3JXnCn1BpRSjCPOtE/vMnDlglPSzNPwvq58QaRBeJEyGQsNh7MDziu7ttJuHt4zCwC7enXnvXG+Exp2k3sHhrTZfmt48lmwTITyxp/iPxuljqb2sF0qJENuN4HNZVYucrU1pv8jGpGrWkoUvXU5XxJZWniXR4pmJlljH3oyM84PX0x/OsC51SHSbeWOyiCyW8B4X+HC8ZPrmrujP/wAI3oUdtqMiKXyuW4x7bj3psmjm48P3yFwC5LiQjrmuuNo77HopcqaR3Pw5Fw3hiylvpA0sqliwHJzW6IjAi7GPC/e9axvCLs2kW8LlVYDym28DIA6Vv39ysaKrRjdjgfnXDK7kzzKt1UaRmavMtugmk5GQSQOx7/8A1qzb+RWvIZrcrsZMbgOua0b+eCG3b7Sm9T/DjOaxzJN5puGgK24XGAOlaRWh1UIvcr67usX84suXYjC9Qe39a7PwYwv7aKRlI8sbc55P+c15VdXEtzfsZN+0A4AyBXsPgZYYtKgRFKtIu4nmniFywQZjH2WH13OjYHbhTj3xms2EiUv5kYAVvlOMVqevNU75jG+QyjgbgfTNcUT52k+g+8SM2zyMowoLZIrhtTijupVjUDzHyqnjB9Biup1i4M9gILB8mRtpZRnC/wD1xXManJZ2jGG5ctdRnerL0yOg9q2pKx6WAjKPqcP/AGVbWUoePAkLlXXHT6Vt6ehlPlR/MZRsAIxg+tYfifVn0q1M6oruTv8AmwUJOMU34c+IHvL92vo1L2484EDIZTx+YzXe4ycOY9yc/dsipY+INQtvit/Yq7JbN4g0ZK8hx1BP4HrXVa3qFtoUsBuYmWK4cqzgcI3Xn861dI02O7uprpIo47n5tsuAGHPHX6VPqWnRa7bCDUIPtEattlV8DPuD2IrBzV1dbHC58srX9TMaf7SqSWkoeI91xg1FbhlvDcSRvlR1zW7pnhey0tWjtllEf3tjSFgPpSTw2W5MFyDgtg8Y96XtE9io4iEtIooRWUTXwuwnz7cZbpipLqWKJXld1RAMux7Ua1rNnaQyhVWJOi5HX6f41wut3sniDQ9WsrJiZ5IsRYIAPPb86cIOWr2KjeWrRrW+u2ur213PpsgeG1cRsQD8zegP+elWtT1+O3s9jOy7k3bFHWuR+Enh3UdF06Sz1mb7IL24RtgIYoB1Jxkc11viXww8Ws3UU0Mk1k6gxSRnlRjn9a1fs4ysVGabUZb7nn+o+PP+JnK0FvL/AGflY03Aq7sPvnPseKs3/na5YwzrPNZaWjeYTGcSysp4X6e9dbcabH9igji0VGt7ZSu5osgDqTnvWZrnh6z17SxBdRkQF/3aoxQLxjPB561qqkdLKxvFScGr3OYOoabrmvRW97p05uYFYwu+NkhAyM56+3vV3VfFtl4e3/2pYNmf5QoHp1/PI/L3rI0/wDfafBqtkJt9s1ujWsrv8yThugHYEZrWu/BcHiHwybPVrmQavblmtpUcEbwPuvntnvVylC1zGU6qhJ21DV9C0XWp7AxWpWwtoiCA+Gj3Dd0z1rvfAWpSad4d+xu0lxbROrqJT8x+YY578fyryWeS48AyNq2qMG/tJFElmFBPmqPvZzwOv516R4I1OPXtLS/W3MAkiZjESDjbzWdWN490aTlSq03CS1R6PcXlnaS3q3ESpc3CLLCjf3SBx+Heq974sLrHDDbmTYvzZ6ZxiuE1mefXPELalb3du+mm3VIohkONrDn6HFdLpVpFb2cl3dOod87VB6Vx+zjFJy3OCOFpqCnVV32/Az7awv4je77K2tLRnLRrBEqbie7cZznvWF4h8aW9ssunWs91qWqREo1paITsx3ZsYAFdBdaxP56NGfm3cFhyB16Vz3jKDU7y3RtIZFuHctMIsKX47ke9bQWq5jp5J2S0R5zpfivXm8TrbXFlf20pdQYyh4XPUjsMV6D4lFlrFhFe6lBJBJECJJYUy7rg8H1Hoe1c6l14gtJIIbhZBIcZkKli3HAyfxre1zxFb2VslvqA2iZdp2HBUYwePzromm7Nb+Rs6b5ff1f3Gp4c1fRdTtpTpU06PCiszHkYPTI9OK2LSMw+JrC+a5aOWEYKR/clU+v0rmvA/hSz8PRPPY373MN3CqKHA5XOQfc81uaq4kiCwKA9v/q5AcZ/z/SsJpc3u7Gai5rlfU9Rini1HeFIWXAyR1A+tcH8SvHNl4FsIJdRQz29xN5K7epOMk59q5jwF47ttdmuLGCQxajbyMnlseWHQ/UGu58Q+H9J8Z+EjpuuxFrePGCv+sRh3B9f51yyp+yl7y0PFnh/q7vF3RQsNSgvdOstRsETZcoHSTbklemOelbFp4nNlbyxvACeTGc8Z9DXP+HrRLaaDRrWOSOyto/LjSX76gdCfTNaN1oI8lm+0ng9CM4q5KDdnsd1SnQl7lbqeFa/4k13VfE8qrclWFwYkiC7iT3wO3NexaHayWmnte3MbT3Cp/qlwDI+PugVI2g2FpeR3UkURmkIzKkQz+dcAPHkkXjDVBJBLFptuRDDGy/NI6nl/YGuhydaKhBbI6L88eSmanhHWNR8V6jcaxqNobKC13WyQbud+fmJ/DA/OnN4PsdW+3W09uWur6ZnuJFkzlQ2QM/TA/CtnTdQjk1eSG1gRLKOISsg4zI4z/Ln61safJbxGa5XKyRqdowfm9qiU2tUrAr047dDntQ0y1uBLpskKNaoojC4wAF9KxNX8Pf2RoNyNPUocFxv/i/GuklvIp5nLYimzke9dPZGHVvD9xa3aBjGvDYxxilKpKEb/ebVKsqCjNryZ4D8PtXkn1S7ttUjE9vE2THKuVbtgivWPFN7bXPhm+k0a8aza2QM4jXblQD8vH9Kwrfw7Fb3rSIkYDsHbC4LHP8AnNeUeGfGGr6P48uBcq8ytdMklu+dv3uOPat5RVeXu6NCxXK3FXu/63PVPA2k3NkJ/Eurkrqd6h+zxZP+ixY4Uf7WMVwHiPQr681m5nktriTcchkYgY7V7Vp9yviJZCzBTndtxjApf7FPHmSqjemDWcKzhO73JpuFO8Z7nlfiexufF3w+8P3EcpjvFkkNxb5wSW43Y9Mfzrat4ZtN0q106QOqwoFJOTvGO9dJZ2yJI0kcSoNwz6AH0/Gs2OcvdPJIwLKQDj09h+VNTbVui/UqlBQcmvU2dMuh/ZLPhSifMygc/lV6W6MsiGIHHXLCq1ogt4hLbsHjP3lIqCWZJJWEzIkbD5wDt79/zrHlTehk0nJsk1C7hSOeedjsgXJC/wARqPSdYF7pcxRowpjU7VO45zxmvP8Axx9oH263g3MiKCuwn7oIJ+vFaHw8sFt/CMk8LOHZ/n3tntxj2rd0oqF2aRgna+2hswMgu0iKCRd3OOOp7V7Lp0MFpp0TKMBI+WxzivGIGtrWeN7meKGIkbjI+0n6Zr0fT/FVpdwvFbMHjSP5Szfe49awxEHK1tjmzSnKqoqnrbc6lp4/s3nbvl25B9a8s8TeP7PT7mWaa5SIk7I0lPDAdSAOak8ReK3t4BDbl4ACRt6n868d8V6Xeanqsd3HFJIkiAYAyQc+noarD4ZXvMjC5c6cXOSueoWvia5urNprS7R4pVADR9hnt71Rv4ZLtVkjlUyjq0rY7Y6VmeDtAnsNMbzTjzJA+zsox61uSvayyrFIxaVAQABjP9K2ajF+6erSSh8K1MLX9LR9HkhubhWd8ESBTtBzkYx/nmtTwp4cHhrT45rli93fBRn+6g5C47fWm6npov3WNWMbKgLRsc8Z4zVLxrq13p/g+9v3kkF1FGkEDZzlyQM4PfGad3JKKJqtW52egeENYs9Un1uCAJE2lyiJy7Abmxk/QVImpTW00MirkT5Zl6ge4P6V4Mmn654l8Iyy6lZx6dchorl764fYJlU8M34cV6JonixNYmElptXRrCLynuG+VZnGOV9FHP51k6Ku2jzYU7yfNrc7SXUZmZpifLGeBweK4jx5r99YWCR6edk9yxRZCM7QB1xW9puoQakWubOZZIY+AyMCAc45pXk0xbh7a/UXcadSqhvm9qILklqjo5OkF9xzPh/w5q2uWCXOqPOtngBJmHXOcnHpXL+Ipg/jGPQtCjb7Nb4Ekq5y747n0HpXs2oeOrdrI2Gm2pR/L8smbC7O3AFcydVsPDVhc35iSCXaC87KCV+lXCpO7bXohUnW+KpG1tl/mX9N8PXkskMlwDEoKnewwSB6CtzxXr40KwlWAGa5EecMe/YmvP7Pxpp+r36pZXgkuSocsWJz/n0rYuZob63uGmRpZJGCcjJIB7VEqcrpzLeHdaUZVNY9kefaV498R/2nNJ4ggukga4EECqCEcE88dMd816ciQX9u8MJSOUkkAMAAfUHPFc14k8CJremWz/apIkhDM6q2Bg9OPas2+8PXWi6DDZaBq0Vxqds3nXMZf94YzxkjsOBWj5JpW0Za5ILlT9Det/B134a06eNrme6gmcyRzPJv2E9s/wCPrXANHqEN7sVsSIdqFV5I9T6nmuu8C/EBL6xNtevHBKz+T5JkwJcdwp71s+KdCTVtNkk0jbYyyAYm5+SqjOdJ2mEJNJKfyaPIvtN0+nPaeLYpLuzS8Vo5GzmFiDuAPXGMcV6NfW8umaPAumkxW5YwDBwRkE5zV3TdP0/TLGOxv7mS/vNgd5TCCrHPGcn6c1de3Go2+JdiW8eZMZ+Yt/eP9BROom9janGMNlp5nF/B66luNF1rSJZC1xpE/mRN6oSQ6/TIz9TXqa2txqGhF7OPGwf6wHv6Y79q4WyvfDfhTU2tHhlfUdUQLPJEBtTLfKD6+p+ldxZ6tJo9nPbQ7XideD/dJH9axrczfMlucklPl5YatPQ4rUrttKsJpbu6CySEKrMOA7fdNcRpcPxFGrX1mZZys1o6Q3KONgz0YN0B/WovEGleNdfuLy1uFRLCWXIHAUKD8uD1rtLS11bSfDVnbeZIXiA3yDPXpiuiyS3V2aVKftd1ZfmU/hg2tRafc2XiiKZWt2AiluH3PJyc49umK6LWPDVhr8GJ7ci4wRG/PTHQ/wCNeUpoOpX3xIa5v7+4SF8zIFfaWAP3R6V7l4eu2gaaW4QbACck4x71FW695bhBTjSd1t57mb4U0W40bQra2v52lliDIGU8AZOAKsO6QSeaEdlKYBYcde9c7/wmEurape2lrDmFRIiAA5BAPP0yKZ4T13UJbC/k1aM+XZwlmbGAcDO30NKUZ6ykOM2leRStfhk114wk1zSNTWzCgXDROpzu74I7V1fhHxPdNqCwyJIplc+Q7YIcqCSD6dKxvhn4rl8WveXF3amC1aQRQKpA/dFcHOPwP412GmeEtNtNUElrJLKI8lPNflBg/dx9azm+W8J9tDkm4q+nutXOkudZs7mVJbyAJOOBInUD0NU4ms9SnknsLyRkXKMqHCk46fzrN129htLnyJ7Wd2I4lj7/AFrC8M+IdFvbi6tbc4aCQiVE4ZWB7g9v0rGNK8bpGdOjBRvC6/H7jrTMbQGK6R59wzGFGTn0Fec67o2jal4nZtR1KNb8IMaXAcOQOQCfXGM16dHc2pdYrWdUAzj5ep9PxrxqHxNBoXxbWO90CG4murhEjuj8vUgFh7jp+FaULuTtvYunJxvK1v1/yPSxHbw3kBtYDDdMm2X0OF6Ul5II9ImRHMZ8wKT9P/1V55428Qai3x2h0zS5GNqCjPH/AAklMk5HtXUfE8Sp4RSCxDG4VUf5OrEnnPtgUlG6g31NKdRVFF/13/4BWhDGRpJXWQE8k9jXonhKzkewkfgeYNuW5AA444ryf4bWV3Pbxx3kcgkflVPOBXvatDpumxxoyBQMZz1PrSxT5fcRGbV3GMacd2ZsHhiyMQjmUlgc7+5rgNf8B22may2oKiu0n/LRkG7d6V7EMBfwrlvGet2VlZujbZLgchR2965adSfNoeZgcbiHWsru/wDXyOFhj8oxx2+7OSW7Y45rp7K0neAO8cchbnc4yaveFYrbVLOO6+zCMMeSP4z/AIV0/wBkQABFVVAwBirnVadmdGMzDll7O2qPnK78c6ZItuq3RtzMwQI4wVI4IPpyetWLiO7ikYRArLIMIX6Zrjdd8AXkbx2kcTXUrysITGOTkYGa9N02+h1CCW1JUz2qrFMxHV1XBP6Gu+fLGzhqj1KVVx93oypot9qsdqy3kCrLv25B+8PXHrXIy6BrvinxRePqTNZWKMFRYT98D/Oa7K51bTbFSslwqygjOT071qaPqljcTBUki/eHjAzj3qeaULyirXCSt7yWxHa6IiF7WZcfuwEIbJxgD8auafp8NjDNbR48pQEXjr9K0tQnhhkEEB3FsfMBWfcIq2zSvdCMow+Rlz1OM5rBNy3MoylJXelzgvG+mlLmKaVJGgZfKcD+Fs9fxqt4Ls5LPTnitt4gWQ7Gc59eOa72eZLiEICJw/8AFjIx/Wka1KwRwwfZodxAzIwXP0roVV8vKzeEuT3pGXpukDU7pZb5lAjHORjOK6K+0u3MaNZGGSKIfMYjkj2qtLblLSeHOxZIym5eSM8Zq94U0m30nT2V7gys+f4SoA9v1rKcutzOtWfxJ7bIoIAhYI0jIFDYx1rF160W7lSY+YgwQQBjIFdTbBI5ZUnjzBMdoOAQpPpS6h4fWRpkG5VZNyBXzg/SpVRReoQxChJOR5r4V8LzaPr95qQnZorhcKhctkn1zW74gFn5ds+oRxSqjqWR29O/HXFPiuHspBC211UYDEdQeMfnXP8Aj7wpe669k1vNtijJEuSeQSOD9MH9a6fiknJnVJ6XijR+JWn3fiDR9I0yzkAs57nfOQf4dv8ALgn8quanoVl/wil1o1nmCeKDdaxR9Hcfwn1zVjQ9Y02SYaNFexSXlrDzEh3EDgc+n0qa/t08z7fMxzbBgABgbjyOfwqFeNo7WOXljZ8r3Z5b8QnvPCnwp0nT7Z3ivtRujPdmPqAo+VMj6A/jXUfDk3V34Lsbu+kZ7lwcO390Hjn1rO+J+qXen2FhbLpP9oSXR80l1LCM8Y6f7Pauh0+7jfT7NXYW8axKgixgLkdBWru1fuXhaLjVnJP+v1OVi1qO38R3aLLLJHJcHc8jg7D3CADOP8a6fxNpA8SaE9m9y1vG5Vi6jcSR0BFZth4WabV3eWSOS1fmONY8Op9S30rpZ9mn205YkRRpyPoP8Kc5RuuU6Wm4OMzgIvAEzeItJi0+eO1tYsG7m3nzSoPzYXHoMV7T4gk0mG0jt9KTcFH+sxyR3OT1rylLs+IWj1G1lm025snWNrgn5XUclTW9Z31nrltdwQTNPEBscEEZDDsampCUrOT2OdULzU27eV9C9aa99t1i80yFJGjghVvtAXMRJA+UMO/PSs7R/C95a+Ldb1aRvOmvo0giXsi4G7Pr91cfjVnTNLtvDunx2VnmKAN5hVWJyT6k1o+I9dk0eztYrFwbi5VnX1wq5OO3eoe9oDlHa9mzOt/A+lRa5HdCy8u8QZRy5+9/u+tYnxT8QNbaTc6dZ3f2aRI9kSBuZPmGSPftWj4Sur690TzrozRzsSN0uSwP1P41Lqenacl/a6hdWsMt7B8iMV3Y54OPXNUtJe9rY1dK6t1/rU888ceHtb026t7PTbu8nvtStYjNEXJ8tAoym4+9dRoUUXgjwtJc+Ir8ebI43htz4OOFGOprpPE2pfY2gkupyskg3GTbluOPy5FcN4m0ifxTeQ2kFzNJavIrDYOjZPJ7dDVpylHXYxjTcE+V+9b5Homg6Xpni1rTULVE8p4y/wBo2Dco/HpWNpt9qh+Io095Fl0yRmhYHBUYHykH8BXVQaB/Y/gn+xNLmKsqAMxb5nb0z6f41Q8LaEljeyy6pGqSybWiAbLJjqc/56Vzqa95p6dCYVr83NtbS3fv/XQ37/SbiwJLwbgRknqB/nikgdXhC3CfIc5AGDXori21C2XcVyw49a5ufTLX5gJI/wB22HAOCK5o1b6M86jmHtFy1FZo5hfClndXqajAokngVgkmSCobqMVJq+lSzaVcpA43su4rG3Nd9bW9ra2QDDaHTOR3rB1ryrW1N3A77IjiToMA+tNVZN2CnjpVZ28zy34feE76O/uZ7zajSJxF18vn17//AF66Lx3qGmeFvDZF5A00F9ILJUXgbmByT+Ga5O11LWbLxwup3d2V0uInzmJGwRnqMd6n+JD6b4otYNS0q78zS7a7F1cKx5yiEDA7cZrqnGUpxctUdlX2s5qNrIu+FvCVl4SkmtdMkldpkDMZTu25HGPzq14i1a00NPt2pXEscZYRhkGQpPQn0FQ2Wuw3Ggpq9uryC5QYGOV9M+wrhp/ElzdNIt3FBd27D97BKgZMelVGnKctehuly2S7Hp+m6w1xFDdRul9ZzL5iyD5gw/8A1/yrB1P4cWl74qXxH4bvpLG8DBrqwK4Enrg9geM8GrOlXVvYw2+m2lsltHtAiQcLHk5zj8ataxrbWl3HJcfPdEgKIxtLY7is+Vqd4aGU6Km09mv62Mjwf4oiu9Yu9NvLObTtTtWO62lb5sA/eB7iuxW3gaGPVJIYGuY3IjdwCwJ7j0NUreOw8TXMF+bdY9esUKyYXaWRhzn1rgPihf3vh7UdOvoZJzD5hDwq3yMoHQj1NCXtJKOz/r8GTBucbTeq39DsrNdOuNel3Rp/aSxl2lAAkYYzVrVJFuFTzVbcUVfYcVxfg+0m1bWtI8UQSyQwXBJlhcncoBIOD3Xj0rs9Vt2VSyOvlqcqxz09P5U5RUZJHTFrnX4Gt4RtoxebowXYRll2jkH0xXb2Nk7hGlK7Ac7SM59K8q8LeJbWw1SNDOjE5DYPX2r0CDxVamG4urzFtBDhQzNwc+tc9eE73PLzOhXc24q6NXW7R7mza2t7p4GPGU+9XC/8IJqiyx/vkdWfLvIegr0DQ9QstWtftVhIssW7bvHXPHFaJGOeTmueNSVN2R5lLHVsJenH8UV7aCKytUhgUKqLgYHHFIkzkHcT14xjkVOOVIA49B3qIpKPuMQvoMVn6nHe7blufN2heKL1PAV3qtyGN7FlVdhyDnArnfC2rT6R4X1DVL52eW5lJBI5c46/mTXod9pFtPotxpqosSv8yADofSuR1NIbO0i0xIUl8sEKGXjPc17MJRldW3Z9lTp80m0ee6tcJd6YdYvp5FBcqIU6n0Jrb8D+K01EmztopIrhEGHPPyjvWq/hManok8EtlL5YBkyhwQQOMdq4fwdFcK9/Z6Rat5sgwZcfOoB6D0zW9+b5BUnKFZRi1y217s9v0y4lkt4FUS7wx3SNzgY5rfKtdQrEVZ1ZdpB4GPWuAstU1bwh4VN34kt2MSMEhRf9ZLnsT2ArY8B+MR4yF/BBaGynSErGd+/Oehzj9K5ZxduZbIzq1YttRV2droEunPqUlhBdQPcwxq5t42BKg8ciue8ZeEtW1nWpmsgqQRINhcYCt1yB3Fcl8Ifhvr2i+JpdV1eQQsiskaRSBzKT/E3+z39a9mtvE1kbN2lk3XKE5Tqc+1YuTpzvTdzh5qrfPFXZR06wWHTraGdlmuQgj645HeteDSV060e4uZg0QO7aw/SuBvdSvE1BrhWJO7eqqeBznp+VXL3xNeXiJDKQI5DuwTxxUypy7nVUwVaVrPR7/wDAO0ube31GylFimAfmRiMc+lePX9v4tl8Z6kto17HYRWzESgnCnZwo988CvVNKvUXRgxYK2AyjI4OKTXBHNZQ3qHaJgB8hxyOopU5um2rHJBSpycHtex88fBiz1SDVbmLUjJAssoAS443PyeM19AeKbXzNDa2tCIJDGwMmOjYIH868k17SdT1W+0/U7FgbVXcNyFK4bg/lXqdvNHf6W0Tv5kmMMwbOTjFb13dxlc6Z03FQSeiPGPglo1jYXN/PK/2jWsskjo5ZFjyO/qSK9J8Q6zFpnh945p43WaUO6qeYgWA+b6nFUfCWi/2NDqB8hIZHlI4OcqO9ZcWhJrGu6tYTO3lXrywliOg/hOfbAx9Kp8spN9EUoxpqKWy1LPijWbKxtbCO8liWe6Xy7ZSMlyB646ZIGa8iuLjWdS8WzJK8uYgFEUYOxTgdP8a9W1HQLdYdOt7xYbmW0QqkzLvZDnGAex4BzTfsel2MV1eCYRtGNzs75xzyfzNbU5KK0OzkUkuaWl7qx0mjq48P5Eii4aMZ2j5wSMVwHivxxDaaidEt7JdUTyvKuJQSpLkc4wD0HWsPTfG179oumin86O4Vgi7D5aEDoPXr1rPsdGstaKXFmbyxupCfMaNiwJJ5H0qlR5G3Iw5nVb5Hua2j+GtPvLu3ji1WZI7pWaK3JJCtj5vY16NoVxYeBdJ+xzeTPcXEp8yWVcmTJ6Y9KyfD3h610e7gvZnEkiLtRRggE8bh6eho8XaJHqkitbZnclSgbIIxWc5e0fK3odLo02+VrQg8aaxFfT3Nlo0to9+XVDbPIFlAbGNuTzTLLSbqLV9MXXdqXNtp5iMBYE5JPTnnjHIrkR4a0nWvHouv7ahivYmUzQQtkh1x3z7c49K2NVsNTm+LOj3EzGTTmhEMTxsSCVQ5yOxJzQnZKJz3kpJ7q9lbXTudjBf2Nm6wrOjMmVEWeR+dZVh4p0q9gu7tvMEVjcmOQPjO7PBHtnpXn0sd63xEVLq3liiFzsyoyoOeD9K7GfQdP8L6DrF5coLpZZVlkXIxuBztX8f51ThFW8zfncve2Wp1/ijSoNcsI2VvmI+RxxnParfh3TbLwjbi/wBakigZ2CQIx6t69PrXI+BvFE+o+NodGvIFWLZ9pQZ/1O0ZK/7XQ1X+K2na94q1uwfT4z/ZqKwLBsCNs8ls9sVlyu6pydkzmquWtOO3X/I9jihSUmbzN0W3du7HI61yvi65uZIkeyQOocKNvXHY47ZqhBNLBplnbnUDJZ+TtLxEMshUbeo7ZFcj438bReGporaONpLiZM+YOQgBwM/hWdOk1LTUUaSo/vJPTob3jDVtatNWsnsb2RLQ2qFNpKrvHDAjvzisbVPEeop4t0W/ZpEt79Ft50BOPMU4P1zn9a6rw+JdW8MWketQDzZTuDDClSehH1FT6j4ZaLTY4rW2WU20huAW5KAdCD6kjp7Vopxh7slqhQhGEknodb4k1waboFxc3G5xbwlztxkgA9vwNeV6D8RBrWuz6I1hJDDdWnnLJKwIIA3cr9PfNLNrcureNm0rzGWzht9zo77g2eBn8xxVTytF8L+IGurXQ55b66Hllo5CINrDk49amnSUFZq7ZNPD8kfd7/1+Jr3N1pF7ZG3snhu2/wBRIsZ3DB4xxXP6xCNA8JRabbWaQWzzP9vG35iDwqj9Oa5b4oQDwldaXqHgxXtrO+RpZQDnY6tjGO3Wt/wZ42t/GGtRya7DcpqEEAiZIyDDcAfxMOze9ax1V1/VjaOJhKoqcou/X/gd/M77wxpzXPhTTRDBHFYSgoI2X58dv/115p41uX8NatcRaVY215aR4acsxLLk9CAePrXr2oazaaXpsYuGlgL5CKg+6MdgPavGZ7SHU/Fl9qOiX89yVkUFNvysMcrg9f8A69TRbcnJ7Di51JOMXa7O68Ea1p3iZUuUt3hngjG9D93njFTeKtHfWir26uDC4wEbBB9QaTwt4h0qKNrBrA216QBJGU25PY4qyvi60W8u9Pt1LXMUgEmMcZ460NS57xQ29bMl8LW0ujTZSSVpdwy8uST7fTFX/HbaNc28d7qqI8ETq3zEABjxg5/KvPvEXipbLx4dK1CaWGAxQ+SI1/jY5yx7dhXUeNdPl1PRtZ02MfvpIQ4PbdgHmokrtTYlGE/fg7tXR02mTadPpSX2jXFvLBbYRkjAIiGemBx+FW73ytUsL6GAhUlVZYyOnvgfTP5V4z4Wma0+D3ir7E0ovNrLLhjjcOMj0rrfCNvqGk+BNAtEmtl1iWyaVIrgnG0uSue/Q1E6dm9dn+lzn5v3nL13X52/A5uLwtfW+uJK+2OBX3Fs9QO2K7DXPCd5448Iz6Vpl2trfCVZV3E7XAH3T7c/pT9eN5baA99JGgvFhBlhXn5u4B9qzPh94jvLqK4bzDFNGN24cDFaz5qkLp7HZWXtqTjHc9J+CHgbUPA/hmW11e8Fxe3Eplk2uWVOAABn+dd/tm804ZcY4Jrz/TvG8kcS/aiCFPzHOciuk0HxXaatMY1Gxh69DXn1oVJSc5HzGJwOJg3OUbo6DLKoB6+w4qMMSPmMmfamX8wht3nbDIgzj8KpWuqwTQq6tgHtgnFYJXOONOUo8yR47BrUOoC5hWAwzWpxIsnX1zXhviHxrdy6pKliojHm7VI5JA4xXU/DBr7UdN13WNQkO5iFeZ+GYD0+nFTeA/CemS3huJpI7s7i6ykjgg9cV7UFGF2j6xc84Xpuy6nq/g6f7Vols9wkXmmIF48cgkc5FXdJ8P6TbXVw+jW9ut43zNsXBPrUHh3Q4dHne8lvRMWzwtMvxZW8TXrTSJdu2VKsR9K43rJqLMEvaydro6LVtGt/EGiS6Zq1uUD4JJHQj0rgdC8K6Z4BS8NpcfaruSTcidRGM9Cep/GpZdRuJpN880k0RPVmyF55/pU0tqsoleOVXcrlQnTNXCMo+63ob0cF7OV5vQ1ZPFF9NZSRwRRQFgN7p1x7f/WrEtGt0uDHCQ9xt3cnr61TWZf7SjtFdBKy/dJz19fepTbwxah5jB4yIyEIJIPYn1A61ooxjojvhRp0k1FWuV11J7OY/uFkbJbJBJwSfwrV0Sw86BLssPLkyTGcEinW9oktnJbRlQZkKrOTkqew+lc9pNy9vN5UrbcNhioJUEE09WrI0t7SL5NGvyNyZNQe5ijhkAwcFBztFWvjG2oaf4OFvo+4zWsHms6HkE9T+GSfwrR8Mxi81KWUkkjlQBzxT/Gl/NBfsY1DFo9pVj39celZczc0ux5WJk6lWNNdE/xPJvhnd6vP8NdUiIFwEcrCZDy2cEjn3r1Lw1pQsNBj+UIWG9uerHkj9KTwuklyPtASKJQceSifJyOwH41qapN5VuQgJA4I9s9aKlRyfKiZJxkqa8iARHyz50iFnPYinWsXm2d3cWUSeexOHB5A9vwrH1a+t9M0qW8uE3jHlxIP42YYH6Z5rn9L8UzReGb3UBbRiW2/d7EY7XB5/lTjTlJXQS1dl0Kfi+zZLxLa01O3t7+cF47aSXYZEBweeg/HrVbR/A+p3Wi6hBq4eH7YjIik8jHO786zPilrPgvUtJgbU4ZpdXOxVe1O141bnHPB57VX0/xtfjxXa6Jokkr2MUaxNGx3MXUcnP14rpip8tlob+2nNuEmuxf+Hnw71LSLHVbO/eExzurQSFC20jIJGRxnI4rrY/B81rLDNM00s0APMabc546ZxW9Z3upRxRy3sJEoHG7nYPXFXtLub+8nnzPECP4cYJ/pXO6k1qTDnoRtCyijnPE/gyTUdLSJLm5soyVd2i64H8P0rlvF8D+GbWa/sbqR7yeJIoRKzFSVPYetej6W8w1N0v5pAS3OTg4z9elS/FfwaninT9JTTb9bS40+fzgzJkMOMg+9KNZwkoyehjVxUqU1Get+vY+XrGS6igk1OOy+y3BulM08UZCkHk59OR9Oa+gPD8I1HSNPuhIpYxgq6jHQetR6z4VGjidp3jW3dMbn5UhhyPoa2rO1tYvD8RsXRYY7YGJIiAq9iPpWtSqpR906nVUYJQlddDhfGWsaXHqkejvJCyF0N1Ocryey+uAc5osNLsfEOkXOkX0rm1MqtE27Dd8EE59O9a2s6HpV4n2nULO2M+QyOU5z6k1yeu3MnhnR2i06SJL2SQeX54zkdOKuNpR5VuNRkotz1R1vhzwdpfg+1m8RXN7MWhgkgR7hsnBzuYn0C56Vp6Etj4k0GW0guQ2mX1sZCCpRynPTvWLY66dY+H9lPrcUNxJCsqTKoJRxnGCD+tcVH4vbT/G2n6gI3ttMWI23kwAENuXaFx044/KoVOc733OdxfK2+vT8j0ez03QtB8Mww6NeyT20LOFVmDBW3cjPoCelc3daX4e8UNINTwBbAN5ynYcdwT36irOpjRdHWawubhovt8zzIW5USMRwPQZFQyeFngtp5IJ3kmKAElcID9P61UVZXbepqqbUeVs6yzksbi2RbKcGGALHgfwjt/KuoupTaaQsbSDa68kemc5r52TWtd07ULbR7CEQxJKfNZl3Eqp5yegHWvY9C1K5vvDtldX+AVQqeOgyT/gKzrUeWzvoZTi6nL5MkfSdGnMszRhb2eMQmbgFlz0/+vWX4m/0aGw0+1DCN8RqQoPK/dX+dXDJHZbZLlkYSDKJxke9Mh1Ox1WPzUEcr2pyOwDdue/U/lSjdO+6N+Rp3T0Keqx22maLqb3FuL4W9sZ2tSMhsDOR9DXD/DTX01u3u7tdKsbeWNwq/ZIgG2HJwe5+tdDoDLceJ43luw08jP8AKvzDaB0J6Ac4xWBpHiYy+M307S9LttP0u2kaOQQqAWIJBZjjue3atVFpteQve9tG73WxLJrEcuoPonjI3NtNK3+iXSIQmCeFPH05/Orvi3w5d+G/B5j8Nxg6q0ySMYMlm+bIPucV1F1oFjqWm/Yb5vtQikLxzNwyj0De1U/Edrb3L2E15fPb39pGEilWXHmoOzoeD9anmu1bT+v6uR7Obk+Xqa+lWdleaZpmoeJIorfWoLfF5LGRlG6gE+uPyzXA/CG2t7jxR4hfUopFuC5mRm+bcpJ+YH0q5d6dfRTTppd5G32h0ukjzkFcclfXsfw9q2rrTNRtvA11NpkSyaw0XkxNOQpwzAtlu/FJrkT13/AzlTcHq/68i14R8WaL4k8WX9q2ixH+zGURyzfM8ig4LA9sH+ddbdwK9xfXqoFATzcLyRnkD8h+tcN4B8L3emRxz3rCa+lX55F/i74+g/pXpOoRrb6ZIgJIx8zHqxJ5NYVlGLtEirFUppRd2/8AM8j+D2qwavoniXzLRbdBccqUzuDE9fpjp71Q1dNTT4wWcskbSQTWyJAoGBGgByPzyfxr1TRdFstP0+b+zFjja+laaX0Zv6VPpenwTXEk06KJEQksw5B9M1ftUpOdv6tYcZqK5pO7X/DFbULGKfT1y6yGQeWyDn1rDs/Di2FshtFMZn+XGCc+38617UwzWwEEhCrI2SBzkUy+v3t5Y1kdvkIx6g1MeZaI6KbntFmPrln5CyKo+VExz6ivN/Cfji+j142lyiQ7z+7K5BHPA5r1qbU7eXeXO4seTt/PNctrui+HrG4h1j7IyTE7f3ILDPrgdK3pStpNbm/POyUjqLjxjcDQHe4nOOVcY5VAOteZp8WXVnHlSqAxA5HI9eldxpkVnqmnTJA6yxSqUfjG31BHY1xsnwvsRLIZJ5clicRj5QKdKNKMmpozcIQuqSRe0rw3qemRa9bX0/mQ3eY4T0UDoMAdO3T2rz3TtfHgW/k04QPO2/EsxIAUccAd6+jWigvVywRwMe/NcX4x8AWGtTJcOWRt+6XavJHWop1021PqcqdlyrRnTaVcxy6VaT25zFKolXI5IP8AI81X8cXUS6dZRGdFzLloyPmI9vzqbw46W9t/Z4RAI1Hln0A7VzfjiwutV1SN7ZFLINpHcc/15rOnG89TP3oVbro7l+PSJ7bQ53dVCtteMZ7H0qpauyxupLxrjAOea6cadfyWMCBPkjjCqrMOQMdh0pmj+F21FJGvHYBs4UcYxTVRW1Z3xxcFByqM8/v7NbPVRdIsjXBK7sn/AD+VbMavf3iG1iMUSnARnJPvz/Sna1plzb6g9sUJPRWHcU6CCazjDTo6YPyE8AGtb3V0zvlUU4Jp6jvCOoRavqN1BGkqZVmQ9NpXjPP+NVoLeWWVnChv3vzMSST6GrOjaRaWV0ZLNJAZQQ7+hJ5H0r0y5k0Lwp4ba7vjFHZBQXd+S3Hb8aznU5XotzgxmMjhZXim720/MreFbez0rSLjUpcIIoyzMey4yeK8ZuPiBYeJdZuLRbeaW9L4gaJRtPPPI9q6fX/Gln4j8PiHw9byDTLiXEoJ2tIo6gn+EVleA/Bq6VqP2uCDJkO4A9QPTPtThFQTnU3OShSnzPEzdr/l2PQfB0DRaYvmIgYnOT97Pof0pddEhkRUSPLEk4P+eavWYQW7Yb51O4hTjms+G5/tDUAvUI+D9Otc+8nIzTbqSqGH4+8P3t7aJDp7Dfs/56bNp4AIJ+tQnRW0vwtp9m4guHky1xIGGGfjiqvxe1C5TQ5TbGWPfMIyyH5QvX69cVzOnaobDw7ZxXcrSxB2kRFG7G4kZ/T/ADmuqnGUqad+pph1JyTkyTXPA+gax4jt9QlV4rhVVZdr/IzL91jjvgAHHFSfADwPcab4xv7zWIV+0oreRu5BOeW9/wD69V/GEN5caXpuowsLOwC+ddBjsY4PHB5Oau+E/F17qWny6hZ2skDWU4WFhk+ZGRg/rg1coydNpMqpQhUTVPR6/j1Poa4hjktZPtQQcEk4GAOea8VudfTSLie+u3ZYUOEOT82eMD6+1WNX8R3eo21s8kssaKCrxj+MHrmsGKS38Y2urQ3kUI0a2YRQvGSsgdeS2f0rCjR5E3LYxwuDqYaL59bm2PGEk2kG80iJXmmUlCQSSQSD1965O28f3tprMdh4kuzJNO42xrgCDPQE9DWxo9ouiadb2VmxnhjUsWb1JJPXt0rz7WrGx1PxObrUdTtoUEgMYTG5unBrppwhdq2h2ujZJqKTPdvEcY1jRIVMoLR4Esbc8ev615B4p0nXND8W6Jcaa9zPpjIYrhI8hQCcnI9MY/Ku+8P6rFqmbdSwTcAHY9OO/wCVO8Yaxp2j2cv2pxKI+COMsccYrGHNCXKjJUlBqDfW5qWcAe1aB41YcBSeAORyM/yrzX4k+DtR17WLZ4ZIoltwVcMTuAzkYHQ11vg3xIni3w1qNxZwPb3Fs0cbKxDKwPT6Hg1BLq0janfNevGIIo1ZnY8KAMH+Qpw5oTfdGkbVbp7f8MefX+o241zS/DSF4YFXyJzbrgNI+Pm9yCF/OtHwAYJtZ1K3WzCQW6BoGmGTnP3iemen0xVzwjpOn6v4uk1O8RTOUE8Kqdoz6+/au9mtoIElWxggjkYHBVcZb1PHNb1Kij7pFNNz5vU8zl8L69da1dTa9fw/2LFL5sZlOVHPAA6g16Poh0m9uvso1AFgRujBHPofpz1NYUdzL4u0a80LXYHbTuULwjY8bDvkc8H16io/AXg3TvCkonVjeXgyglORmPOcHPespNtNS6dilGcbxS+d/wDgHpQ0JXae1SyspjOADLsG7HpnFbKaAg0lISQqINuwYH+fpVe11RYYkuIVBY5G1zgD8R9aw/EF9qN4jMgQqDkIG/L/AD7Vw+9J2PKca85WTsl+ZS8Q6OxiACqyx8BvbHauEvLELp9xpkccsYvFZWkUfdPQGu78NnU7iKaHU5lFvGd2ZAMhf970q3d6josLyGCOIrGPmmkbIGfYV0KTj7u56lPEOC9nNc39dTn/AIYfD99E8NTTztGtwF3rnOXxnB56VyPg3w5dxLfzXkeyWZ2keVjgcknJP516YdZ+22Qgt2iS3dQgkXPTGK8+n1C9XU9YsfELiz8PxgxWilwpmyPvhs8k57dMgVcJTcpX6kUXUjK8t3t5I6TT3hMfkNMCVO3cq53HvzWN418N22rQW4mtrm6lj+TML7G+hJ7UzwC/hfQ0u7fSR+9uvmYyzeYI8Z9ema7MX7/2efJumkhjXcGXGMfXGaJOUJXRtKU38S/H/gHAabaXFh40sftETWlpaaftijRSQpzgLu7n1P1rc0fxqvi+XU9Cms3sDavxdg8MAcZ6cfSqA1+bUtQWyby5Y5W2ldxZ1BHXP61L4c8O/wBnyXFyLq4uGePy2WXGBg5BxxVSimrz3/4IeyjJJvdM7LRoJLC2iiaVlZ87ppTktz29BWJq3iw2/i+TwnJA7AWy3C3LdJAecD0AP8qludXtjP8AY7qdGvU/5ZdSo9Onp2pNWfSb7UluEkhl1PTbcwzBeSmTuCn04PNYKOt5f12Zz8nNUjJ+Zu+DtVjvbee1KL5to4jd1P44+oq5f6KbkXR+0SRxOOqHkc15T4B8U2dp421qZ7kJp1xGJyJBtAYgDGPXOa9gS8ikt1lt5A8Mgyrg5qa0HTlfuc1VThNyj1Ocmij0m3SCEDaE3ZHb3NPt7MaxJvBBJTkn26mq+sW39oGTEzRMCFUgfStDwAkouZbedTuVSCSvUZ6/SqvaHN1O2b9nQdRP3kcp4ms57RX+yJtkHyD8DVK0Wc2iyOWDffKhjjPbiuy8ToLe7lilBWNj8rN6/WsuVbcCJHYKHGF/2jWkJ3ijro1+amm+pU0jUoYbpXuLeLzHYBio2lhn+Kup1S0FxOk1hDiJ0BO04Gef/rVxt3biG4D7l2npj9a6zS3f7BCPPIAXAzWdVbSiY4mCi1Uhocd4A8QaTql5e2elTyToihmkClQpPbnntXVW+safJctax3kVxcqCCiNlhj1xWZLpekeErO81Ow03aAu6VbZcuwHt361heC9D0TzZfEmgLLm6BMYmBV4uTu4PqQaTUJXl06HE5+0ldnWxGG2v45QUCTsUXf6mtm3WNUeU7QR82cc/WuI1nQhrd3Yy+fPHJbHzV8o4Ge+R710scwtysckm6Nhtdcc4IpTirKwq0HJaPUg8IeMbbxJfT2tnkLCzDcTwcHB/pXZZNlcMyHfkbmHfNc34T8L6V4fmnvYJF3TEltwwq55/OtwPC+8rOChHDA8fmKzqKLl7uxxT5ZOyWhhpKl9rryvny40wSRgZ9/ToKm1qOG5NvaKE2Fhlh2XvWH41uJbPwndSaVl2kY72A5HrWB8ItS1DVYtQn1JZTFZhRHK65ByOfyx+tbKHu+0vsdilrzrTl2PUobiBYI4La3CovG49/wAK8p+Ouh6nrb6Z9lYS2kZKyW4kxhj0OO/eu+/tLyolEBiJIO5uhBHNZ9tYQyyrPfS4kLfLF1IHqeeKmk3TlzGVKklLml/nc83W7t/h38PY7jUoVlneYtDb5wJJD/D9AOTXZfDvxG2paGl7dxxx3MigBEB24PNedftGCWTTbPy0/wBGt33nB5XPTP1xWj8D7m81Pw089+g8uORYY8DqoH3j9M10TSlDme7N4z56kqctrKx6i0M91pd1LbSmKQEjeo5+bjNeMeG9W1Hw78VLXTtYvp7jzGELPJ8qlT0IHfnvXu0SSC0Vd67P4gBncM5zXjvizRdJ1LxZPqOmPKmpwp5qJJho5WQAke3FRh2neL2BNybS2/Q9N8QaRDrDvYXbMbd5BIoU4w3Q1yXj+3h8Lrp+nWVsrJOhO9kyUVMfmcmuk07UjcWdrfGF4iyB9g6g8VJ4kji1zy5dSiRoYFIUseVPtU024SSeyKUJxmktupwfhmaTU9Qjt9XU3lg+AQ46Dt/9eus1OKLSQ9lHAkcUa5j8pRgqT19qW2mtoRbwNGIIsfIwP3h6+hrd1mwj1DTVu4xm8tUPTo6j/Oa0nU95X2NpSdOcebRbHE3VhcTwPcpHmMAAkDoayJo/K07y42+zWkcgmYr8oYg8k128zpFZrFFKVllO50zxtxkcfWo7vwpbaz4Ya3GGWZTkBgpPfr2pqqo7nVLEqMff+R5v4xv9Zie0utDK/wBnTxnOFDK5B5BP4jise50OdFtdXfTwILhVJhyQMjqPbv1r3jwV4dttK0CLT5rfzAhzh/n47Y4rauNCW9kBlUhAgAXGAAOn4UfW1B2SPOqYyPM4yeh5v4Zs7VdPN3bB43mx+7PG3jgVleOvBl34nuLKCC6jgkiPzmTO0qe5+leoxeHmTYVKhc5GBUt9osUsc0r3SM7IEVl5XArL29pcyKli6T925zPgfwxp2h6Rc6LaXbSTzMHlmVcKXA42+w5715/p/hbXdO8f6rb6zG7addqSsrjKyLuzx+ftWf8AE3xjqej6/FZaLewmKMbXWEhm3Z6Hjj/69eieGbvUNT8PW15q0csLPjaHJ47A8nvz+VapTivaN7lU1apzKX/D/wBdDZi8NadbwW1ykDRy28GF8sfwjOB6d6z9JljutSa1MTGQJ5mAe3p9auXWuwWMCw3s5AdgAGbAOO3t+FU59X0y11LIuoo7wphI2ON2eOCfrWaUnvqOLnFST6lXW4Bo8k76YieVKpmaQk5z/dIA5Nc144XVNQ8NY0xzBrCeXcJHFx5yjqg9+Qce2K3vHcdzphXVdMvzGZbcxx2ssm2HzfU0vhhdRm0O0fxaLaS/JLpJAMgr1U//AFx7VcX7qkO7qRtd69f66nVeGI7iXQLJtQRoboKDMjcbG6la5XxF4puINQjtNMhVh5gX7u4k56fT/Ct3UdUbz7COOWJGZwFR5QnmNjjGeCfasKx1bTZPGNzHY2fkaljZNIBjHHO3Pf6VnBe85NEQpScm3qbmrJPf+H7nT5GW1u5YmjLIe5HFeZz2V/4aKWNhpzXqXMqi8LZ2gBQCwP4V6NdWt1qE8s1tdlLkcFQMlxnk4/z+lM1GVILj7LJMueVAY/eNVTly6Lqb0oqOi3Zi3WoR6JpsskUayukbFI933sVxNtqFn8RQ2k6hDDEQC0Msb5dG9QOOK7jXfCcWsPFcTTBFjBGCMjH6Yq14a8A6do9xJqFsgUtEQXz0Hoo7ZrTnpqLb3CpON3zPQ8osXstF1qz8O6GIr6cyMmozFS21Fxxk8AZySfau98N6iLWNLCMOsMm9oGkIO5CTtyO3GD+Ncdc6ZZ+HfEd/Fb2jSPckI5ZyXkD8sRg4wDgdK6/TtLlfVN90wTqVVmOQoGBitZaxvLqZ0ua/vG/apaWMxlS1t0kkHLKgDH8fwrc0CaGa+WGWEKhwdx9BXJeIJbWDTlub+Zo7eIh/NX0Bqx4K8X6VqupIbC6WQhvmRgchScEge1c0oOUW0aVYJxaW9izfaLo3g/V7vxP4kufO82d3trQKR8zEkk+uOwrmPBvhhoNd1zxDZXIuNC1dJLiByxLoxYllYdiGyK3fin4evvEt+LWAgskqmPc2ByOMfnXTaJoQ8L+BmsDcLM0CNuCnJ3Oef51HNampN6vT5HBFcjhNu7e3z0PJrnwYEl10QfL9qtkS2DHO48En8Gr0j4fWOrWHgCFPEKKl80mVI4JQHiua1zwxc+LtQ02Wy1lrKztW8t4thyHHJI5GfSvR9ZuETShH8xS1jCAk9fU06tRuKj3/AE/zN60ryjCK66/16mI+D5jHeWLbhgdfpW54OEouZLhwTsjO7PBx/nNcUmvW1yYNsqq6LgxbhkH/AArQsvF9noEJ/tCSRFmOzcqZ9cdPxonCXK0kbYihUnScYrVnqL29hrURWaJZFXqG6g1yOtaJZgebaLh1JC5zjFaehrHe6YbjSru42TrkSEYx+BqzY2UotHSebzHHBbHpXGrwbszxKUpYaTtN2T2/M8k8YSzwaeZbZMuOFyOM+9Z2meIZUs0DGQnvjmuw1zTw/n27sH7hsYP4VwU1nCsjKVYEHoucCvRpSUo6n1eGUaq1eh6N4f1CPU7fcoBjkTzI2z1GOlVtRFxb6Tex2CqtwEZo8jkPjj8M1wngvWZNMks7CaNoiEwp37+fQ/n0rP1nVtf8N+MLvVtU1C2OiXsuUt5JvmIGANoxxgVn7FqWh4848r8n17G18PfEL3GjT/vJzf2j+XdGZSNz+q10VpLcT2j7nMkrPw7n7uOax/Dx1eS/1Ge6+zS6Lcss9nNERwrfw8Dt71q6xe2umWEj3T7AAQAOp+tU9ZWRtBrk1Wv+RdW5uCDFKSq465yGqzYTqiuY23ljkxtjlfUE/jxWBpF+uo2AnteI5VYKx6g8jp04NQ+DfDdxpn2q81C7nur2dxmWR93loOwH+e1JxSTuEoW06Ha2sywkRof3TNyjJnH0Hepr6dbbTfJt7UxKxyQqBV/LjmqCOWcq7At1ye/asHxJ4huNF3nWUj/sx2CrMXPy+xFZqDk9DF0U5Js3LJ0Cbgm5gdwRvX39qz7G4gi1i4gkuXnvQfOcEdAT0/CtKx1CyvvDH2nTxuknX93JyO/B+leBab4sk8Ja1q+qeI3klvbpigs0OGJB+8f7o7D1rWnDmUn2CdWMG3LRHvGq6Zb6y7JcRLKjx+W0bKGDjjg+teYeK/F1r4E1qz0iz03bYNGWMUJAPzH9eg/Ou/8ABWvza74etb25gEEkoEnlf3V5xj6jFc/438IjW/E2n6lawp5sbBWZzwFB4474p09Jcsivet7uh33hW4lu/D/nyLKpaLcvmLgqT6jt1rxqe11q08e6PFfi3itGuCxdTjzSeOmeeK9202Hy7KREOd4wZAM7sd8fhXOeP9Hg1M2E0c0EN3bOHRXxuyCD+WKypVEpNdzOnUXtWu7LtrCJLlIwD5YYDB9BTPEwUQvDKAA7blOcZBPOai0DWbSS/nhjnimkXiRAwyPXj0rF+Len31/Ho09irPbR3CtcKsmwsgPOfXFEYvnSehqm1Wjc1/F9lo+p6Jb/ANlXXl3VmMxgEnyzwcHHTPvUthqJTSE3KPPjcbjnouOc+1eVeBrDU/8AhIddnmeRBckrFCXwsjZyDz6dB9a2pNW1S18PPLd2sltcuCssbDJUDOD+NbOjpy3ubU8P7nJJu976mXe/EG1ufGaWlpAJIJWEW5Tjae4HtXoWiXEsrrbthIQSSc8KP84rjPCOlaSLCPXruzigubgswYLknnGfb8KybLUtQ1L4qR2tncuLG0h3TW6g7WH+OSKuUYv3V0NGuWFpa62X9PsfQfhmF3bmQmPPykH+VWvE2v2OmRSWzSqLllwozjBPSqOgRSQIhTvglfSvMPjF4es/E9+9nBfhbiJt+yN/mX6r6CuCEFUqWex4ioRr4l8z226a+Zpa/r95omiStbMZCqeYVebYCO4J7VzHhD4pareWGoRHw6TbohZZ0YshPQ84wfwrMgj8Tpc2OkzaRDrtkVVDcLIySKo4JYnOfyr06/s7fw94QvJLKONrq2t3ZEGCEIB52+34812SUIKzV7npVvZrRrW+1vxucX4U8Madq9+2t6vZQC8aUSRB94PHcgcenWvS3dlgntdSUS8BkAGB24/TtXl3wL0zUdTs7zVNTuZnt53wgYn5mHUgHp17elek3Vm7ssImUoq70kY/d9fx+lRX+Plb2Mm4Skle39dzgvFOkPeW6PcxyvFE5JIGdvHBx+VeV+JNH1CXVdOAmmkSIBVkIJIIPA47mveYr5SbjSvOaWAErIYh8wBH3h+VeNPJrHw28Q6pJzqNi1uskE8iHa6tIAN3+0MkH/69dNGo17v3GtaSveS3PT/Fvhi816xhvdMUS3Vp+7ngZsAqWzuGe/Y/hVmG1utP0awS5O2SCDYDnjK9AOma858KfEnVG8SW10zRRWcsqiWDoHRjg4zzxXd/FTRNV1yytorKYp9nmEyNnhgM9cduaylGcGoS2FTup6arocBol7H4t8SwpqTTt9ll+1QOJMbJVb7vuOleu+XFbs92toJZxzvwM/p+NYPhbwza2ziU2yw38+BcOgOAcckDsOM1tW3inTtM8Wx+G5RN9onQyJIyYU4J7+vB4pVpKTtBF1Jez03f5/MyWtbs63Dqq3ZhskViyk4Dcfy+tc/rmt6Ut/EZ9TdUaXyi5iYkt/dDdq7/AMaacJ9Eu7bT44/P2gj5/wASMV5XbeBrrUbyC6vLh7eNHSRIUTnI6kk9qdGUZLmk7WKjV9pqken3jC1tbJICrLOm4KW54PJqzea5Z6X4XRtrSTSSGONCepz0+lcxfwyazq1pqGlzpNpthCIUCYO9gTnPvkVcFo2r6asNxCyOGLJgZKnP9cVk4Ky5hSp+0ppvvf8AyLfhTT01+WLV7i0CGIsTuwRuHTHHrWBqWhqNebVpppXkMTxKjEhRnOT+Wa7KDT102wsrCOQiVSZHzwBu9eP8815Z4s1+8vPE+rRajfTW3h7To2cxwLtaULgYBHqTVU25TfLt+hnCo736flY7WIafcaWLNjbXaIu14Thhnrg5ribPSvDnhe+m1jdJa3E04tUttvyISc5GP/1Vxemzav4l8VW76RDe2Gm7kWDc5CxgcliRgc8mvSPiD4UtvEOqQXuk3wge3kBeCUHypcHOQRkg/mK1soSV3v8A1+I+dtpqLO58Q6zLpHgfU/ENrGkt7aWWIif4WzjP5GvOvgNrOoa94Z8VNqczzSeZC6lz1LFs/wAq7+9tYrnwDrltckBZbZUJjPGScVz/AMIfDM2i2eoReUWieUSkdS2BwMfnXNGyjP5fmmczpNVJVL6Jr9GZvhfxHdQfEPUNCnjkLIrXBO3gZ5AH4HrXda4kt34eun3MoZMKw/H/ABrUmt4RdSXXlfvmi+bjt0rynwbf6jD4+8UaRfGeS3nHnQeYSQi54xnsQf0oT9rstUvyNo1HOSk1qcbpHhbV21oTswW1DcuW5f6DrivSx8Pp9c0VhFM6yBwyF+nTp+RrbubW2s1LsCWXhR6H6V0nhvWF+zR22x85xwO2K1qVpON4nXXxNWlS5qHc3vDWkS6FoFtp9vJ5ksS85PHcn9TUd9f/ANmZluEAEg+6OeajTVXaGZZJQksfIOD09PXpXO3GttfyRw3sOYkYMpPBJ+tcKjKcm2eFRw1SrUcqiv3M69E9wJ57hioOSAByM1zMmlzTuZIBlCerYBzXpcMtlc2dwi7RJgjIx1/z/KuYDPAzKhXBOeQTj9a6adS2iVj2sLiZapK1jkLPwvBp95511cs94vKKDhVP079Ks+KfDEXiTSkt723SZC5/fAlXjyOMfjW5IsdzdLLIvzdC2eg9K6K0Fu5hjYjCsMIp59eacqsk+Ywm0oWavc80+ENlc6b4Y1PSL53eS1vGjQkngDHTNUfiXomq6t5L6YN6qxWV2fAUHHJJ7V6jfQLC0zqmxXkDBscHjv8ApXHeMrW5vLNxYMckhWiLYDe9XRn+85kKnblSXl+hN4P0yHT9AtrNLhbjyVwZFOQSTk4/Ot6LMW09QzbMdMA1zPhWzm0jQnW8LebI2SAfujgf1rXst9vJ5byM6IQwU9D6f1omrt6m27saVnJFIPOyUVJMMS3Ydc9q4j4keMfC93pl9ot95lxcLtQCNQcOehU/7Oc12trpsN1ZX1k7mKOdW+cdRnnrXFaP4J0nw2b7xJ4lf7YbbdIjlRtXnghe5+vSlDkTu9+hhVcbvsjrPBWlwaV4bsYbWQy23l7k80/MBweR1H0rhvGnw58OpPqOtay99JJcP5kfk4UKehXHPHvXVeEfGmm6zPaCxctJNuxEwwQQefxq/qlyPEFve6VdoIUiJ3LG3b+FgaFzRnqE4OpKzWh5/ZeLLfT/AAbd3NpbMLq3iSO2jUllC4IUn3HFT/A65v7/AEu5bUppHRZj5TyHPJ+917f41raF4bsrS1uoZViuUm42sgORnuO5rorK3i8PabDa2sEYycBAMbe+a1qSjZxjuzZxalf5HRlnsSrKwcFSvcgdDVS90aDUIkmuSxeMn7r44I6ZqC31Mcx3cfmAjgE/d/zivPvi3q0QbTjZ6ldIoYR3FsshVWixliQPTA/OuenTlKVloYOnNPz7nRaF4JtNFuJLuydri6ldssz7jg8kcV1N0IzosqTSrHLGThDzXkvgj4maZHrM9rYW04WRf3cLncFwOxzmvTdTklvNMF5Cm4SJvEfXBHYVVSMuZcxp70uVt6X38+xxdm+yZpGwjb9qe/c1ev3tryARPGGD9R/eB9az4L5JtWa1ntHS8VDKu4bRjHI5rYitYbixl/s2NpWQ5ZtwO0j0xW0tNz0faxlZsms7eEaX9ga2V4Yx+7C5Hl+v1qndSaH4UmW9nkiiu7wYYKPnZR0zjtV2ygnJWJHCyEYaJSGOP6VDrmgaLBFJc+IJI1bABVHBK+gZu3rgVCavZs56sktLnU+APF0WqQ3EkIPkRozhmGAwHIrwbwbcX+r/ABYl1KclY4p5Z5m52hecD36gfjXqvhrxLp0ShNNgifTs7W2qQ3PBOe9O1/wulvoV/aaE0e5yHjIGHKdQGPtRDlpSkmrX0OH2MadVzta/9M2dOvEmiddPmjLN+73g8Lmuc8NeJI9cn8QNbRZSAeRAM8yBSefbOP1rK+Hmm3enDV7i8V4BJtRfMO0qcHLf/XrH0ixn0K4lutPmDpvJ3RncGGeBVKlG8kmdEad5XOz8AfEGz1hRpttZG2li3/u1jCjfnnGKua3czXT7kdWxk4Jxj/CvLdattKj8c2R8KyrZ6qpDXMZJ2ux+Y8dB3r1nULO2S0jubSRZg64mjL4OMc8fnSnCMWpJbhRhCEua1m/6+RwOhLqGjeIbhGKTxTKGSTqVHcZ6H/61dVf3lvcaRdmURTW2GE8TgEMD6j2P5ZzWL4ospNQ0UWumSPauMAOrYxzzz9M1XsrSLw54TnmvPMl060UlwWBd+cnmrnaau9zrlCKjeW39aEegeA/D+o2g1CweSJoJs+UXDD0KjPvj1r1u1gtp/IInR8AZKkMCMdOK8Z8LmCfw3rKaBdF7eWf7RGhkwVU4Pl/XqMVqeFrfUrW8kkmeeG2Lcb8qDjknGPwpVYOd7y2OCcHPZ2ueh6zD9ktJpbe5IjwcDocjjIrxjwfqr/6fqUutDUbKIkrvUiWNs9Ppj0NelaxrkDt5txdxWlguEiEoyenXjJz9K5HVfCenWmlavcaXNJDeXTpcrt+eNwAfuAD+IN34qKPur3uprSU6dr6vr3/rubXhvxhpeuT3NlbTO11Dy6MuDt7kdsCt64hEcf2iFD82SWPQe2PpXkHgvdpml6vqFkbdrhRsZwAXHPQ98e1eg/C3xW19JcaRr0sBEzAWrnALtnleODxzV1aTim4dAqydOPN/VjP8HabceFBdwajqSz2M0ha1UDYwJJJ6V6XoqQyIHiURsPRsluDnPtXkqeGtWvfG0r61n7LYzs8ciH5GQfdVQPbrXcaB4/0rVbySz0p4mW1xuWNGG0Zx1OM1nWi5pOOr6mNROcFGC/H+rlbxf4li8P3tqs6MZLqXyiQcY/zmq3iLSItUR4hHE6TIFLHowxwD7Vc1mBbrxNHFeQJNa7WdTImcMehHpXKf2d4ktfGz3epX8NrogwsMCtu3oc7SRj5T3JPpRC1l0ZrTla3mVLCy1Wx16HTLK1MVlEqvPdMPlYAZ2r+NejT2dtJZwWkeTLgM0vXnPFUILa2k23Mlyq265LuxwAO5rT0zXdJkR1tH3AcpKPmDccHP51NWTey2Nq05yd1ds0ZtNN1Db6PZuoAPnTuTxx0z/OszTvGmgWepy6Pp96vnQNiWY8KxyA2PXFZPirUNS0fwxMdFJ/tG9crLKyktHH1IHox45rxm2fw3qBjsb65vPtMs/wA0lso4JPzZ7n8qdGh7RPmen69zi9i5aTfu/m+rPpS+8u7umls598Torbxk5J+lUdQjSORAnlGYIFMu3n2B4zgVXiubbQtLhgsxtgiVQCTk9P8A9dcdrOt38s2+HeYSeSorOFNt6bG2Hw0peiKUeoa1pni5ND8QXdtey3kbT20sKbQu0Hg+uce9chp+ta9Ya9bz2d0zXTz7JEc8MM8rtNdufGmlW91Auuaas08Y3Q3GMSRjp970rbsRp+qFbqC1gMp5FwsYEn4n1xxmuqMnDWUTSFOcVyzV0jf0K63wzC7dhJKdxYdf881pQ6SuoRs9u7FUbDEjp71im14cKW3cAZ9Peur0nU7ax0YR+WxkYsG2j/PbFcdTTWJyYpyh79HdsoappEGnJIyu4fAywPWuTuWk84+TJC6dmckE11OtzSud5kzGw+Xnj/69cZfti5I8hxgDIUAgVVFPdnRgedxvN3Yn2uQySZiJ2IcKMA56ZFV/C2gXekhr5Lma7u7lt0oJ+5nnA9cZq1qlks+k3pE7QqqiQsvXAOa6D4dGGy0mFpZ5LoBfllPGQemR64/lVSnywuialT2cW4q9uhU8f+IE0LwoJrjY0xUNsJwx9ePbNeM/FLXtSl03w7qXh26ukiuN3ELEhm4IBA79a9i+IfhrSvEEaT6hsMca/LvbaF59c1janPpvhPwu9xJGotbRVaCOPBBY8AKffPWqouKirbnNFKVJq9upc8M29zqHhiK5vlf7R5aGZSuMEjJ/KrthZwXOm3F3FMRNGchf7wFZfw+8b2nifw/dW6xPDJHLmSJzkkMPbqKVNYsbaW4soryJLvacwcjcO4zjGaTUrtG3NJtvbVWNnTdYtW1L7JPPALkL/q943EY9OorM+LOrXGi+ApZLK0hufOfy5VkGRsbIyR9cVw2m+BLm7+JU+vwXYtkhZHKNGXMjbfm79OvNenXFn/bHhme0uMKGlZQreg+7wfzoajCaZE4c8rPTW3y7/wDAOG+EMNre2a3l3apbX0Z2rHDhdqeyjp612lnZ2unareTW8rM1wMOjkbCf7wHXP41xnhXwddaR4oOoT3JMflmFIU5Bz3pLHVhrnjIiz0+9WK0JjF1MpRN2eVwa0mueTaeh2VKdNVOVS06HX2mkwR6qbgvIbqRc7d/BA56dKwfH3iiTSZ90CQowQSTSsu4qCcAKPXg11iBo7hpRwwBCkdu351z/AIr8Nrq5huLa5SNvKCOrrkHn68Gpptc/vmcm20zN8OavdapayNNH++TB6Y3KRuFa8en6beLIL22WUPGY33LyEbg/SjT7OPRLGLdLvJAMszYG7HT6elSvqEZt3ns5BI8QDMowRj0yOlVJ3fum+so2scpb+CPC/gnUJdTVJprXqXkJcqp6hffnv6V6P4VutI1XRFn0iXz7FshEz8ynPOc98/pWBc29v4n0SezuBtEykOAeQSMAj9K5H4P6B4h8I+KtT0y6ti1mVOJC3yOeoI98VMlzxd3qjjrQcUqS0t+n9bnoPiPR7DVbLyXhC6pDGWUt8u+Pnj3+lePJc6t4XvkigeaFLtgMPwoG3kfrXvWqwC4t4wQGkQYLL1BxyMj/ADxWdrOm6Xr+gw2mpQK88bCOM9CM8DBpUa3KrPVE0anJaW6v93/AOElubnS9Fk1yVnUjDMRgZBPA/Os3XrOfxfoUIYTWcfEhBIG7cOufWtfx/wCHNUu/DcukWIkYwmNVVm/1iqDjH6Vltcaha+F7AXSpb3KuscqsuNvBGcfh/KuiLT95b3O6VSNW91oYUIbwVpdxfX14biBUCiKIDr0H0+tei+CPFtprfg1tdeaa1WxYedIy5BUAggj8K5Mwab4p0h7FJA16qB5IZQQAueOfoRxXSp4bRfh8dBgIja+wCI1ztUEgHHv/AEqar5vi3Mq0G17m369flYi0PxxpPjCa6sLO3METZDq4AJQ8bgRXHar4G1fwfrMEcV00+h3rb2MUxAT3HoRxV/Q9M0bwHFNE94moai5CzPH0iGehOSM8jgV6Jo3iDRL+SbQdWMUs0DF1Bb5kBA/+t+dJv2bvTV0RKnKnGFS3+fqv61PEfEN14NbViYL65uJhKu6aGLJXA5IckZ6Dsa9s0G80ZmjMNxI8Dw7VeUc7iP4h2rN8Q/DHw3fWNzf6J9nW5jUyBfKAJx9OtcR4Ws9dTXUS7BNuWaNim3y2j7EY5BBFO8a0N9UFF+1Tu352Vrep0HizTNcmjhh8PXsVrJBdAzqw5ZMf09OK6i80qO/8A6jZ3UKzAth1XILjHNcXpHicazd6pZCJob2xleNiTzKoOA+PqOlSeDPGWrtqT2bQRJAlz9nYyEqWX+8KmUJOOnTU3nTdSHNB3u7/AHbnGpoMuhWrabp9y6rcbZvm+X5gTgZ9uRXZ+KLTVLvwhZxWk4GoRzRymSNtuCAcke3P6VveOtGgvY2uIjLG3lFtq8cd+2T061h/DuZn8OxJdoZXVmU7j+R/WtefmgpdiYQjKFktDC+O8dzZQ+HriGFGhuFV51Tg7sAYUenWodV1Yaj4VudI0SfN5aIjeUMmRQfvBfp3xmvWtcFreWdh9oQSKqARq4ByM5H4jn8hXgmteE9c8N+JH1zTonmhjuAyMT/rAwOQfbFTRkpRSfQxh7SMdNbv5rpoQeBdKubiHUbaC5X7TtG6INhjye31xXa+Dvh9f6Z4g0/Urq9gnitJBM0aEB1AOcY9OO1cx4VvTo2t6tqlwhMc0JkQEY3MzD5c9uePwrsdOl1bxdoOna7pkD6dqFlL5iRM/wAk0ecMMgDg9Oa2qzkttEU4xcLdf+Cbtml/qWha6beaOxurqVzHLMCwjBxnH4VS8JeENOh1Jbi0uTdXyxiGSSMgRhurnHqfc09vEVtfXTWQJivgQJLeVSu0+3Y1s+AfBl3pkepa5dSb7MB5Ft1PLY5OOwFc0pezi23Yqoo0Y+0k/JevQ7ucW32RN6rIoTYCvOcVh6npsF/aANA4kMYjZXHytxgMPw61jeHPEsPizw5qF/o5kj+zM7CJxhiRn/61ZPhq81fUNWtrVJXe5J3EDkbT/Ic9fasI0mr9LHJTjyXfNsafijQbC68JXumRXmdyCOQwkDZ6ACvPrwzeFvB2nWU1zE1xNOLYFPkCJ1Pv0HX/AGq9In0VdKW+Kz/aJJDmXb92MD3HX+deD6smr33i68t54nkCykpjJxGehH/Acfma6cOuZ2vpudEZtR573bPS/EnjiDRNLSTUHW5kmb93HbHG9ex57AEVDpuj6FBqEWtQWqieUB0DfdBIznHTNR3Ph7R4fDNvqGo2ayyW6FkZyfm/2AO/auO0/wAUXmp6slswj8pc7AFxtx/OrhFO/KddCKcrT67Ho+rXbTTNEhJRQGbI5/GtjT7GCaLYeRgcYxjn9frWFpglmSC4dRwPLY9j3HT616X4P0+Ga42sR+6HBx361hUlyRKxlZYam32PLviJ4RlurSC609f9KtwyyRhf9Yp7fhWR4EvbrT7wQSl1OcjI2kY7V7trFjHDev8Aas4mBVGXoMeteea5Fbw6pM4jUFcDeV+YfpRRr80eVnNg6/t/ma5uZHjLbgAw/hHX15qCO8aOQAkhTxjGTVDSbhZC6M7Kv3l46cVdkjDsjqocYPznGAaVktDeUFF8rM74ma5Lpul2oiDoZBgSYwOPeo/A2qy6poS3FzumYSFVfruUYx/M1P46jj8RafZ6ffMI44DkFV65GP5VFov2LRtOisbC2Lwxcby+Cx7k04Jezs1rcwpUp2tY1by9tLWJluCNjKUJA+8Md+OlQ6aLS2soUsrtZYHJbacgjLEk89efSuK+DxfXtCv5talnmYTgI5b5hkc4Jz+Va2vSx6Lq1ta27PdafuKj5NrRZ6g+tTyWfIFKNObSV7nW6zpNr4n0ifTr92Nu7D5kbaTg8DiszxJ4Wtb3wvHozl4rVowisg5TYeCPpxXKeGbnXNM8d26+YZdAunYSqqDbGCMgk9QBxzXqV+jL5aFTKpGI8H86mXNSkkn5nJKPLJxezOH8GeB7TwfDcypftcyTSKN5TGVxxgenJrLv/CjPrz3MVzF9i3F9+PmAJyRxXa+INFm8SaO1lHI8UmzYXU7cAHgetcP4d8G6p4O1WWR7v7RZtG2Y2Y8nt+PvW0Jt3lzal02r8vU7/To/KEMkRGw/KDjCnjpV0OrbowpVicjBxtPpXEL4sb+07XTRHthMgLAnueAR7V2UE6wzh3U4VTz744rGcHHcqcGtWPffDC0qryvyZHfPWobNrW4iBZmEpOAOw/DFAmDoCXCIFLZfoK4afxbDc6xDBY2pQAlQwY/MehP6U4Qck7Fwhz+71OyklitVKZbbuIHr1p8SBQf7rjgfriuZvb9rt1w+AMAj1Nb2mGSVFVz8meG96bjZG8qTpw1KHi2KaTQrmCKNDkDCcmuM8BW07apd3EodYBbvCzEcMSMAAfXB/CvSrizuZWfyyJABu9D/APrqnbwiSWM+Zg4yVIwRVxqJQcSVZrcNAtZYYQVQlG6deWFdF4j1m20WxSeZkXf0BbBIHpUFgkzD92ygRAqgVRjPqa4D4geH77X9Mmhe5b7VGCIFjPG3uDmsUlUn7zOeovbVby6HY+EdattchkWzukRlXcRjlv8AZyKh1ydrTXLeyCsrSxGeNs9WQjIH55/CsHwB4ek8P+HLONTmcODKehXua7jxIsUNlFqoiWSS0O8ZHJU8MB+GaJWjPTYmpJU6qa2fTzOG+LpvdR0WxvdMu5rQgkyGFyh3DjGQfrWH4FN7d6XPc6q0s8rvhTcfMxUdCc/jXoHi6G4sdHuLjTkWWGZBLEGTIOcYOPXFctoF3qqssWtoiXvlb2+QD3yAPbFbU5/u7JGuFUXrH+v+GJ9D8O21heyt5gSe5yztK+HfA5A+vpWzqtvNeaXdQW92tvcXFvtikAx5Z24H5ACub1bStRvvFWn3wYm2gPzOpJUEc/rVvxcXhFtDBK4aV13LF12kjIoa5mtTR+/ozzXQfh5q+m3iQaxc28lnFOJ3ETks/GQc46Z9al8GeHZbLx1d3sEoubRWkHzSbmOTxn/Gt1JvEl9qNpPBFFb6XIu2eGYjzQOQT6nIx+VGiaJeWXiVWa4DQr+7BQYDKectn3rpvo7voOFOPupa8v8AkdP4T8T3cXii9tDYyJFa8lmJKSqRgiuk1LTLORG1bRZsRA/vIC3+pP49RSXen2trpsl1JdxQuqb3GeKreE9R064ilhSdZ7S4YASJwVJI5IP41xStL349DKTTbq03qt/Nf1scDq2gR6jrcur6Bew22qQkpdxYG2UHr05DdOvWnW/h2aDxJaX9vdSq5UCeFRlXYLjOe3/1q7O78M2ukeIb2WJH865CmQg8OB0O31xWzoeiPYeIIYXG5vJ3jcc9Rn8609taOjNVXpwg5/NGP43vY7CLSPt237SybTGGx7Z/Wsx9W03SNCkuIhF5X3FVehb0/wDr07xta2/i1Weyu0WSJ2iEo+bGeGHHTjFZviHwPZXXhu30zT7yXz0uPPLN0J6YP5U4KPIlJ6k05SUFFr+tzZ8Ha9D4r0SIXkLWt9CW2g/3QcDOe3v2qn4umeGApKQsoZQEIznBwf51Y0zwrN4ejtbWxkb94olnkY5z7D0GcmsX4uJqU2mwS6UqS3IlWUqw+coAckA9ecEikuXn93YunUVJ88dV2LZh0vTvD1y9+EFoQZpC6bguccAfXn6mrfgfV45LNXaRJ7dHMe9E2nbj07HFZ0fh+XxD4It7XU5ZhNPEjyOygEP1Axx37VzOjaRrOgeNItPtXnk0gKWYhNquxXnI9c9B7VpyqSlFvUJTTdraMb40k0xPEkl9YNJI5cbdoO7I6cV6roCXev8Ah7znurnTNOVNslwZDGCe4A7ipfC/w+tNP1i91LVyJLaZd0cTDBTPJGPxpus3rarrOy4tp4tJs2X7PHbjKnH8RA79fyrCdSMkoR6dTgqYl1Pch06/11G+EtHjtJLtJLlLmBMNBJbKE8wZ53ADAIPB9am8U+J7fw7oV7dQW8djZxLmTyI/3jZPGT6k1mzXZtIy8eLdLi5L/OcbVC+/QnH61leL9XtT4WvrS4xMkysikLuLZ4/IZzUuDm9SnD2jvPVrv0OK0nx/q9zpQlksorfTb64MEDDOen3sk84JFWfh7IfEqWV1cymPUtJkMFxuX/WRnO059Rz+Va3h3T9I8ReGfDllBfJbrpzmOSCSMAvIGDZHPU8V0en6Pa+F9JktWkHnyTNNK3ALOxJ/lgV0ylGN0t/6X5GlJybSkYvi1zeN9mhZpIEyoXAANcvofhP/AImCNAr7j0HB28c12LWQbzGZZQxPy9/z966HwZpUd5cy/aWZHcEqM46dqnnUI6HrTrQoUuZr4SbwloolLrJGNluAOmOfUn/PSt/wLK41KZJtnouD1/D/AD1rQnls9F0yeK3wzE4bB9B/n865KxuUe5M9tMFkX5gU9feuRt1L9jxJSljY1L6J7HoHiWONLOSeWVYURSwfupryAl76GS6y4ALMDJwcDviu1nuLjWrOWC8dpGhYHZkYcVL/AGLbOfLEbEIuOD1qaT9ktScFJYKDjUd2cBooWRh5pAVSQe3BrUtbaRLfZbTmPqVJ56nr9KfHp8dpLK2SS4IwOg9KvtuNssSsAuM89K6ZSu9D1KlTmd4nExSXN1r/AJJRpAHILYJGB3rfNjLKdwGM+gq84WHHmriR8ruGCT/Wtiz0u4mt1khTzUbncB1onNJImpiORJyZxGh28Hg5IYLicJYqAQ7kKu7t9T1rX8TWlhfWgvLe1aecuCojYAHPQk+lZHxc8MSatpdkLa9RZ45OEJwOn8uTWhomky6VpNhZvdGcRxhXOc8j+lTeLSqJ6s4qc7y507M0LU/6HbNJHHHcRqPMjUcKehFW9TuWFoN+F/iXPUemKhngLT28cZVY25HGOnvXG/GdL0JoDadPPDBJcmKXYx5yFxnH41MY80khtrmidh9rn8lpbScLcqpC7u/19qh0a5v/ABVZzyzosTQfIUHUt3xXD6Br2qTeLNVtJhHFYQRqYAOXKnHJ9e9dl4L8Vac0t1c2X75UkMb4XZlh1zkVc4OCdlqOpBpc0Fr/AJM4/wAUwaTHeW8V1cC3ulIbKqTgepxXa2Os6fd3C2tvIJZPL3kdiOleXfFphPrUOqTeXEtyPmRMsVC8ZxWboupR6b490topX/s+eAR+Y/A3EYzj6iumVPngn5GrlzpOR9BanbWZiitofvSAqx3cAEd680HhwadfTzl/MIyi5ONoruY5pPsu3owHDgDPXHPrxmo9Y0/+0tNaKL5ZXiOdgyVPTP06Vy05OGlyaD9i9dTkbOSG6kt44XDGNTvw2e/Sur0yJvKaMMdoGQAO/wBa4TQ/BlzpV2JZ7hHJzu2knd6V3lpH5MeQ/puB4C+taVbdGddaalHQs2+rizmmtXeP7SoBZQ2SffHehnjimPlASK4BBbjHSuD16+g0bx+pRxKbyIQhpVAAbHAH1rs/CvnvbxvqxV7kZyygfhntWcoKK5jl5YqPtEZ3iXxbZ6LdWtteyMskp+SOIZJOev0962tL1C1uLZbqMNuYfLg4x9awfF1ppUd3HqM8MbXEcZSMtyVBP5ZNU/DutwXlxJbwQmOREMigncGAPOPwqvZqULoagpQOz05nkuVRomNux647+9bdzAksMgcBkKkMG+7g9jXGNqM9nKtwiSCKT5Qeo9xW5pWrx6mqpjDB9rAjrisKkGtTmxNCfxrY1Lc+borWchSSKIYjY9AvYfhXC6rDcwanaS2uXZWKI2fuqff2Nd8sDibYiDy2Gc4/DqKzL6yia1GxQzZ5APp1NKnNRZnhasacn2Z5V8FvFer3vjfVtJ1ecyMRLshYDCMpPyqK7C80/NwVBZbjYUEm3JX8Ko+HPCtpB8Qhq2DFMcsdvAc45P8AKupmshca1eJNIY1bcQ2/24Irec4qV49jbn9jNp9V/meVaGw0+cxWatqTvcNHcTBztiAJ6n1x2rt0hikhmEIMTSKSsgGdpx/OpfCfw9tdE037FC5Nv5jOru4Zsk9eMe1cbr3hvxhp3iqR7G0uLqCZ1MMsBLIq+hGMCteaNSVkzb61Sso31G+EZdUuL670rVFaaCNGZpX5IbIB57g9a3NF0KPw+blVffHP9zBwBjOPx5ruodA/0ZZdRaG1cgFwTwDjn3qp5GkIv+tkuGXIBVOPrWcq6k9CKeIg/hu/Rfqcb4/8WXum6lpFzZxLNb+V5c27qzDGcE9OK7vQ72S91PT7iNedowCMZUg/41VdbDespidlUBvKZAyk+vtWq2u2ltCJLS3j+0lTyoPymspyTiko6nPUUuXlhC97r0POb3wJ4v0XxPJPoUcc1hPMZirNwAT0I9uefpXocltY6Om69eIzsMFM5Oc9hXnVhrviafX2juL+8SN5G/d7SY9ucZzx2qxqehvLq8VwtxNuVi7SAlh19+fWtZRlKym18jSFKrK0KkrLyOv+w6nfXsQtAzWj/dZv+WY9COwrX1Pwcpkt7jzo5fKHzCUYXtXHP4sfQLUvqesQwBflJbapAJ4G3rUV/wCMTerAYrma8ilK4MTjByeuPzrL2dRtcuwnSxLmlCSSX3nZ6VqOiWobTxC0jscSSSJhSfbPam2juHklsbSPyCfllkHI+nU4qnb2ltK/mNHLJtHHHB/D9KvXUt0sGRiJMY2ZyT7Vm0r6HPOEVJqN23vdnM+ObXVrrRZotIuyt8/I+fAJ54z2rgvCPg3WvDdhe6jq+oNfai8bbLGFt67sEjc54Jz2FehiO4e9Wed14beMDg/h9as24RnlkdhuTkAckmtoycI2R1KHLZ327HjWi6l4lu9XS21O3lmhuAVxJbErAT/EMDp/jWvY28Rhu7PxhepawRExpIrlQOTwOM4xjtXp7b7uNEIcOTtO1sY5/lXBfGrwaz+HLi9tWeS4iVXEca53Ddzx64Jrb28ZPltYrnUdHvqS6d4C0fTns7+2vZJ7SN/tMUnmBlfpg5HpisD4tLfXl9E9sGe2YnITnJPT9O9Xvgnpl3qXw8udL1bzo4ZbtmhcnaTHtw23vjOa7WTSorKaOzZgwjjCrIy/ewKHNxqe87tFYecX8Wj/AEOd+F9lffY4La5LliSU8wE7QB3yK9QbSIYfsz2aypP0kYcYHr7Uvh/UNEs40QMDLJwzMOma1fERmOmm30/YxZfLLbhlc8ZrkrVZTntY4MViqkqygk4rbXqc/qIjW1+zoInBJ3bm+bJHX3PFc1HZCOQzWiICxy3GM1Yh8O6lZWxW4nEcDSBmdj1I/XNaRtYY5ZDcb/LZsxMgGPXP61cWo7O5205QpK0ZcxHpkbRDzr9SsLHBw3Kn1qfUb6Qo0VpIAwHB9Rj/ABpusXcMulXKphiFUAt16Dr79a4+O4uBcQqsi7OvI6Uox59WVSouu3Ulo10J9c1OXTdGuryeFCYAqp83Uk85/MVrygfZILuXb5bruyT1FUtT0r+2PD95p3lEtcIy5HX1BrG8JrqEfh6PS9cVhNbfIGz94Dp+Pb8K1Sun5Gibc7Gxp11Bql8sayOrMcDjjGcGuwuNdh0xxaQA7UAyQcZP515db2ZtL9ZHdkRW3Hnrz0qe6v4XmZnZg568d6KlNO2uhpWwca0lzfCjp9Y0iy1i4trrUYFlSzLSIiqW5APbPNeeeF9e8Q3nja7hurS6j0dt3ktcW/lFVGMc4/Suu04nw7Zane3d7LcwKDKzOnKgjp9ORXk2t/FbUZtUiGmW+LCBgxLR/M4b+Q7U6UG047rocKShJXen+Z6lq/jSyhv7W2UFI/NEQmzwGzj8s11S2tvqyRLexq6hjIvsfUV4Rqmi3WqXmlXds6pbXMi/Lu5iJbOfzNe56N5gyHK/uzz+dKvTUEnEupDlVtmjnLXwla2fiPVdTjmxdOkaGIDAUev44FcV4xim8M+Dr1rBhHLPeF2eIcc9Tn1rZ+MOoapaXlvc6HLJGRgSoOBIAePqPansJvFHgOQa1a+UZMlIxwR7+xrWDlaM5PR2HBzkr9Tk/h5ax+M9Mn/t4tdNbuqpn5cDHqOp/wAK7ay0HRbu0l0v7IpNsxkQ9Svrzmq/w+0m30B5ba3jIic5Jbkk49fwrZtbCS21m4ucYhkyD+NE5u7SfoXJNaMdqd/HpWgTXiKzNbRHCk4yRxzXNW/j+fUPB+mXcFmttqF/qBs0J+YbFAJYD8ce3Nb12trqOnXNsknmR/6uXGOD6H864jwa2gz+PorSzDNHpUbYRhgMfMG9h6nFKMI2bfQKq95O+h0virxtNptxHDptgdSlBKzBT9xuwIHSuR1nxtq2oaddw2CNDPH5fyRjJDE859ulad78ONT03x/fa/a6vANNubhpo0Vz5jKxJ2MvTjOKzdZ8N+ItC1ZrzwtGpiuyDM7BWZdxzjB7e9aU/Z2VtyKc+aHPa1xNL0HUPEt3Z6rq16gmt7jkbOXVMEHHT2/CvbPC9mktw3nh2ROfLAyf89K891G//wCEY8NJq2vMPtTFUEEJ4eQggAf1rpvAs+q2eipqGsjdcXRaQqPlCg9FFZV25LQqtrB04PUq+P8ATWupXjiRot7BwG4BxXP+EfDsum302p6g7G5MJhjjRvlCk5LH347V31pEdXuf9IlCBj8voM84/WtKXw2LaCUGcbVJJ+Xg8DvUKtyR5GDrU6fLTqPU5PWrmWPwzdSWsXzIpkDt0B6A/rXn3w18c3N94gk03UwXkJby5BhcY4wfWvX9Pjh1XT1tHTMXmZdexUDBrgIvAFlpfiy71e3uS1tyiRsMMpI6+/SrhKNnGRam3P2e3c9j0G+gnhSQyb12AAL82D6Gue13xToOjaitvrl59mL5fcygKc9PfPNYuhSXOmP5qqzKSd+W7HuRUutaHpXiZRJq8UUygADY5DE/0rm9nGMtdjjqYNU6kmnozQvbvSJ7ZNVtdVsRY84uPOAQ46jP9KPDV1p/iKH7RaXyzxl2jV16kjrjPbpXHah4Dg1e4hsZA8WkW+AttH2XqcehJ7112kx2vh3S47PRbNLWCMHH8THnOSetXKMVH3XdlOM7ckXqbN5pq28RMTvI5+7s/rVDTxrFvftEgkijYfIwbK9eR7VwuvfELWNA1mOCCJpYQBJJnkY9veu3sPFUGpW9vPIWyMPuXjOeelJ05xV2rpg6VeMWmlJf10Kmpm8/tN4r2CbIHMkmQhPYA1q6dHO1nt+xogbgSdCwrL+IfiS4u/Cso0e0M1xGRkbd5K98D1rgPBnjjxlquqLCdJKWNlCWlQxsGYKOmT3NEaUpwva1ib1JU0ppJo7++uvL1NYEjSE5+VXGQ2Ofy7Vdso4LqQlY0AIzgcA8981g6drdtqmrWy6vDBbyyxnyGVsnIwMHPTNb1zEFuJY43WCKCPcxznilJNaMu+nLs7FXVb6GwnEdtFGZGbGCwJHv39qwvEus3lro01xpNg9xdEhFULkqfXHesmWK41K5Nsdkud/lyoDuL8HrUviU6n4f8GveRXkdtd2nzzeaPMDjpg8epFaqCja+5rFKK97c4W3+GGveMmW51e4azunkLfvE3fLnOTg8Hn/9VeueFPCcPhe2TT7MmZiwd5JFGCcAHA7Dj+dV/hpd3o8HWdzqd2ZbuYs4kyGyCflycdKq/EfV73SbW6SK4Im+T98APlDEc4qqk5zm6eljGEJObtpp+R1l5rYspZFWEPsXAIbjNc8+pXN5MZXds5J9hz2rjPhpLqOuy39nLJPcyQyK4L8nnOR9OM16daaNZWWoJa391HHJMoKoxAbIHpUShGi7Pc6F7DDr+9+JkyzTNNsjLSED5e2fwqaeKdYfuskgHKZJwa6Cy0y1t7u6ufNV4Y4wykcnI6VyHjjxfBpcIvryGWOE4QbV3FjzjHYd6UZcztFChW9pK0Fot2SQXU0N2qsXUk8sQenrXUXUkNtYia4kYoke5i3PGM9wfavLfDvi2z8R6wEsFmDxkGTzhtIX1HXNenakkSWbGXZJEISFUt99sYxjpSrxcWrixVm4tHLeEfGdlrxu/wCy4QI0Yp5hOM4PUDOR+VdBqEJudPglkkU3IyOOCRzXzpY6zNZ3trPpek29sY7owSypESxyfuE5OO/5V0nxC8SavpGu2MEBkR47llCBv9YoYADHccGuiWH95KPUS5b82zR217KIJY0jGw5AZm6Z/wA4rrNJ18xnZPkhBznrntXE+LoW1XSRd6Y+cMDIn9w8Z6ehqJb+SO2gVlxM8QBx2xjmpcFOOp3SpRxMVGSPavtWj6vBFp/mK4OG2hsYP1riPHF/DDdRWdhLiOAcuWzk56A1m6Ber5STo3zqpDFRzwKw9YuvM+4oZtxcNjk5Jzn1rGFHln5HLhMuVGto20uj7vqacVwzRhJm3RS/P6Z9/rUEcCQvIs52RFj/ABdOnf8ArUOnxia0VXPly5z6Vh+NpLrULu006wuHhg2M886rk5UAhfbNbpa2R3TfJdIseJfFM8HiWxjsryE6cr+TMi9SxPX6dOa6DxhLqFp4durzSIVnu7faCjZOeeuB171598JdAfXNZEktvE+r2aAxu0mFdRwCy92Hr9K9E0az1O1W6i1ckXDSsQu7OOelE4xjaKeqOOO/Lez7dTjPBmtat4r1aOzvNKa2jALSzSKyBcfX+XvXYz+G0MrbZhtHA+UnNdrZaVF9mR5CCSA20DAPFVrrRGuJjJbzGCMjhY2IH1rKddN6LQyWPcXa9/kjg9Q1fS9N0M6frF0TJcL5Qz8zH1J9vrXHeF/AuoRx6m+tss8G0C3cc7l3ZHHYZxXOQWGoeOfHTQQBxbrNlifuwxg8n2r3vT9RFo6RyKH09Pk2Mm7CqOOffH61tNuj7sdylJ3cor5HC2tlez39taowTyyFTaCAvPJPp/8AWr0+ziiILKT5fAD4++QOT+NZMd0J5f3ccNlC3SMKN+D6mtuCZDaiPPmHHr0+lclWbYsTUc0tLGdqlpb3JjWeFH9yAdtYFgloIr2K0uZrkNIS3mfwHA4X2yKg8ZeHzqA/tSz81L+3TbE8czL8uTn5R14NReHLya5top2tnt8/u23rgvj+L8a1jF8t0x0Y3un0HWcvkXGW4CDDKPr1rd1C/gsBbQSz7HugNinqwzXi+v6/qtr8QxbRzyx2Mc6qYhwrJkbs+veuu+Ll9KnjnSoLJiVtYockfwknJrZ0m5JPqrinPmnGP9aFmw+2XEHioaaNt0tw3ldgTsHT8a5f4TeBtW07xxDrmtxtDbEM5x8xk3Aggj05rsfAMrSWVzdvwtzcu4IzyMkV2dxLsg8w+mAD3pTm1eNtx1qKm43/AK0KOpx20O4qo+9kAnGR6Y/Gqr38ruUCEpkZPYe1Rw6Xc69Dd3EDPvtnUlWHGOc/iOK8hT4gave+No7DRbYR2XmCAxlNzbQeXJ9e9KMb6djV1qVJqEnd7G/8Uxfa14v8O6Haxl4RPHMVCk8k9SfQDNexa1Mq2kFmR5ZRQGBwNxz61Bp8cCMLiKJftJCkuF5IHvXlXxxttev/ABPaC1WVoEiDB0bC7j3JzgdKhfvJKK0sctuWpe3meveGbIXd/FGykJnLEeg7V6O1tE0DQlAY2G0j2rgPhberHodp9rkhe5+zrvdW3Fj35HH+TXoYkQqSGUgd89K4q7fPY8bNak5VrbJHKX+kw6bd2ptAsMJyjc9c9Kxr+x+zo5wCd5GRyMdq1Nb1Rb+5+z25/dqSA/qw9PxFZuos0EKRO3GcAHkn3/PNaQ5tLndhvapR53qzHv8AULfSND1W91AZtbe3ZmxxnHIArivhN4n/AOEtlvc2wgEUm9I1b+FuOp713Hirw/H4o8N6npN67LHcbW3qdrcEMDn8Olct4U8O2fhdRaWEb7QV3SHlnIzya6IWcZdztpOc5ys7K34npF6kaq/l7RIQAACM+lYhYMhBHHU5FaknlmZBCMFFEnOeSO1ZkASWQpGwJJyNxrKGxnQVo6mZceHLTVp2N3CGYL8rpnIGf5VoX/hz+xbdHt41+zyYRHPGPwrsbHRma/in8yL7MvzMqH7zY6EV0ckUckJikRWjIxtI4x9KiWIaaXQ4q2aunNcmq6nlkGnyRQq5O0YBJAwPX+lUIPEdlbX5jilkJU7Gcj5D685/Wu/1TS1iLIkpQOCFx05zmvCF0bxDDPcaffWhMvmPHCYlIVoyeG3dK2pWq35jso4lYhO7PRW8N2N/eR3sRaF1bLIBkN3HP4VqTadMTIrurpIpUsB1HYc1VsPtVnFiXgoNvOcNjA/rVi3lnncSGTy4c4yeefSs5OXfQUlNNtPQbY6Hb28I3REPG29CCBg+ufWoPFeiWutaLPZ3BBt5ANxPPQg5+ua0L28ezsLi5hRrx4lz5IO3Ncj4d8WXXia3njaw+y+W4TCtuDHv/SiKnJ8/YmCqVJcz2RGGttOtrPTLQ4it4wm7HHTvVPWpP7d1B7S/QMpQRHH8Qxxk+o9a09S0+QnzI9jcYZTxuPpV3QfCU0t8mp3Ux8qNxtQDIYg9K6OaK95npOpRpQ55M6T4Y+CbXwtaPNEm2WbByTk4x1NeUfFnw14tk+LEWo6XaXd1azBBC8fzLGAMEH+7619Hqd65AHA5p5+YEnpXHDESjU9o9WfJxx9SNZ1nuzzXS18vTZNL+2xSXSt95VIwAOlc74n0S11m3ex1BjLGW/vYKlehB7V3GuaXp+mXT3UEX+kupbPp7185a7aeJ9R8Ty/8fsT+efI2Z2MmeMEcYA6murDr2krp2PfwtSNROpHZ97bnbeGPBVj4Z1GWe1llmmlAUmVugz0r0O5SE6UQVEk8MZkVckZ78VyOoz32ieC7nV7mIXMtkmNoP33x/Idam+HF5q174dS/8TSpHfT5aFI1I2Ifug/h2oq809b7F1mm0o9Ow3wTpcNokz2rJ9puHM7sygb+TjI9R60/U/CNrqevW2p3EbS3cJOzJ4BGefrzmsifwhr9z8RtM1nQbtILUhUugX+RVU5IA9/THWu+ltr9tXhkhmiFozM0hZSWYegOeOO9KU7NST1InWSm7aGZpGhjTtFlht03sys4L9Wbrk+1cJp2r6bq9zJaNJ5WpQErJbvwykccHuDx0ruNb8faFomsJpt3M6XAIQjaQi5Axk9Kqz6BaS3X9prY26ySkHz1UbiOuM9cU6cn8U+uxrha8k7y0TKVpHHYK3lKXJyT+NQRW6zROrL83QZzWzfRQW0O+1iSSQ/wEnGazvtF1czLb2UXljcMsDy3tVKV9TthNy95FTWL+Pw7pd1OF894I9+0Dj8TWb4P8ZW2v+ctxaKhiOHjxnep7g+tejweAhqOi3Md6ATcRMu09WBHc1g+GPh0nhnQ5Rb+bO7OSzyAFwPTj0pRq02pJ7nD9doyny81+nzGaF4Ut9Pa5udCu2na4jY4U4dPwzWvbwCwd4pGdpGj+YPyQe3P5VxNlqk+geJArP5ayAgNnpk8H9a7ZbxJIwwkUuWyXPVs1M4yWu6ZtXjUUryd0+vU4K4+ImpWvi57UiFdLRhCTnL56bsfrXq1nrS+QpMbNnnKDINeTav4Fe68RnUIjG0MzB3i2ktuHp9a7KK8NiphLGM5zt3FcfhVVIQcI8u5jPDQqq1ir8RraHw98Oc6LGtm0uN7RjluvU9TXlvwp1jUNSvL2G/upJ4oUVkR8EKc9cUUVVHWm2wwbfs4+bZ2l1LJ5krb23ZJzmtXw5czF2BkYjJHPNFFEkuQ9KrFezehtOxLAdi2DxVmYA2+CBgcdPaiiufqedLoeOeL7aFviDGTGMsFz79KsfEJidd1Z8/OlsWU9wfKHNFFelD7Pp/kEunzN/R2Nv8ADuBoSUKWG5SOx21oeGbue+8FaPc3UhknkiBdyBycEUUVzS/U6H8aR6L4RmcaKyAgKVfjA9RXiXhZEb4g+LBsRQFJwqhed/tRRWVHeZwUElXqPzPV9FRW0dJCo3jgN3xxXhv7Ql3cLrGn2izOLZoWkMYPBbcRk0UVVH+IxVm7z9TpvgNPKfBsoMjEfanXGe2Bx+pr2Hw9dTNC6tIxG3v9KKKjEL3mKuk6F35GWgC6k23IzLjr71tazbwnxBZRmMbBnj6KKKKxe69DOs2qkbfyv8jFVR9mmbJyHwOT71lXhMc77CR82OtFFaw+I78PrJl6Al7eR3JZg4UE+nNUtMH724HYYx+dFFPuP+Y7vwc7eVKm47M5wfoK6NwCBntzRRXFV+I+Wx2ldmPrrEXMOCRx/WslnY37Jn5cE4/GiiqhsdeGX7tehm6bNJLqlzHI25ADgEdORTY1Ae+jA+QJkD3FFFanovSTt2RXuiTocpPVhtY+o/ya82+CDsl3rUSswSO/CKM9Bk8UUV0U/wCHM3j8Mvmeq6sAoBXjcxz711Okqo8PxYHVMn60UVyT+FHlYz+DD1L2nncnPPBq2SQBz2/rRRWTPHqfGzx34z3U8Ph+aaKRllM4TcOu3niua+G17czaBG8szOyLIqluSBmiivSopew+Z9bg/wCCkYvxB1K8t/EWkafDcyLZXG3zYc/K3J7V6HB/x5KOeAMUUUS/hx+Z1P4fmTaBPKEmG87QRgdulcDrniDVbT4kR2FteyR2ZtVYxDG3Jbk9KKKmEU6juYyS9pIT42WNtI2lTvChmkXLvjBbgda9F02GNNItlVcKLcED0wQB+lFFVL+DH1ZzrZGVCA16A2eRnr9a6Lwjbwvrbq0YKqAwB9cjmiisqj91muNbVKVux6HTdqgEADDcn3oorzj488P+KVjbJdEpCoKXG1SOw5rmdeu57SxsmtpWjJvLZTj0MgzRRXr0dYQv3X6H28G/qafkj1e+iSOwVkBVjhsgnOax7cmZC0x3tnGW5NFFYU9Y6nPh9abb7n//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23881=[""].join("\n");
var outline_f23_20_23881=null;
var title_f23_20_23882="Natural history and management of nonalcoholic fatty liver disease in adults";
var content_f23_20_23882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history and management of nonalcoholic fatty liver disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Sunil G Sheth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/20/23882/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/20/23882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis when no other causes for secondary hepatic fat accumulation (eg, heavy alcohol consumption) are present. NAFLD may progress to cirrhosis and is likely an important cause of cryptogenic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the natural history and treatment of NAFLD. The pathogenesis, clinical manifestations, and diagnosis of NAFLD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244507317\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53583253\">",
"    <span class=\"h2\">",
"     NAFL versus NASH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without evidence of inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation that histologically is indistinguishable from alcoholic steatohepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other terms that have been used to describe NASH include pseudoalcoholic hepatitis, alcohol-like hepatitis, fatty liver hepatitis, steatonecrosis, and diabetic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53583246\">",
"    <span class=\"h2\">",
"     NAFLD activity score",
"    </span>",
"    &nbsp;&mdash;&nbsp;One way of differentiating NAFL from NASH is to obtain a liver biopsy and calculate the NAFLD activity score (NAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/7\">",
"     7",
"    </a>",
"    ]. The NAS is the sum of the biopsy's individual scores for steatosis (0 to 3), lobular inflammation (0 to 2), hepatocellular ballooning (0 to 2), and fibrosis (0 to 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/7\">",
"     7",
"    </a>",
"    ]. An NAS &lt;3 corresponds to nonalcoholic fatty liver (NAFL), 3 to 4 corresponds to borderline nonalcoholic steatohepatitis (NASH), and a score &ge;5 corresponds to NASH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=see_link&amp;anchor=H9#H9\">",
"     \"Histologic scoring systems for chronic liver disease\", section on 'Nonalcoholic fatty liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonalcoholic fatty liver disease (NAFLD) may eventually develop cirrhosis. Cirrhosis develops when simple steatosis progresses to steatohepatitis and then fibrosis. Among patients with cryptogenic cirrhosis, up to 70 percent have risk factors for NAFLD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. While the risk of disease progression among patients with NAFLD has been evaluated in multiple studies, the results have been variable, and the risk of developing advanced fibrosis among patients with NAFLD is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/3,4,8-18\">",
"     3,4,8-18",
"    </a>",
"    ]. However, it appears that patients with simple steatosis on biopsy are at very low risk for developing significant fibrosis, whereas those with nonalcoholic steatohepatitis are at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, some patients with fibrosis show regression of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243002537\">",
"    <span class=\"h2\">",
"     Risk factors for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for liver disease progression have been identified in patients with NAFLD. One of the most important risk factors is histologic evidence of hepatic inflammation.",
"   </p>",
"   <p>",
"    This was examined in a systematic review that included 187 patients with paired biopsies that were assessed for both inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/10\">",
"     10",
"    </a>",
"    ]. It found that 4 of 23 patients (17 percent) with no inflammation on initial biopsy went on to develop advanced fibrosis, compared with 84 of 170 (49 percent) with inflammation. The median time to develop advanced fibrosis among those with inflammation on the initial biopsy was 4.2 years, compared with 13.4 years for those without inflammation. After adjusting for potential confounders, the presence of any inflammation on the initial biopsy increased the chance of progressing to advanced fibrosis 2.5-fold compared with patients who did not have inflammation.",
"   </p>",
"   <p>",
"    Other factors that have been associated with disease progression or advanced fibrosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age greater than 45 or 50 years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/10,17,20\">",
"       10,17,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated serum aminotransferases (&ge;2 times the upper limit of normal in one study) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of ballooning degeneration plus Mallory hyaline or fibrosis on biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Body mass index &ge;28",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher visceral adiposity index, which takes into account waist circumference, body mass index, triglycerides, and high-density lipoprotein level [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coffee consumption has been associated with a lower risk of progression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several statistical models have been described to predict fibrosis, but none has been extensively validated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/17,20,22,26,27\">",
"     17,20,22,26,27",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Heavy alcohol use among patients with or at risk for NAFLD is associated with hepatic steatosis, hepatic injury, and fibrosis progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. As an example, in a study of 71 patients with NAFLD followed for a mean of 14 years, 17 patients (24 percent) had fibrosis progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/31\">",
"     31",
"    </a>",
"    ]. Heavy (more than 60 g of alcohol on one occasion for men or 48 g for women) episodic drinking was more common in those with fibrosis progression than in those without progression (47 versus 11 percent).",
"   </p>",
"   <p>",
"    Some studies suggest that the consumption of as little as two drinks per day in those who are overweight (and one drink per day in those who are obese) is associated in hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/29\">",
"     29",
"    </a>",
"    ]. However, other data suggest that light or moderate alcohol consumption may have beneficial effects on the liver. This was seen in a cross-sectional study that compared 251 life-time nondrinkers with NAFLD with 331 modest drinkers with NAFLD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/33\">",
"     33",
"    </a>",
"    ]. Modest drinkers had lower odds for fibrosis (odds ratio [OR] 0.56; 95% confidence interval [CI] 0.41-0.77) and ballooning hepatocellular injury (OR 0.66; 95% CI 0.48-0.92). However, prospective studies examining the effects of light or moderate alcohol consumption in patients with NAFLD are lacking.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53583283\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is associated with cirrhosis due to NAFLD. In a systematic review of 61 studies and case series of patients with NAFLD or NASH, the risk of HCC among those with cirrhosis ranged from 2.4 percent over seven years to 12.8 percent over three years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/34\">",
"     34",
"    </a>",
"    ]. Among those without cirrhosis, the risk of mortality from HCC was 0 to 3 percent after follow-up periods of up to 20 years.",
"   </p>",
"   <p>",
"    As examples, individual studies found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 137 patients with NASH and advanced fibrosis, the five-year cumulative incidence of HCC was 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report of 195 patients with NASH-related cirrhosis, the one-year cumulative incidence of HCC was 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients who reported regular alcohol consumption were at increased risk for HCC compared with nondrinkers (hazard ratio 3.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HCC surveillance is recommended for patients with NASH-related cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H162498331#H162498331\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Other causes of cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243002891\">",
"    <span class=\"h2\">",
"     Recurrence following liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of NAFLD has been reported following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In a series of 622 liver transplants, eight patients, all female, had features consistent with NASH pre-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/39\">",
"     39",
"    </a>",
"    ]. At a median follow-up of 15 months, six developed persistent fatty infiltration, three of whom had hepatic degeneration consistent with NASH. In two of the patients, the histologic progression from mild steatosis to steatohepatitis occurred within two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243002300\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is the most common cause of death among patients with NAFLD, though patients with NASH are at increased risk for liver-related death compared with patients without NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/13,40-42\">",
"     13,40-42",
"    </a>",
"    ]. The association with cardiovascular disease suggests that there should be a reduced threshold for surveillance for cardiovascular disease in patients with NAFLD or NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H147569346#H147569346\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Associated disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether patients with NAFLD have increased overall mortality rates compared with the general population is not clear. The largest study from the United States suggests that the overall mortality rate is not increased, whereas smaller studies and studies in other populations suggest a slight increase in mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US study examined 11,371 adults participating in the Third National Health and Nutrition Examination Survey (NHANES) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/44\">",
"       44",
"      </a>",
"      ]. Using hepatic ultrasound and serum liver tests, NAFLD was diagnosed in 2089 participants (16 percent), and NASH was diagnosed in 426 (3 percent). There were no significant differences between participants without hepatic steatosis and participants with NAFL or NASH with regard to overall mortality (15 percent, 22 percent, and 13 percent, respectively), mortality due to cardiovascular disease (6 percent, 9 percent, and 4 percent, respectively), cancer mortality (4 percent, 8 percent, and 3 percent, respectively), or mortality due to liver disease (0.4 percent, 0.3 percent, and 0.7 percent, respectively). However, a limitation of the study is that the diagnosis of NAFLD was not based upon liver biopsy, so some patients may have been misclassified, potentially masking differences in mortality rates.",
"     </li>",
"     <li>",
"      In a smaller population-based study from the US (Minnesota), 420 patients with NAFLD (diagnosed by imaging in 83 percent) had slightly lower overall survival than expected for the Minnesota general population (standardized mortality ratio of 1.34, 95% CI 1.00-1.76) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/45\">",
"       45",
"      </a>",
"      ]. Higher mortality was associated with increasing age, impaired fasting glucose, and cirrhosis.",
"     </li>",
"     <li>",
"      Higher mortality rates in patients with NAFLD were also seen in a population-based study from Sweden. Compared with the general sex- and age-matched population, overall mortality was increased in the 118 patients with biopsy-proven NAFLD or NASH (standardized mortality ratios of 1.69 and 1.86, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/42\">",
"       42",
"      </a>",
"      ]. Of the 47 deaths observed during the study in patients with NAFLD (23 with bland steatosis, 24 with NASH), most were due to cardiovascular disease (30 percent), followed by extrahepatic malignancies (28 percent), and liver disease (19 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54336987\">",
"    <span class=\"h2\">",
"     General approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies have been investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). Weight loss is the only therapy with reasonable evidence suggesting it is beneficial and safe.",
"   </p>",
"   <p>",
"    We recommend the following approach in patients with nonalcoholic fatty liver (NAFL) or NASH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss for patients who are overweight or obese: Options to promote weight loss include lifestyle modifications and, for patients who are candidates, bariatric surgery. A reasonable goal for many patients is to lose 0.5 to 1",
"      <span class=\"nowrap\">",
"       kg/week",
"      </span>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       lb/week).",
"      </span>",
"      Pharmacologic therapy can be used to aid with weight loss in patients who fail to achieve weight loss goals through diet and exercise alone. (See",
"      <a class=\"local\" href=\"#H53583857\">",
"       'Weight loss'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H54338666\">",
"       'Other pharmacologic therapies'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"       \"Drug therapy of obesity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis A and B vaccinations should be given to patients without serologic evidence of immunity. Additional vaccines recommended for patients with chronic liver disease include pneumococcal vaccination and standard immunizations recommended for the population in general (eg, influenza, diphtheria, tetanus boosters) (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link&amp;anchor=H8#H8\">",
"       \"Immunizations for patients with chronic liver disease\", section on 'Vaccines in chronic liver disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of risk factors for cardiovascular disease: Patients with NAFLD are at increased risk for cardiovascular disease and often have multiple cardiovascular disease risk factors. Management of patients with NAFLD includes optimization of blood glucose control in patients with diabetes and treatment of hyperlipidemia. Statin therapy has been shown to be safe in patients with NAFLD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Statins'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H147569346#H147569346\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Associated disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In general, we do not suggest using pharmacologic agents (eg, vitamin E,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      ) solely for the treatment of NAFLD. However, we do suggest vitamin E at a dose of 400 int.",
"      <span class=\"nowrap\">",
"       unit/day",
"      </span>",
"      for the subset of patients with advanced fibrosis on biopsy who do not have diabetes or coronary artery disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Vitamin E'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest that patients with NAFLD avoid all alcohol consumption. Heavy alcohol use is associated with disease progression among patients with NAFLD. Whether light to moderate alcohol consumption is harmful is not as clear. It is possible that light or moderate alcohol use may have beneficial effects on the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/33\">",
"       33",
"      </a>",
"      ], and there are potential cardiovascular benefits as well. However, it has not been shown that the cardiovascular benefits of moderate alcohol consumption extend to patients with NAFLD. In the absence of more definitive data, we suggest that patients with NAFLD avoid all alcohol consumption. (See",
"      <a class=\"local\" href=\"#H243002537\">",
"       'Risk factors for progression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H242879397#H242879397\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Association with other disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53583857\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss and increased physical activity can lead to sustained improvement in liver enzymes, histology, serum insulin levels, and quality of life in patients with NAFLD, and we recommend weight loss for all patients with NAFLD who are overweight or obese [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. One of the few randomized trials of weight loss included 31 overweight and obese patients (body mass index 25 to 40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    with biopsy proven NASH who were assigned to a weight loss and exercise program or structured education [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/50\">",
"     50",
"    </a>",
"    ]. After one year, average weight loss was higher in patients assigned to the weight loss program (9 versus 0.2 percent body weight). A higher proportion of the participants in the weight loss group had histologic improvement (72 versus 30 percent), particularly those who achieved the study goal of loss of at least a 7 percent reduction in weight.",
"   </p>",
"   <p>",
"    A reasonable goal for many patients is to lose 0.5 to 1",
"    <span class=\"nowrap\">",
"     kg/week",
"    </span>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     lb/week).",
"    </span>",
"    More rapid weight reduction may be associated with worsening of liver disease. In one study of 41 patients with morbid obesity receiving very-low calorie diets (900",
"    <span class=\"nowrap\">",
"     kcal/day),",
"    </span>",
"    the median weight loss after a median follow-up of 261 days was 34 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/52\">",
"     52",
"    </a>",
"    ]. A quarter of the patients developed slight portal fibrosis, which was associated with faster weight loss (median 0.28",
"    <span class=\"nowrap\">",
"     kg/day",
"    </span>",
"    for those with portal fibrosis versus 0.15",
"    <span class=\"nowrap\">",
"     kg/day",
"    </span>",
"    for those without portal fibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/52\">",
"     52",
"    </a>",
"    ]. This suggests that patients should avoid rapid weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H2#H2\">",
"     \"Dietary therapy for obesity\", section on 'Goals of weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H4#H4\">",
"     \"Dietary therapy for obesity\", section on 'Rate of weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic improvement has also been observed after bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/48,53-61\">",
"     48,53-61",
"    </a>",
"    ]. In a systematic review that included 21 observational studies of bariatric surgery in patients with NASH, an improvement in steatosis was reported in 18 studies, decreased inflammation was reported in 11, and improvement in fibrosis score was reported in 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/62\">",
"     62",
"    </a>",
"    ]. However, in four studies there was some worsening of fibrosis. Taken together, these data suggest that bariatric surgery is a promising approach in obese patients with NAFLD. However, given the potential for worsening fibrosis in some patients following bariatric surgery, patients should continue to have their liver function monitored closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54337183\">",
"    <span class=\"h2\">",
"     Pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapies have been studied for the treatment of the subset of patients with nonalcoholic steatohepatitis (NASH). However, most trials have been too short to determine an impact on important patient-centered clinical outcomes (eg, decompensated cirrhosis), instead reporting on surrogate outcomes, such as serum transaminase levels or histologic findings, often with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/63\">",
"     63",
"    </a>",
"    ]. As a result, we do not suggest using pharmacologic agents (eg, vitamin E,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) solely for the treatment of NASH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E decreases oxidative stress, and initial observational studies suggested improvement in aminotransferase levels in patients with NASH who received vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/64\">",
"     64",
"    </a>",
"    ]. However, subsequent randomized trials reached variable conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/65-72\">",
"     65-72",
"    </a>",
"    ], with the largest trial suggesting a benefit in patients who do not have diabetes who received 800 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/67\">",
"     67",
"    </a>",
"    ]. However, observational studies have raised concern over a possible increase in all-cause mortality with high-dose vitamin E supplementation (&gt;400 int.",
"    <span class=\"nowrap\">",
"     unit/day).",
"    </span>",
"    We suggest vitamin E at a dose of 400 int.",
"    <span class=\"nowrap\">",
"     unit/day",
"    </span>",
"    for patients with advanced fibrosis on biopsy who do not have diabetes or coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H33#H33\">",
"     \"Vitamin supplementation in disease prevention\", section on 'All-cause mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis that included five randomized trials deemed to be of high-quality found no histologic benefits with vitamin E, though there was significant heterogeneity among the studies with respect to the formulation of vitamin E used, the patient population, the duration of treatment, and the addition of lifestyle modifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest randomized trial included in the meta-analysis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH; PIVENS) did suggest a benefit with vitamin E. The trial included 247 adults with NASH without diabetes who were randomly assigned to pioglitazone (30 mg daily), vitamin E (800 int. units daily), or placebo for 96 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients treated with vitamin E were more likely to have improvement in their global histology score compared with patients who received placebo (43 versus 19 percent). By comparison, histologic improvement was not significantly different with pioglitazone compared with placebo, although there were significant differences in some histologic features such as hepatic steatosis and lobular inflammation. Patients receiving vitamin E or placebo gained less weight than those receiving pioglitazone.",
"   </p>",
"   <p>",
"    We suggest vitamin E at a dose of 400 int.",
"    <span class=\"nowrap\">",
"     unit/day",
"    </span>",
"    for patients with advanced fibrosis on biopsy who do not have diabetes or coronary artery disease, though a",
"    <a class=\"external\" href=\"file://www.gastro.org/journals-publications/gastroenterology/NAFLD_Guideline_6-12.pdf\">",
"     joint guideline",
"    </a>",
"    issued in 2012 by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, and the American College of Gastroenterology recommends a higher dose of vitamin E (800 mg daily) as first-line pharmacotherapy for nondiabetic patients with biopsy-proven NASH (not just advanced fibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/73\">",
"     73",
"    </a>",
"    ]. We reserve the use of vitamin E to those with advanced fibrosis because, while vitamin E appears to be beneficial, we believe additional studies are required before recommending it more broadly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54339533\">",
"    <span class=\"h3\">",
"     Insulin-sensitizing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of insulin-sensitizing agents in the treatment of NAFLD is based upon the role insulin resistance plays in the development of NAFLD. Whereas the thiazolidinediones have been shown to improve histologic parameters in patients with NASH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has not. However, thiazolidinediones are associated with significant side effects and are thus not routinely used for the treatment of NASH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\", section on 'Insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254497165\">",
"    <span class=\"h4\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , are insulin-sensitizing agents that improve liver biochemical and histologic parameters in patients with NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/65,67,74-79\">",
"     65,67,74-79",
"    </a>",
"    ]. However, their use is associated with adverse events, including weight gain, painful swollen legs, and heart failure. In addition, it is likely that long-term treatment is required to achieve a clinically important benefit because the improvements seen with thiazolidinediones may reverse if the drugs are stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/74\">",
"     74",
"    </a>",
"    ]. Our approach is to use thiazolidinediones for the treatment of NASH only in patients with type 2 diabetes who are otherwise candidates for treatment with a thiazolidinedione. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H18#H18\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of thiazolidinediones on histologic parameters in NASH was examined in a meta-analysis of four randomized trials that compared thiazolidinediones with placebo in 334 patients with NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/80\">",
"     80",
"    </a>",
"    ]. The analysis found that compared with placebo, thiazolidinediones were more likely to improve hepatic histologic parameters such as ballooning degeneration (odds ratio [OR] 2.1), lobular inflammation (OR 2.6), and steatosis (OR 3.4). Improvement in fibrosis was not seen when all thiazolidinediones were examined, but when the analysis was limited to three studies that used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , there was a significant improvement in fibrosis among patients treated with pioglitazone compared with placebo (OR 1.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54339426\">",
"    <span class=\"h4\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    lowers blood glucose by decreasing hepatic gluconeogenesis, stimulating glucose uptake by muscle, and increasing fatty acid oxidation in adipose tissue. However, it does not appear to be effective for the treatment of NASH.",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for the treatment of NASH was evaluated in a meta-analysis that included three randomized trials of metformin with histologic data available both before and after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/81\">",
"     81",
"    </a>",
"    ]. There was no difference between the patients who received metformin and the control patients with regard to histologic response (steatosis, ballooning, inflammation, or fibrosis), changes in alanine aminotransferase levels, or changes in body mass index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54338666\">",
"    <span class=\"h3\">",
"     Other pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other drugs have been examined for the treatment of NASH. While some have shown initial promise, none has been studied sufficiently to recommend its use as a primary treatment for NASH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876395\">",
"    <span class=\"h4\">",
"     Orlistat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    is a gastrointestinal lipase inhibitor used in the treatment of obesity and type 2 diabetes mellitus. Studies of orlistat as a treatment for NASH have reached variable conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. We suggest using orlistat when needed as an adjunct for weight loss, but not as a primary treatment for NASH. (See",
"    <a class=\"local\" href=\"#H54336987\">",
"     'General approach to the patient'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H16#H16\">",
"     \"Drug therapy of obesity\", section on 'Orlistat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    may be effective in the treatment of NASH independent of its effect on weight loss, whereas others suggest its benefit is only through weight loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pilot trial in 44 patients with NASH randomly assigned patients to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/82\">",
"       82",
"      </a>",
"      ]. Both groups also participated in a weight loss program. A similar amount of weight loss was seen in both groups, but a reduction in ultrasound-assessed hepatic steatosis was only seen in the orlistat group. Serum aminotransferases declined in both groups, but did so to a greater extent with orlistat (48 versus 26 percent reduction from baseline).",
"     </li>",
"     <li>",
"      A biochemical and histologic benefit from treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      was seen in a case series of 14 obese patients with NASH [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/83\">",
"       83",
"      </a>",
"      ]. Improvements in steatosis were related to the degree of weight loss, whereas changes in inflammation and fibrosis were independent of weight loss.",
"     </li>",
"     <li>",
"      No benefit on liver histology, insulin resistance, or liver biochemical tests was observed in a randomized trial involving 50 patients with NASH [",
"      <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/84\">",
"       84",
"      </a>",
"      ]. However, in subgroup analyses, those who lost &ge;5 percent of body weight over nine months had improved insulin resistance, and those who lost &ge;9 percent of body weight also achieved improved liver histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876403\">",
"    <span class=\"h4\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA) may have antiapoptotic and anti-inflammatory effects in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/85\">",
"     85",
"    </a>",
"    ]. A potential benefit of UDCA in the treatment of NASH was suggested in a pilot study of 40 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/86\">",
"     86",
"    </a>",
"    ] and in studies that combined UDCA with vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/68,87\">",
"     68,87",
"    </a>",
"    ]. However, larger randomized trials have failed to show a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. As an example, in a randomized trial of 185 patients with biopsy-proven NASH treated with UDCA or placebo, there was no significant difference in overall liver histology between the two groups after 18 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876410\">",
"    <span class=\"h4\">",
"     Probucol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probucol is a lipid lowering agent with antioxidant properties. It was studied for the treatment of NASH in a randomized trial with 30 patients with biopsy-proven NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients were assigned to receive probucol 500 mg daily for six months or placebo. Patients in the probucol group had a larger change in alanine aminotransferase level than patients in the control group (-57.5 versus -0.6 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"    In addition, more patients in the probucol group achieved normal aminotransferase levels than controls (50 versus 0 percent). However, the effect on liver histology was not assessed. Probucol is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876417\">",
"    <span class=\"h4\">",
"     Betaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"     Betaine",
"    </a>",
"    is a normal component of the metabolic cycle of methionine, which has a protective effect against steatosis in animal models. Favorable results in a pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/91\">",
"     91",
"    </a>",
"    ] prompted a randomized controlled trial involving 55 patients who received oral betaine or placebo for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/92\">",
"     92",
"    </a>",
"    ]. Thirty-four patients in the study underwent liver biopsy. While hepatic steatosis improved in the betaine group, there was no significant effect on markers of hepatic inflammation or oxidative stress. Thus, the benefit of betaine therapy remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876424\">",
"    <span class=\"h4\">",
"     Losartan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II is involved in the pathogenesis of hepatic fibrosis and enhances iron deposition and insulin resistance. A pilot study of the angiotensin II receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    in seven patients with NASH suggested a benefit on blood markers of hepatic fibrosis and serum aminotransferase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/93\">",
"     93",
"    </a>",
"    ]. Further studies are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876431\">",
"    <span class=\"h4\">",
"     Atorvastatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pilot studies found a benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    on aminotransferase levels in patients with NAFLD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. The use of atorvastatin was then examined in a secondary analysis of a trial looking at the effect of atorvastatin, vitamin C, and vitamin E on the development of cardiovascular events in healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/96\">",
"     96",
"    </a>",
"    ]. Two of the exclusion criteria for the study were the presence of diabetes and serum aminotransferases &gt;1.5 times the upper limit of normal. At baseline, 80 patients had NAFLD based upon imaging criteria. After a mean of 3.6 years of follow-up, fewer patients in the treatment arm still had NAFLD compared with the placebo arm (34 versus 70 percent; adjusted odds ratio 0.36, 95% confidence interval 0.16-0.83).",
"   </p>",
"   <p>",
"    However, the conclusions that can be drawn from the trial are limited because patients did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    alone, only in combination with vitamin E and C, because the diagnosis of NAFLD was based upon imaging criteria and not histology, and because the exclusion criteria (diabetes or elevated aminotransferases) limit its generalizability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876438\">",
"    <span class=\"h4\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    inhibits production of tumor necrosis factor-alpha, which has been hypothesized to contribute to the progression of NASH. Biochemical improvement, and in some cases histologic improvement, was described in several pilot studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. However, in one of the studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/97\">",
"     97",
"    </a>",
"    ], 9 of 20 patients dropped out due to side-effects (primarily nausea).",
"   </p>",
"   <p>",
"    A subsequent trial randomly assigned 55 patients with biopsy-confirmed NASH to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    400 mg three times per day or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/101\">",
"     101",
"    </a>",
"    ]. After one year, patients treated with pentoxifylline were more likely than those treated with placebo to show a reduction in the histologic NAFLD activity score of at least two points (39 versus 14 percent). (See",
"    <a class=\"local\" href=\"#H53583246\">",
"     'NAFLD activity score'",
"    </a>",
"    above.) Pentoxifylline was associated with improvements in steatosis, lobular inflammation, and liver fibrosis scores. Three patients receiving pentoxifylline had to decrease their medication dose from three times daily to twice daily because of nausea, which resulted in adequate symptom control.",
"   </p>",
"   <p>",
"    A smaller randomized trial was unable to show a difference between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    and placebo with regard to aminotransferase levels or histologic findings, though patients who received pentoxifylline did show improvement in serum aminotransferases and the histologic findings of steatosis and cellular ballooning compared with their baseline values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027876445\">",
"    <span class=\"h4\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have suggested a benefit of omega-3 fatty acids in animals and humans with NAFLD or NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/103-111\">",
"     103-111",
"    </a>",
"    ]. In a meta-analysis of nine studies with 355 patients, treatment with omega-3 fatty acids was associated with improvement in hepatic steatosis as well as aspartate aminotransferase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/20/23882/abstract/112\">",
"     112",
"    </a>",
"    ]. There was also a trend toward improvement in alanine aminotransferase levels. When the analysis was restricted to data from randomized trials, only hepatic steatosis continued to show improvement with omega-3 fatty acid treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150642600\">",
"    <span class=\"h2\">",
"     Patients with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cirrhosis due to NAFLD is similar to that for cirrhosis due to other causes and includes management of portal hypertension, screening for hepatocellular carcinoma, and consideration of liver transplantation for patients with decompensated cirrhosis. A general approach to the management of patients with cirrhosis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150642859\">",
"    <span class=\"h2\">",
"     Follow-up liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During follow-up, some patients will require a liver biopsy. In patients who have never had a liver biopsy, or who had a liver biopsy that showed steatosis but not steatohepatitis, we obtain a liver biopsy if the physical examination or laboratory findings suggest progressive liver disease. Findings suggestive of progressive liver disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral stigmata of chronic liver disease (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Splenomegaly (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Cytopenias (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Serum ferritin &gt;1.5 times the upper limit of normal (suggestive of NASH and advanced fibrosis)",
"     </li>",
"     <li>",
"      Age &gt;45 years with associated obesity or diabetes (increased risk of advanced fibrosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who had a baseline liver biopsy that showed NASH and who have a stable or improving physical examination and laboratory findings, we repeat a liver biopsy in five to seven years to assess disease progression. We obtain a liver biopsy sooner if there is evidence of worsening liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53584735\">",
"    <span class=\"h1\">",
"     WHEN TO REFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with steatohepatitis on biopsy be followed by a hepatologist. Patients with nonalcoholic fatty liver without steatohepatitis can often be followed by a primary care physician, provided the diagnosis is clear. However, if the patient develops significant aminotransferase elevations (twice the upper limit of normal) or evidence of cirrhosis, we suggest referral to a hepatologist for further evaluation and management.",
"   </p>",
"   <p>",
"    Patients who develop cirrhosis and have complications (eg, ascites, variceal bleeding) or a model for end-stage liver disease (MELD) score &ge;10 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) should be referred for a liver transplantation evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38114?source=see_link\">",
"       \"Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/47/12018?source=see_link\">",
"       \"Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple therapies have been investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). Weight loss is the only therapy with sufficient evidence suggesting it is beneficial and safe. (See",
"      <a class=\"local\" href=\"#H53583857\">",
"       'Weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend weight loss for overweight and obese patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition to its other health benefits, weight loss, either through lifestyle modifications or bariatric surgery, has been associated with histologic improvement in patients with NAFLD. A reasonable goal for many patients is to lose 0.5 to 1",
"      <span class=\"nowrap\">",
"       kg/week",
"      </span>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       lb/week).",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"      can be used to aid with weight loss in patients who fail to achieve weight loss goals through diet and exercise alone. (See",
"      <a class=\"local\" href=\"#H53583857\">",
"       'Weight loss'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H54338666\">",
"       'Other pharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic liver disease, including NAFLD, require vaccinations for hepatitis A and B if they are not already immune, the pneumococcal vaccine, and standard age-appropriate vaccinations (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link&amp;anchor=H8#H8\">",
"       \"Immunizations for patients with chronic liver disease\", section on 'Vaccines in chronic liver disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all patients avoid heavy alcohol consumption (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Heavy alcohol use is associated with alcoholic liver disease and numerous other adverse consequences, including cancers of the mouth and esophagus and injuries due to accidents. In patients with or at risk for NAFLD, heavy alcohol use is associated with hepatic steatosis, hepatic injury, and fibrosis progression. (See",
"      <a class=\"local\" href=\"#H243002537\">",
"       'Risk factors for progression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link&amp;anchor=H7#H7\">",
"       \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\", section on 'Adverse consequences'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with NAFLD refrain from any alcohol consumption (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Data are mixed regarding the risks and benefits of light or moderate alcohol consumption among patients with NAFLD, with some studies suggesting harm with alcohol consumption of one to two drinks per day. (See",
"      <a class=\"local\" href=\"#H243002537\">",
"       'Risk factors for progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H54336987\">",
"       'General approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with NAFLD are at increased risk for cardiovascular disease and often have multiple cardiovascular disease risk factors. Management of patients with NAFLD includes optimization of blood glucose control in patients with diabetes and treatment of hyperlipidemia. Statin therapy has been shown to be safe in patients with NAFLD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Statins'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link&amp;anchor=H147569346#H147569346\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Associated disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest vitamin E at a dose of 400 int.",
"      <span class=\"nowrap\">",
"       unit/day",
"      </span>",
"      for patients with advanced fibrosis on biopsy who do not have diabetes or coronary artery disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Limited evidence supports a benefit with up to 800 int.",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      of vitamin E in patients without diabetes, but some observational studies suggest a possible increase in all-cause mortality with higher-dose vitamin E (800 int.",
"      <span class=\"nowrap\">",
"       units/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Vitamin E'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using thiazolidinediones primarily for the treatment of NASH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Thiazolidinediones improve histologic parameters in patients with NASH, but likely need to be used long-term and their use has been associated with serious adverse events, including heart failure. Using a thiazolidinedione is reasonable in patients who are candidates for thiazolidinedione treatment for type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H254497165\">",
"       'Thiazolidinediones'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Thiazolidinediones'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with NASH-related cirrhosis should undergo screening for hepatocellular carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115544744\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/1\">",
"      Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/2\">",
"      Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/3\">",
"      Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/4\">",
"      Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/5\">",
"      Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/6\">",
"      Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/7\">",
"      Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/8\">",
"      Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/9\">",
"      Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/10\">",
"      Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/11\">",
"      Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/12\">",
"      Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/13\">",
"      Ekstedt M, Franz&eacute;n LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/14\">",
"      Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/15\">",
"      Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/16\">",
"      Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/17\">",
"      Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/18\">",
"      Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/19\">",
"      Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/20\">",
"      Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/21\">",
"      Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/22\">",
"      Francque SM, Verrijken A, Mertens I, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/23\">",
"      Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/24\">",
"      Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/25\">",
"      Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/26\">",
"      Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/27\">",
"      Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/28\">",
"      Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/29\">",
"      Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/30\">",
"      Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/31\">",
"      Ekstedt M, Franz&eacute;n LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/32\">",
"      Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther 2009; 30:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/33\">",
"      Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/34\">",
"      White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/35\">",
"      Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 Suppl 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/36\">",
"      Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/37\">",
"      Carson K, Washington MK, Treem WR, et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997; 3:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/38\">",
"      Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/39\">",
"      Kim WR, Poterucha JJ, Porayko MK, et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/40\">",
"      Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/41\">",
"      Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/42\">",
"      S&ouml;derberg C, St&aring;l P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/43\">",
"      Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/44\">",
"      Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343:d6891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/45\">",
"      Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/46\">",
"      Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/47\">",
"      Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/48\">",
"      Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/49\">",
"      Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/50\">",
"      Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/51\">",
"      Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/52\">",
"      Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/53\">",
"      Furuya CK Jr, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007; 22:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/54\">",
"      Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/55\">",
"      Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012; 22:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/56\">",
"      Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/57\">",
"      de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/58\">",
"      Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/59\">",
"      Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/60\">",
"      Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/61\">",
"      Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/62\">",
"      Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; :CD007340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/63\">",
"      Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/64\">",
"      Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/65\">",
"      Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/66\">",
"      Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/67\">",
"      Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/68\">",
"      Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/69\">",
"      Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/70\">",
"      Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/71\">",
"      Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/72\">",
"      Ers&ouml;z G, G&uuml;nar F, Karasu Z, et al. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 16:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/73\">",
"      Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/74\">",
"      Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/75\">",
"      Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/76\">",
"      Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/77\">",
"      Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/78\">",
"      Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/79\">",
"      Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/80\">",
"      Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/81\">",
"      Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/82\">",
"      Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/83\">",
"      Hussein O, Grosovski M, Schlesinger S, et al. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007; 52:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/84\">",
"      Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/85\">",
"      Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur J Gastroenterol Hepatol 2005; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/86\">",
"      Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/87\">",
"      Pietu F, Guillaud O, Walter T, et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol 2012; 36:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/88\">",
"      Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/89\">",
"      Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/90\">",
"      Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/91\">",
"      Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/92\">",
"      Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/93\">",
"      Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/94\">",
"      Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/95\">",
"      Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/96\">",
"      Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/97\">",
"      Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/98\">",
"      Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/99\">",
"      Satapathy SK, Sakhuja P, Malhotra V, et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/100\">",
"      Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/101\">",
"      Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/102\">",
"      Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/103\">",
"      Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/104\">",
"      Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/105\">",
"      Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/106\">",
"      Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/107\">",
"      Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14:6395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/108\">",
"      Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010; 61:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/109\">",
"      Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/110\">",
"      Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94:3842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/111\">",
"      Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med 2008; 56:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/20/23882/abstract/112\">",
"      Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56:944.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3600 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23882=[""].join("\n");
var outline_f23_20_23882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244507317\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53583253\">",
"      NAFL versus NASH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53583246\">",
"      NAFLD activity score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243002537\">",
"      Risk factors for progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53583283\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243002891\">",
"      Recurrence following liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243002300\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54336987\">",
"      General approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53583857\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54337183\">",
"      Pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54339533\">",
"      - Insulin-sensitizing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H254497165\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H54339426\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54338666\">",
"      - Other pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876395\">",
"      Orlistat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876403\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876410\">",
"      Probucol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876417\">",
"      Betaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876424\">",
"      Losartan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876431\">",
"      Atorvastatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876438\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2027876445\">",
"      Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150642600\">",
"      Patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150642859\">",
"      Follow-up liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53584735\">",
"      WHEN TO REFER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115544744\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3600|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=related_link\">",
"      Pathogenesis of nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/47/12018?source=related_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38114?source=related_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_20_23883="Available IDUS systems";
var content_f23_20_23883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Available intraductal ultrasound systems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Electronic ultrasound probe (Endosonics&reg;)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanical sector scanner probes (ALOKA&reg;, Olympus&reg;, Microvasive&reg;)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Combined sector and linear probes (Fujinon&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scanning method",
"       </td>",
"       <td>",
"        Phased array",
"       </td>",
"       <td>",
"        Mechanical/radial",
"       </td>",
"       <td>",
"        Mechanical/radial or linear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency (MHz)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        15-20/12-30/20",
"       </td>",
"       <td>",
"        12-15-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transducer elements",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        1/1/1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Working length (cm)",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        192/205/200",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diameter (mm)",
"       </td>",
"       <td>",
"        1.2/1.6",
"       </td>",
"       <td>",
"        2/2.0-2.4-2.9/2.1",
"       </td>",
"       <td>",
"        2.0/2.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23883=[""].join("\n");
var outline_f23_20_23883=null;
var title_f23_20_23884="Key considerations for breastfeeding";
var content_f23_20_23884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F87060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F87060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key considerations for breastfeeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key considerations for breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human breast milk is specific to the needs of the infant and is the most complete and ideal source for infant nourishment in the first year of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key recommendations for initiation of breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurement of levels of lead in breast milk is not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mothers with BLLs &lt;40 mcg/dL should breastfeed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mothers with confirmed BLLs &ge;40 mcg/dL should begin breastfeeding when their blood lead levels drop below 40 mcg/dL. Until then, they should pump and discard their breast milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These recommendations are not appropriate in countries where infant mortality from infectious diseases is high (World Health Organization Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality 2000)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key recommendations for continuation of breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breastfeeding should continue for all infants with BLLs below 5 mcg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants born to mothers with BLL &ge;5 mcg/dL can continue to breastfeed unless there are indications that the breast milk is contributing to elevating BLLs. These infants should have blood lead tests at birth and be followed at regular intervals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For infants whose blood lead levels are rising or failing to decline by 5 mcg/dL or more, environmental and other sources of lead exposure should be evaluated. If no external source is identified, and maternal BLLs are &gt;20 mcg/dL and infant BLL &ge;5 mcg/dL, then breast milk should be suspected as the source, and temporary interruption of breastfeeding until maternal blood lead levels decline should be considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key recommendations for use of reconstituted infant formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant formula requiring reconstitution should be made only with water from the cold water tap. Flush the tap for at least 3 minutes before use and then heat the water or use bottled or filtered tap water known to be free of lead.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Guidelines for the Identification and Managment of Lead Exposure in Pregnant and Lactating Women. 2010. Available at:&nbsp;",
"     <a href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"     </a>",
"     (Accessed November 12, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23884=[""].join("\n");
var outline_f23_20_23884=null;
var title_f23_20_23885="ALAD porphyria lab findings";
var content_f23_20_23885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biochemical findings in four patients with ALAD porphyria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Patient",
"       </td>",
"       <td>",
"        German B",
"       </td>",
"       <td>",
"        German H",
"       </td>",
"       <td>",
"        Swedish",
"       </td>",
"       <td>",
"        Belgian",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Sex",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Age of onset",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        At birth",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Clinical course",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Tests",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\" rowspan=\"1\">",
"        Test results in percent, Upper limit of normal = 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Plasma",
"        <br/>",
"       </td>",
"       <td>",
"        ALA",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1155",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PBG",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coproporphyrin",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        327",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Urine",
"       </td>",
"       <td>",
"        ALA",
"       </td>",
"       <td>",
"        2449",
"       </td>",
"       <td>",
"        2373",
"       </td>",
"       <td>",
"        8150",
"       </td>",
"       <td>",
"        794",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PBG",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        447",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uroporphyrin",
"       </td>",
"       <td>",
"        361",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        888",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coproporphyrin",
"       </td>",
"       <td>",
"        5380",
"       </td>",
"       <td>",
"        4698",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total porphyrin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7247",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Stool",
"       </td>",
"       <td>",
"        Coproporphyrin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        284",
"       </td>",
"       <td>",
"        285",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythrocyte",
"       </td>",
"       <td>",
"        Protoporphyrin,&nbsp;Zn PP",
"       </td>",
"       <td>",
"        3192",
"       </td>",
"       <td>",
"        3164",
"       </td>",
"       <td>",
"        663",
"       </td>",
"       <td>",
"        408",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythrocyte",
"       </td>",
"       <td>",
"        ALAD activity",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Enzymes",
"        <br/>",
"       </td>",
"       <td>",
"        Activation by dithiothreitol",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activation by Zn+",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PBGD activity",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     -: Not determined.",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: Sassa S. ALAD porphyria. In: Seminars in Liver Disease, Berk PD (Ed), Thieme, New York 1998. p.95.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23885=[""].join("\n");
var outline_f23_20_23885=null;
var title_f23_20_23886="Myopia nearsightedness";
var content_f23_20_23886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/69617/myopia_conv.mp4?title=Myopia+nearsightedness\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myopia is also known as nearsightedness. The image of an object twenty feet or more away (optical infinity) is focused in front of the retina resulting in blurry distance vision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the University of Michigan Kellogg Eye Center, file://www.kellogg.umich.edu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23886=[""].join("\n");
var outline_f23_20_23886=null;
var title_f23_20_23887="Retropharyngeal abscess plain radiograph";
var content_f23_20_23887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retropharyngeal abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral neck radiograph demonstrating widening of the retropharyngeal space and reversal of the normal cervical spine curvature. The retropharyngeal space is considered widened if it is greater than 7 mm at C2 or 14 mm at C6. The epiglottis and subglottic area in this radiograph are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joe Black, Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_20_23887=[""].join("\n");
var outline_f23_20_23887=null;
